Novel compound, use and preparation method thereof, composition containing compound, method for preparing 4-trehalose amine and microorganism
By developing 4-trehalose and its related compositions, the blood sugar rise and stability problems caused by trehalose decomposition in the body are solved, multifunctional starch, protein and microbial protection is achieved, and cheap and efficient preparation methods are provided. Excellent effect.
Patent Information
- Application Number
- CN202280059966.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-09-06
- Filing Date
- 2022-08-24
- Publication Date
- 2024-11-08
AI Technical Summary
Trehalose is rapidly decomposed into glucose by trehalase in the body, causing an increase in blood sugar value and affecting the stability of symbiotic bacteria and products in the organism. Its molecular structure is complex and difficult to synthesize modified derivatives, and the market lacks effective substitutes.
Develop a new compound 4-trehalosamine and its related composition, which is prepared inexpensively and efficiently through the culture process of Streptomyces sp.MK 186-mF5, with inhibition of starch aging, protein protection, microbial protection, surfactivity, blood sugar control, and autophagy It has various excellent effects such as induction and acid-resistant bacteria staining, and is prepared by chemical reactions using it as the starting substance.
It realizes the protection of starch and protein in frozen or lyophilized state, prevents microbial damage, controls blood sugar levels, provides convenient acid-resistant bacteria staining and protein extraction, and is versatile and efficient.
Smart Images

Figure CN118922553A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, use thereof and a preparation method thereof, as well as a composition containing the compound, a method for preparing 4-trehalosamine and a microorganism. Background Art
[0002] Trehalose is inexpensive and has moisturizing and protective properties, so it is widely used in various fields such as food. In addition, there are reports that it has therapeutic effects on various diseases, and research is also underway to develop it as a drug.
[0003] However, since trehalose is rapidly decomposed into glucose by trehalase in the body, a large amount of trehalose needs to be used in order to exert the above-mentioned effects. Such large-scale use of trehalose will cause the above-mentioned glucose to cause an increase in blood sugar levels. In addition, there are also problems of affecting the symbiotic flora in the body and causing product corruption due to assimilation by microorganisms.
[0004] Therefore, there is an urgent need to provide a trehalose substitute that has the same effect as trehalose and is not decomposed in the body. However, there are no trehalose analogs on the market, and one trehalose molecule contains multiple hydroxyl groups with the same chemical properties, so it is difficult to synthesize derivatives that modify specific sites.
[0005] On the other hand, 4-trehalosamine is known as an analog of trehalose, and although its antibacterial activity is known, its other uses are not known (see Non-Patent Document 1). Prior art literature Non-patent literature
[0006] Non-patent document 1: THE JOURNAL OF ANTIBIOTICS, Vol. XXVII No. 2, 1974, p. 145 Summary of the invention Problems Solved by the Invention
[0007] The present invention aims to solve the above-mentioned problems in the past and achieve the following objectives. That is, the following substances are provided: a protective agent having excellent effects such as inhibiting starch aging, preventing or inhibiting the reduction of protein activity when stored in a frozen or freeze-dried state, preventing or inhibiting damage or killing of microorganisms when stored in a frozen or freeze-dried state, pH buffering effect, a surfactant having excellent surface activity, a blood sugar control composition that does not increase blood sugar after administration to an individual, an autophagy inducer having excellent autophagy inducing effect, an acid-fast bacteria staining agent that can simply and efficiently stain acid-fast bacteria, and a protein extracting agent having excellent protein extraction effect.
[0008] In addition, the purpose of the present invention is to provide new compounds with various excellent effects, including the effect of inhibiting starch aging, the effect of preventing or inhibiting the reduction of protein activity when stored in a frozen or freeze-dried state, the effect of preventing or inhibiting damage or killing of microorganisms when stored in a frozen or freeze-dried state, pH buffering effect, excellent surface activity, the effect of not increasing blood sugar after administration to an individual, autophagy inducing effect, at least one of the acid-fast bacteria staining effect that can simply and efficiently stain acid-fast bacteria and protein extraction effect, or its pharmaceutically acceptable salt, or its solvate, and a composition containing the above-mentioned compound.
[0009] In addition, the object of the present invention is to provide a method for preparing a compound, which can prepare a new compound cheaply, conveniently and efficiently.
[0010] In addition, the present invention aims to provide a method for preparing 4-trehalosamine, which can prepare 4-trehalosamine cheaply, conveniently and efficiently.
[0011] Furthermore, an object of the present invention is to provide a microorganism having the ability to produce 4-trehalosamine. Solution to the problem
[0012] The following are means for solving the above-mentioned problems. <1> A protective agent, a surfactant composition, a blood sugar control composition, an autophagy inducer, an acid-fast bacteria stain or a protein extractant, characterized in that it contains a compound represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof: [Chemical formula 1] However, in the above general formula (1), R 1 is -NH2, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14; [Chemical formula 2] [Chemical formula 3] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond. <2> A compound represented by the following general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof: [Chemical formula 4] However, in the above general formula (2), R 2is a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14; [Chemical formula 5] [Chemical formula 6] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond. <3> A composition containing a compound, characterized in that it contains the compound described in <2>, or a pharmaceutically acceptable salt thereof, or a solvate thereof. <4> The method for preparing 4-trehalose amine is characterized by comprising culturing Streptomyces sp.MK 186-mF5 (commission number: NITE BP-03495). <5> A method for preparing 4-trehalosamine according to <4>, wherein in the culture process, the culture medium contains at least one of 3% to 9% by mass of soluble starch, 0.001% to 0.02% by mass of zinc chloride, and 0.1% to 1% by mass of potassium chloride. <6> A method for preparing a compound represented by the following general formula (3), characterized in that it comprises using 4-trehalosamine as a starting material, reacting the 4-amino group of 4-trehalosamine with CH3(CH2) p COH (wherein p represents an integer of 6 to 13), 2-azido-1,3-dimethylimidazolium hexafluorophosphate, 5-carboxyfluorescein N-succinimide ester or D-biotin N-hydroxysuccinimide ester: [Chemical formula 7] However, in the above general formula (3), R 3 Yes -N(CH2) m CH3, or -N3, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), wherein m represents an integer between 7 and 14; [Chemical formula 8] [Chemical formula 9] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond. <7> The microorganism is Streptomyces sp.MK 186-mF5 (commission number: NITE BP-03495), which is characterized by having the ability to produce 4-trehalosamine. Effects of the Invention
[0013] Through the present invention, many previous problems can be solved, the above-mentioned objectives can be achieved, and a protective agent with excellent various effects such as the effect of inhibiting starch aging, the effect of preventing or inhibiting the reduction of protein activity when stored in a frozen or freeze-dried state, the effect of preventing or inhibiting damage or killing of microorganisms when stored in a frozen or freeze-dried state, and pH buffering effect can be provided; a surfactant with excellent surface active effect; a blood sugar control composition that does not increase blood sugar after administration to an individual; an autophagy inducer with excellent autophagy inducing effect; an acid-fast bacteria stain that can simply and efficiently stain acid-fast bacteria; and a protein extractant with excellent protein extraction effect can be provided.
[0014] Through the present invention, many previous problems can be solved, the above-mentioned objectives can be achieved, and new compounds with various excellent effects can be provided, including the effect of inhibiting starch aging, the effect of preventing or inhibiting the reduction of protein activity when stored in a frozen or freeze-dried state, the effect of preventing or inhibiting damage or killing of microorganisms when stored in a frozen or freeze-dried state, pH buffering effect, excellent surface activity, the effect of not increasing blood sugar after administration to an individual, autophagy induction effect, at least one of the acid-fast bacteria staining effect that can simply and efficiently stain acid-fast bacteria and protein extraction effect, or its pharmaceutically acceptable salt, or its solvate, and a composition containing the above-mentioned compound.
[0015] In addition, the present invention can solve many previous problems, achieve the above-mentioned goals, and provide a method for preparing compounds, which can prepare new compounds cheaply, conveniently and efficiently.
[0016] In addition, the present invention can solve many previous problems, achieve the above-mentioned purpose, and provide a method for producing 4-trehalosamine, which can produce 4-trehalosamine cheaply, conveniently and efficiently.
[0017] Furthermore, the present invention can solve many of the conventional problems, achieve the above-mentioned object, and provide a microorganism capable of producing 4-trehalosamine. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] [ Figure 1A ] Figure 1A The absorption spectrum of the compound (4-trehalosamine) represented by the structural formula (1) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 1B ] Figure 1B This is the proton nuclear magnetic resonance spectrum of the compound (4-trehalosamine) represented by the structural formula (1) measured at 600 MHz and deuterated water at 25° C. The horizontal axis is in ppm. [ Figure 1C ] Figure 1C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (4-trehalosamine) represented by the structural formula (1) measured at 150 MHz and deuterated water at 25° C. The horizontal axis is in ppm. [ Figure 2A ] Figure 2A This is the absorption spectrum of the compound (IMCTA-C8) represented by the structural formula (2) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 2B ] Figure 2B This is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C8) represented by the structural formula (2) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 2C ] Figure 2C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C8) represented by the structural formula (2) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Figure 3A ] Figure 3A This is the absorption spectrum of the compound (IMCTA-C9) represented by the structural formula (3) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 3B ] Figure 3B This is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C9) represented by the structural formula (3) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 3C ] Figure 3C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C9) represented by the structural formula (3) measured at 150 MHz and 25°C in deuterated methanol. The horizontal axis is in ppm. [ Figure 4A ] Figure 4A This is the absorption spectrum of the compound (IMCTA-C10) represented by the structural formula (4) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 4B ] Figure 4BThis is the proton nuclear magnetic resonance spectrum of the compound represented by the structural formula (4) (IMCTA-C10) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 4C ] Figure 4C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C10) represented by the structural formula (4) measured at 150 MHz and 25°C in deuterated methanol. The horizontal axis is in ppm. [ Figure 5A ] Figure 5A This is the absorption spectrum of the compound (IMCTA-C11) represented by the structural formula (5) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 5B ] Figure 5B This is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C11) represented by the structural formula (5) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 5C ] Figure 5C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C11) represented by the structural formula (5) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig. 6A ] Fig. 6A This is the absorption spectrum of the compound (IMCTA-C12) represented by the structural formula (6) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 6B ] Figure 6B This is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C12) represented by the structural formula (6) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 6C ] Figure 6C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C12) represented by the structural formula (6) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig. 7A ] Fig. 7A This is the absorption spectrum of the compound (IMCTA-C13) represented by the structural formula (7) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 7B ] Figure 7BThis is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C13) represented by the structural formula (7) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 7C ] Figure 7C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C13) represented by the structural formula (7) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig. 8A ] Fig. 8A This is the absorption spectrum of the compound (IMCTA-C14) represented by the structural formula (8) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Figure 8B ] Figure 8B This is the proton nuclear magnetic resonance spectrum of the compound (IMCTA-C14) represented by the structural formula (8) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Figure 8C ] Figure 8C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C14) represented by the structural formula (8) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig.9A ] Fig.9A This is the absorption spectrum of the compound (IMCTA-C15) represented by the structural formula (9) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Fig. 9B ] Fig. 9B This is a proton nuclear magnetic resonance spectrum of the compound represented by the structural formula (9) (IMCTA-C15) measured at 600 MHz in deuterated dimethyl sulfoxide at 25°C. Horizontal axis: in ppm. [ Fig. 9C ] Fig. 9C This is the carbon 13 nuclear magnetic resonance spectrum of the compound (IMCTA-C15) represented by the structural formula (9) measured at 150 MHz in deuterated dimethyl sulfoxide at 25°C. The horizontal axis is in ppm. [ Fig. 10A ] Fig. 10A This is the absorption spectrum of the compound represented by structural formula (10) (IMCTA-fluorescein) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Fig. 10B ] Fig. 10BThis is the proton nuclear magnetic resonance spectrum of the compound represented by the structural formula (10) (IMCTA-fluorescein) measured at 600 MHz and 25° C. in deuterated methanol. Horizontal axis: in ppm. [ Fig. 10C ] Fig. 10C This is the carbon 13 nuclear magnetic resonance spectrum of the compound represented by structural formula (10) (IMCTA-fluorescein) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig.11A ] Fig.11A This is the absorption spectrum of the compound (IMCTA-biotin) represented by the structural formula (11) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Fig. 11B ] Fig. 11B This is a 600 MHz proton nuclear magnetic resonance spectrum of the compound represented by structural formula (11) (IMCTA-biotin) measured in deuterated methanol at 25°C. Horizontal axis: in ppm. [ Fig. 11C ] Fig. 11C This is the carbon 13 nuclear magnetic resonance spectrum of the compound represented by structural formula (11) (IMCTA-biotin) measured at 150 MHz and 25°C in deuterated methanol. Horizontal axis: in ppm. [ Fig. 12A ] Fig. 12A This is the absorption spectrum of the compound (IMCTA-azide) represented by the structural formula (12) measured by infrared spectroscopy. Vertical axis: transmittance (%T); horizontal axis: wave number (cm -1 ). [ Fig. 12B ] Fig. 12B This is a 600 MHz proton nuclear magnetic resonance spectrum of the compound (IMCTA-azide) represented by the structural formula (12) measured in deuterated methanol at 25°C. The horizontal axis is in ppm. [ Fig. 12C ] Fig. 12C This is the carbon 13 nuclear magnetic resonance spectrum of the compound represented by structural formula (12) (IMCTA-azide) measured at 150 MHz in deuterated methanol at 25°C. Horizontal axis: in ppm. [ Fig.13A ] Fig.13A This is a graph showing the results of detecting 4-trehalosamine in the culture solution by TLC analysis (phosphomolybdic acid staining area) in Test Example 1. Horizontal axis: Production Example number. [ Fig. 13B ] Fig. 13BThis is a graph showing the results of measuring the 4-trehalosamine content in the culture medium by LC-MS analysis in Experimental Example 1. The horizontal axis is the production example number, and the vertical axis is the 4-trehalosamine production amount (mg / mL). [ Fig.14A ] Fig.14A This is a graph showing the results of the protein extraction efficiency of IMCTA-Cn in Test Example 4. Vertical axis: extracted protein (mg / mL). [ Fig. 14B ] Fig. 14B This is a graph showing the results of SDS-PAGE after protein extraction with IMCTA-Cn at a final concentration of 0.05% in Experimental Example 4. Vertical axis: molecular weight (kDa). [ Fig. 14C ] Fig. 14C This is a graph showing the results of SDS-PAGE after protein extraction with IMCTA-Cn at a final concentration of 0.5% in Experimental Example 4. Vertical axis: molecular weight (kDa). [ Fig.14D ] Fig.14D This is a graph showing the results of immunoblotting of membrane proteins extracted using IMCTA-Cn in Test Example 4. "0.05%" or "0.5%" in the graph indicates the final concentration of the test sample. [ Fig.14E ] Fig.14E This is a graph showing the CIP activity results of proteins extracted using IMCTA-Cn in Experiment 4 (n=3, mean±SD). Vertical axis: CIP activity (A 420 ). [ Fig.15A ] Fig.15A This is a graph showing the evaluation results of starch (corn starch) aging degree when the final concentration of the test sample is 10% in the enzyme assay 1 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), gray circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig. 15B ] Fig. 15B This is a graph showing the evaluation results of starch (corn starch) aging degree when the final concentration of the test sample is 2% in the enzyme assay 2 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), gray circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig. 15C ] Fig. 15CThis is a graph showing the evaluation results of starch (corn starch) aging degree when the final concentration of the test sample is 5% in the enzyme assay 2 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), gray circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15D ] Fig.15D This is a graph showing the evaluation results of starch (corn starch) aging degree when the final concentration of the test sample is 15% in the enzyme assay 2 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), gray circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15E ] Fig.15E This is a graph showing the evaluation results of starch (potato starch) aging degree when the final concentration of the test sample is 10% in the enzyme assay 3 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15F ] Fig.15F This is a graph showing the evaluation results of starch (potato starch) aging degree when the final concentration of the test sample is 15% in the enzyme assay 3 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Figure 15G ] Figure 15G This is a graph showing the evaluation results of starch (rice flour) aging when the final concentration of the test sample is 10% in the enzyme assay 4 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15H ] Fig.15HThis is a graph showing the evaluation results of starch (rice flour) aging when the final concentration of the test sample is 15% in the enzyme assay 4 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15I ] Fig.15I This is a graph showing the evaluation results of starch (flour) aging when the final concentration of the test sample is 10% in the enzyme assay 5 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Fig.15J ] Fig.15J This is a graph showing the evaluation results of starch (flour) aging when the final concentration of the test sample is 15% in the enzyme assay 5 of Test Example 5 (n=5, mean±SD). White circles represent the control (Control), black circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: decomposition efficiency (%). [ Figure 15K ] Figure 15K This is a graph of the dynamic viscoelasticity measurement results in Test Example 5 (n=5, mean±SD). White circles represent the control, gray circles represent trehalose (TRH), gray triangles represent 4-trehalosamine (4TA), black squares represent sucrose (SCR), and white triangles represent the results of glycerol (GOL). Horizontal axis: time, vertical axis: Tanδ. [ Fig.16A ] Fig.16A This is a graph showing the evaluation results of the CIP protective activity in Test Example 6-1 (n=3, mean±SD). Horizontal axis: test sample number; vertical axis: CIP activity (A 420 ). [ Fig. 16B ] Fig. 16B This is a graph showing the evaluation results of the ADH protective activity in Test Example 6-2 (n=3, mean±SD). Horizontal axis: test sample number, vertical axis: ADH activity (A 340 Test sample / A 340 (control). [ Fig.17A ] Fig.17AThis is a graph showing the evaluation results of the baker's yeast protective activity in Test Example 7-1. [ Fig. 17B ] Fig. 17B This is a graph showing the evaluation results of the protective activity against Escherichia coli in Test Example 7-2. [ Fig. 17C ] Fig. 17C This is a graph showing the evaluation results of the protective activity against Bacillus subtilis in Test Example 7-3. [ Fig.17D ] Fig.17D This is a graph showing the evaluation results of the acid-resistant bacteria protection activity in Test Example 7-4. [ Fig.18 ] Fig.18 This is a graph showing the results of the pH buffering effect in Test Example 8. Gray circles represent 4-trehalosamine (4TA), black circles represent trehalose (TRH), white triangles (△) represent tris(hydroxymethyl)aminomethane, white squares represent MES, and white inverted triangles (▽) represent the results of HEPES. Horizontal axis: amount of sodium hydride or hydrogen chloride added (μL), vertical axis: pH. [ Fig.19A ] Fig.19A This is a graph showing the evaluation results of the decomposition by trehalase in Test Example 9-1. Black circles represent the results of trehalose (TRH), and black squares represent the results of 4-trehalosamine (4TA). The horizontal axis is the substrate concentration (mM), and the vertical axis is the free glucose concentration (mM). [ Fig.19B ] Fig.19B yes Fig.19A Enlarged graph of the curve of 4-trehalosamine (4TA). The black squares represent the results of 4-trehalosamine (4TA). Horizontal axis: substrate concentration (mM), vertical axis: free glucose concentration (mM). [ Fig.19C ] Fig.19C This is a diagram showing the results of Western blotting to confirm the presence of trehalase in the cultured cells in Test Example 9-2. [ Fig.19D ] Fig.19D This is a result diagram of confirming the decomposition rate by trehalase in Test Example 9-2. White circles represent the reaction solution of trehalose and human pancreatic cancer cell KP4 cell extract (TRH C), black circles represent the reaction solution of trehalose and KP4-TREH10 cell extract (TRH T), white triangles represent the reaction solution of 4-trehalosamine and human pancreatic cancer cell KP4 cell extract (4TA C), and black triangles represent the results of the reaction solution of 4-trehalosamine and KP4-TREH10 cell extract (4TAT). Horizontal axis: time, vertical axis: residual rate (%). [ Fig.19E ] Fig.19EThis is a graph showing the cumulative amount of 4-trehalosamine excreted into urine over time in Test Example 9-3. White circles represent trehalose (TRH), and black circles represent the results of 4-trehalosamine (4TA). Horizontal axis: time, vertical axis: cumulative excretion in urine (mg / mouse). [ Fig.19F ] Fig.19F This is a graph showing the cumulative amount of 4-trehalosamine excreted into feces over time in Test Example 9-3. White circles represent trehalose (TRH), and black circles represent the results of 4-trehalosamine (4TA). Horizontal axis: time, vertical axis: cumulative excretion in feces (mg / mouse). [ Figure 19G ] Figure 19G This is a graph of 4-trehalosamine blood concentrations in subjects to whom 4-trehalosamine was administered in Test Example 9-3. Horizontal axis: time, vertical axis: 4-trehalosamine (μg / mL) (n=5). [ Fig.19H ] Fig.19H This is a graph of trehalose blood concentration in subjects administered trehalose in Test Example 9-3. Horizontal axis: time, vertical axis: trehalose (μg / mL) (n=5). [ Fig.19I ] Fig.19I This is a graph showing blood glucose levels in mice (n=5) administered with 4-trehalosamine in Test Example 9-3. The horizontal axis is time, and the vertical axis is blood glucose (mg / dL). [ Fig.19J ] Fig.19J This is a graph showing blood glucose levels in mice (n=5) administered trehalose in Test Example 9-3. The horizontal axis is time, and the vertical axis is blood glucose (mg / dL). [ Fig. 20A ] Fig. 20A This is a diagram showing the results of Western blotting to confirm the expression and phosphorylation regions of autophagy-related proteins when human ovarian cancer cell OVK18 cells were treated with 4-trehalosamine in Experimental Example 10-1. [ Fig. 20B ] Fig. 20B This is a diagram showing the results of Western blotting to confirm the expression and phosphorylation regions of autophagy-related proteins when human ovarian cancer cell OVK18 was treated with a trehalose analog (IMCTA-Cn) in Experimental Example 10-1. [ Fig. 20C ] Fig. 20C This is a diagram showing the results of Western blotting to confirm the expression and phosphorylation regions of autophagy-related proteins when human ovarian cancer cell OVK18 was treated with a trehalose analog (IMCTA-Cn) in Experimental Example 10-1. [ Fig.20D ] Fig.20DThis is a diagram showing the results of Western blotting to confirm the expression and phosphorylation region of autophagy-related proteins when human malignant melanoma cells Mewo were treated with 4-trehalosamine in Experimental Example 10-1. [ Fig.20E ] Fig.20E This is a diagram showing the results of Western blotting to confirm the expression and phosphorylation region of autophagy-related proteins when human malignant melanoma cells Mewo were treated with a trehalose analog (IMCTA-Cn) in Experimental Example 10-1. [ Fig.20F ] Fig.20F This is a diagram showing the results of Western blotting to confirm the expression and phosphorylation region of autophagy-related proteins when human malignant melanoma cells Mewo were treated with a trehalose analog (IMCTA-Cn) in Experimental Example 10-1. [ Fig.21A ] Fig.21A It shows that in Experimental Example 10-2, in the presence of an autophagy inhibitor (BM or CQ), the expression results of autophagy-related proteins LC3-I and LC3-II were confirmed by Western blotting when human ovarian cancer cells OVK18 were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14), and the expression values (expression ratios) of LC3-II added to each compound group were calculated by image analysis when the expression level of LC3-II in the control (Control) was 1 (n=10, mean±SD). [ Fig.21B ] Fig.21B The results show that in Experimental Example 10-2, the expression results of autophagy-related proteins LC3-I and LC3-II when human malignant melanoma cells Mewo were treated with 4-trehalosamine or trehalose analogs (IMCTA-C14) in the presence of autophagy inhibitors (BM or CQ) were confirmed by Western blotting, and the expression value (expression ratio) of LC3-II in the control (Control) was calculated by image analysis (n=10, mean±SD). [ Fig.22A ] Fig.22A The results show that in Experimental Example 10-3, the expression results of the aggregation protein Q74 when the neuroblastoma cells SH-SY5Y were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) were confirmed by protein blotting, and the expression levels of Q74 in each added compound group (expression level ratio) were calculated by image analysis when the Q74 expression level in the control (Control) was 1 (n=5, mean±SD). [ Fig. 22B ] Fig. 22BThe results show that in Experimental Example 10-3, the expression results of the aggregation protein SynA53T when the neuroblastoma cells SH-SY5Y were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) were confirmed by protein blotting, and the expression levels of SynA53T in each added compound group (expression level ratio) were calculated by image analysis when the SynA53T expression level in the control (Control) was 1 (n=5, mean±SD). [ Fig. 22C ] Fig. 22C The results show that in Experimental Example 10-3, the expression results of the aggregation protein Q74 when human neuroblastoma cells NH-12 were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) were confirmed by protein blotting, and the expression level of Q74 in each compound-added group (expression level ratio) was calculated by image analysis when the Q74 expression level in the control (Control) was 1 (n=5, mean±SD). [ Fig.22D ] Fig.22D The results show that in Experimental Example 10-3, the expression results of the aggregation protein SynA53T when human neuroblastoma cells NH-12 were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) were confirmed by protein blotting, and the expression level of SynA53T in each compound-added group (expression level ratio) was calculated by image analysis when the expression level of SynA53T in the control (Control) was 1 (n=5, mean±SD). [ Fig.23A ] Fig.23A The results of Western blotting in Experimental Example 10-4 show that the expression and nuclear translocation of the autophagy-related transcription factor TFEB were confirmed when human ovarian cancer cell OVK18 was treated with 4-trehalosamine or a trehalose analog (IMCTA-C14). [ Fig. 23B ] Fig. 23B The results of Western blotting in Experimental Example 10-4 show that the expression and nuclear translocation of the autophagy-related transcription factor TFEB were confirmed when human malignant melanoma cells Mewo were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14). [ Fig.23C ] Fig.23C The results of confirming the expression and nuclear translocation of the autophagy-related transcription factor TFEB by immunostaining in Experimental Example 10-4 when human ovarian cancer cell OVK18 cells were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) are shown. [ Fig.23D ] Fig.23DThe results of confirming the expression and nuclear translocation of the autophagy-related transcription factor TFEB by immunostaining in Experimental Example 10-4 when human malignant melanoma cells Mewo were treated with 4-trehalosamine or a trehalose analog (IMCTA-C14) are shown. [ Fig.24A ] Fig.24A The trehalose analog (IMCTA-fluorescein) was used for staining in Experimental Example 11-1. Mycobacterium smegmatis Result graph. [ Fig. 24B ] Fig. 24B This is the staining with trehalose analog (IMCTA-biotin) in Experimental Example 11-1. Mycobacterium smegmatis Result graph. [ Fig.24C ] Fig.24C This is the staining with trehalose analog (IMCTA-azide) in Test Example 11-1. Mycobacterium smegmatis Result graph. [ Fig.25A ] Fig.25A It is shown that in Experimental Example 11-1, staining with trehalose analog (IMCTA-fluorescein) Mycobacterium smegmatis The fluorescence intensity of each bacterial amount was (n=3, mean±SD). [ Fig.25B ] Fig.25B It is shown that in Experimental Example 11-1, staining with trehalose analog (IMCTA-biotin) Mycobacterium smegmatis The fluorescence intensity of each bacterial amount was (n=3, mean±SD). [ Fig.25C ] Fig.25C It is shown that in Experimental Example 11-1, staining with trehalose analog (IMCTA-azide) Mycobacterium smegmatis The fluorescence intensity of each bacterial amount was (n=3, mean±SD). [ Fig.26A ] Fig.26A It shows that the trehalose analog (IMCTA-fluorescein) stained in Experimental Example 11-2 Mycobacterium smegmatis TLC analysis results of lipid components of bacteria (phosphomolybdic acid staining pattern). [ Fig.26B ] Fig.26B It shows that the trehalose analog (IMCTA-fluorescein) stained in Experimental Example 11-2 Mycobacterium smegmatis TLC analysis results of lipid components of bacterial cells (fluorescence detection mode). [ Fig.27A ] Fig.27AThis is a graph showing the results of confirming the residual rate of 4-trehalosamine in the culture solution of 12 kinds of cultured microorganisms in the presence of 4-trehalosamine in Test Example 12-1. Vertical axis: residual rate (%). [ Fig.27B ] Fig.27B This graph shows the growth of 12 microorganisms when cultured in the presence of 4-trehalosamine in Test Example 12-1. 620 . [ Fig.28A ] Fig.28A This is a diagram showing the binding model of trehalose and human trehalase in Experimental Example 13. [ Fig.28B ] Fig.28B This is a diagram of the binding model of 4-trehalosamine and human trehalase in Experimental Example 13. DETAILED DESCRIPTION
[0019] (New compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof) The compound of the present invention, or a pharmaceutically acceptable salt thereof, or a solvate thereof, is a compound represented by the following general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and is a new compound discovered by the inventor, or a pharmaceutically acceptable salt thereof, or a solvate thereof. [Chemical formula 10] However, in the above general formula (2), R 2 is a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14. [Chemical formula 11] [Chemical formula 12] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
[0020] <IMCTA-fluorescein> In the above general formula (2), if R 2 is a substituent represented by the above structural formula (A), then it is a compound represented by the following structural formula (10), or a pharmaceutically acceptable salt thereof, or a solvate thereof. The compound represented by the following structural formula (10) is also referred to as "IMCTA-fluorescein" hereinafter. The physicochemical properties of IMCTA-fluorescein are shown in the following Synthesis Example 9. [Chemical formula 13]
[0021] <IMCTA-Biotin> In the above general formula (2), if R 2 is a substituent represented by the above structural formula (B), then it is a compound represented by the following structural formula (11), or a pharmaceutically acceptable salt thereof, or a solvate thereof. The compound represented by the following structural formula (11) is also referred to as "IMCTA-biotin" hereinafter. The physicochemical properties of IMCTA-biotin are shown in the following Synthesis Example 10. [Chemical formula 14]
[0022] -use- As shown in the test examples described later, the compound represented by the above structural formula (10) or (11), or a pharmaceutically acceptable salt thereof, or a solvate thereof, can be preferably used as an active ingredient, for example, in the acid-fast bacteria staining agent of the present invention described later, because it has the function of conveniently and efficiently staining acid-fast bacteria.
[0023] <IMCTA-Cn> In the above general formula (2), if R 2 It is composed of -NH(CH2) m If the substituent group is CH3, it is a compound represented by any one of the following structural formulas (2) to (9), or a pharmaceutically acceptable salt thereof, or a solvate thereof. Hereinafter, the compound wherein m is an integer between 7 and 14, or a pharmaceutically acceptable salt thereof, or a solvate thereof may be collectively referred to as "IMCTA-Cn". In addition, "n" in "IMCTA-Cn" is an integer, which is the same as the substituent R in the general formula (2). 2 -NH(CH2) m The integer of "m+1" in CH3 is the same.
[0024] The above m is 7 (ie R 2 When the substituent is represented by -NH(CH2)7CH3), it is a compound represented by the following structural formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is also referred to as "IMCTA-C8" hereinafter. The physicochemical properties of the above-mentioned IMCTA-C8 are shown in the following Synthesis Example 1. [Chemical formula 15]
[0025] The above m is 8 (ie R 2When the substituent is represented by -NH(CH2)8CH3), it is a compound represented by the following structural formula (3), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C9". The physicochemical properties of the above-mentioned IMCTA-C9 are shown in the following Synthesis Example 2. [Chemical formula 16]
[0026] The above m is 9 (ie R 2 When the substituent is represented by -NH(CH2)9CH3), it is a compound represented by the following structural formula (4), or a pharmaceutically acceptable salt thereof, or a solvate thereof. Hereinafter referred to as "IMCTA-C10". The physicochemical properties of the above-mentioned IMCTA-C10 are shown in the following Synthesis Example 3. [Chemical formula 17]
[0027] The above m is 10 (ie R 2 It is composed of -NH(CH2) 10 When the substituent is CH3, it is a compound represented by the following structural formula (5), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C11". The physicochemical properties of the above IMCTA-C11 are shown in the following Synthesis Example 4. [Chemical formula 18]
[0028] The above m is 11 (ie R 2 It is composed of -NH(CH2) 11 When the substituent is CH3, it is a compound represented by the following structural formula (6), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C12". The physicochemical properties of the above IMCTA-C12 are shown in the following Synthesis Example 5. [Chemical formula 19]
[0029] The above m is 12 (i.e. R 2 It is composed of -NH(CH2) 12 When the substituent is CH3, it is a compound represented by the following structural formula (7), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C13". The physicochemical properties of the above IMCTA-C13 are shown in the following Synthesis Example 6. [Chemical formula 20]
[0030] The above m is 13 (ie R2 It is composed of -NH(CH2) 13 When the substituent is CH3, it is a compound represented by the following structural formula (8), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C14". The physicochemical properties of the above IMCTA-C14 are shown in the following Synthesis Example 7. [Chemical formula 21]
[0031] The above m is 14 (ie R 2 It is composed of -NH(CH2) 14 When the substituent is CH3, it is a compound represented by the following structural formula (9), or a pharmaceutically acceptable salt thereof, or a solvate thereof. It is hereinafter referred to as "IMCTA-C15". The physicochemical properties of the above IMCTA-C15 are shown in the following Synthesis Example 8. [Chemical formula 22]
[0032] -use- As shown in the test examples described later, the compound represented by any one of the above structural formulas (2)-(9), or a pharmaceutically acceptable salt thereof, or a solvate thereof has excellent surface activity and excellent autophagy inducing effect, and therefore, can be preferably used as an active ingredient, for example, in the surfactant composition of the present invention and the protein extractant and autophagy inducer of the present invention described later.
[0033] Whether the above compound has the structure of the compound shown in general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof can be confirmed by various analytical methods selected as appropriate, such as mass spectrometry, ultraviolet spectroscopy, infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, carbon 13 nuclear magnetic resonance spectroscopy, elemental analysis, etc. The above analytical methods can be used alone or two or more can be used simultaneously. In addition, although the measured values obtained by the above various analytical methods may have errors, it is easy for those skilled in the art to identify that the compound has the structure of the compound shown in the above general formula (2) or a pharmaceutically acceptable salt thereof or a solvate thereof.
[0034] The above-mentioned salts are not particularly limited as long as they are pharmaceutically acceptable salts, and can be selected according to the purpose, such as hydrohalide salts such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; inorganic acid salts such as sulfate, nitrate, phosphate, perchlorate, and carbonate; carboxylates such as acetate, trichloroacetate, trifluoroacetate, glycolate, lactate, citrate, tartrate, oxalate, benzoate, nitrate, butyrate, maleate, propionate, formate, and malate; amino acid salts such as arginine, aspartate, and glutamate; sulfonates such as methanesulfonate and p-toluenesulfonate, etc.
[0035] The solvate is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include hydrates and ethanolates.
[0036] The compound represented by the above general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof, can be obtained by appropriate chemical synthesis. The chemical synthesis method of the compound represented by the above general formula (2) or a pharmaceutically acceptable salt thereof or a solvate thereof is not particularly limited and can be appropriately selected from known synthesis methods according to the purpose, but can be preferably obtained by the following method for preparing the compound of the present invention.
[0037] (Method for preparing compound) The preparation method of the compound of the present invention comprises using 4-trehalosamine as a starting material, reacting the 4th amino group of 4-trehalosamine with CH3(CH2) p COH (wherein p represents an integer between 6 and 13), 2-azido-1,3-dimethylimidazolium hexafluorophosphate, 5-carboxyfluorescein N-succinimidyl ester or D-biotin N-hydroxysuccinimidyl ester (sometimes referred to as "reaction process"), and may include other processes as needed. [Chemical formula 23] However, in the above general formula (3), R 3 Yes -N(CH2) m CH3, or -N3, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), wherein m represents an integer between 7 and 14. [Chemical formula 24] [Chemical formula 25] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
[0038] As the starting material, 4-trehalosamine can be a commercially available product, can be obtained from a microorganism that produces 4-trehalosamine, or can be obtained by appropriate chemical synthesis. However, preferably, 4-trehalosamine obtained by the method for preparing 4-trehalosamine described below can obtain a large amount of 4-trehalosamine simply, cheaply, and efficiently.
[0039] <4-amino group of trehalose amine and CH3(CH2) p Reaction of COH (wherein p is an integer of 6 to 13)> The 4th amino group of 4-trehalosamine and CH3(CH2) p The method of CO reaction is not particularly limited and can be selected from known methods as appropriate, such as reacting an aqueous solution of 4-trehalose amine with CH3(CH2) dissolved in a solvent. p COH, allowed to stand, then added with an aqueous solution of sodium cyanoborohydride, allowed to stand again, etc.
[0040] The 4th amino group of the above-mentioned 4-trehalose amine and CH3(CH2) p The reaction conditions such as reaction temperature and reaction time, the compounds used and their amounts, the solvent and the like in the COH reaction are not particularly limited and can be appropriately selected according to the purpose. 4-Trehalosamine aqueous solution and CH3(CH2) p The reaction temperature and reaction time when the COH is left to stand after mixing are, for example, 20° C. to 45° C., and 1 hour to 72 hours. In addition, the reaction temperature and reaction time when the solution is left to stand after the addition of the sodium cyanoborohydride aqueous solution are, for example, 20° C. to 45° C., 1 hour to 72 hours, and the like. The above solvents, as long as the 4-amino group of 4-trehalosamine is in contact with CH3(CH2) p There is no particular limitation as long as COH can react, and it can be selected according to the purpose, such as 1-propanol, 2-propanol, methanol, ethanol and other lower alcohols and dimethyl sulfoxide (DMSO), etc. One can be used alone, or two or more can be used simultaneously.
[0041] Through the above reaction, the above general formula (3) can be obtained. 3 -N(CH2) m CH3, a compound wherein m is an integer between 7 and 14 (IMCTA-Cn). In the above general formula (3), R 3 Yes -N(CH2) m The compound wherein CH3 and m represents an integer between 7 and 14 and R in the general formula (2) of the above-mentioned item “(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)” 2 Yes -NH(CH2)m The same is true for the case where CH3 and m represents an integer between 7 and 14, and the physicochemical properties are also the same.
[0042] <Reaction of the 4-amino group of 4-trehalosamine with 2-azido-1,3-dimethylimidazolium hexafluorophosphate> The method for reacting the 4-amino group of 4-trehalosamine with 2-azido-1,3-dimethylimidazolium hexafluorophosphate is not particularly limited and can be appropriately selected from known methods, such as mixing an aqueous solution of 4-trehalosamine with a DMSO solution of 2-azido-1,3-dimethylimidazolium hexafluorophosphate and a DMSO solution of N,N-dimethyl-4-aminopyridine (DMAP) and allowing the mixture to stand.
[0043] The reaction conditions such as reaction temperature and reaction time, the compounds used and their amounts, solvents, etc. in the reaction of the 4-amino group of 4-trehalosamine with 2-azido-1,3-dimethylimidazolium hexafluorophosphate are not particularly limited and can be appropriately selected according to the purpose. The reaction temperature and reaction time when the 4-trehalosamine aqueous solution, 2-azido-1,3-dimethylimidazolium hexafluorophosphate DMSO solution and DMAP DMSO solution are mixed and allowed to stand are not particularly limited and can be appropriately selected according to the purpose, such as 20° C. to 25° C., 2 hours to 72 hours, etc.
[0044] <<IMCTA-Azide>> Through the above reaction, a compound can be obtained, wherein R 3 It is a substituent represented by -N3 in the above general formula (3). In the above general formula (3), R 3 The compound in which the substituent is represented by -N3 is a compound represented by the following structural formula (12). Hereinafter, it is referred to as "IMCTA-azide". The physicochemical properties of the above-mentioned IMCTA-azide are shown in the following Synthesis Example 11. [Chemical formula 26]
[0045] <Reaction of the 4-amino group of 4-trehalosamine with 5-carboxyfluorescein N-succinimidyl ester> The method for reacting the amino group at position 4 of 4-trehalosamine with 5-carboxyfluorescein N-succinimidyl ester is not particularly limited and can be appropriately selected from known methods, such as a method in which an aqueous solution of 4-trehalosamine and 5-carboxyfluorescein N-succinimidyl ester dissolved in a solvent are mixed and allowed to stand.
[0046] The reaction conditions such as reaction temperature and reaction time in the reaction of the 4-amino group of 4-trehalosamine with 5-carboxyfluorescein N-succinimidyl ester, as well as the compounds used and their amounts, solvents, etc. are not particularly limited and can be appropriately selected according to the purpose. The reaction temperature and reaction time when the 4-trehalosamine aqueous solution and the 5-carboxyfluorescein N-succinimidyl ester DMSO solution are mixed and allowed to stand are not particularly limited and can be appropriately selected according to the purpose, such as 20° C. to 45° C., 24 hours to 72 hours, etc. The above solvent is not particularly limited as long as the 4-amino group of 4-trehalosamine can react with 5-carboxyfluorescein N-succinimidyl ester, and can be selected according to the purpose, such as methanol, DMSO, dimethylformamide, etc. One type can be used alone, or two or more types can be used simultaneously.
[0047] Through the above reaction, a compound can be obtained, wherein R 3 It is a substituent represented by the structural formula (A) in the above general formula (3). In the above general formula (3), R 3 The compound having a substituent represented by the structural formula (A) and R in the general formula (2) of the above-mentioned "new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof" 2 When they are substituents represented by the structural formula (A), their physicochemical properties are also the same.
[0048] <Reaction of the 4-amino group of 4-trehalosamine with D-biotin N-hydroxysuccinimide ester> The method for reacting the 4-amino group of 4-trehalosamine with D-biotin N-hydroxysuccinimide ester is not particularly limited and can be appropriately selected from known methods, such as mixing an aqueous solution of 4-trehalosamine with D-biotin N-hydroxysuccinimide ester dissolved in a solvent and allowing to stand.
[0049] The reaction conditions such as reaction temperature and reaction time in the reaction of the 4-amino group of 4-trehalosamine with D-biotin N-hydroxysuccinimide ester, as well as the compounds used and their amounts, solvents, etc. are not particularly limited and can be appropriately selected according to the purpose. The reaction temperature and reaction time when the 4-trehalosamine aqueous solution and the D-biotin N-hydroxysuccinimide ester DMSO solution are left to stand after mixing are, for example, 20° C. to 45° C. and 24 to 72 hours. The above solvent is not particularly limited as long as the 4-amino group of 4-trehalosamine can react with D-biotin N-hydroxysuccinimide ester, and can be selected according to the purpose, such as DMSO, dimethylformamide, etc. One type can be used alone, or two or more types can be used simultaneously.
[0050] Through the above reaction, a compound can be obtained, wherein R 3 It is a substituent represented by the structural formula (B) in the above general formula (3). In the above general formula (3), R 3The compound having a substituent represented by the structural formula (B) and R in the general formula (2) of the above-mentioned "new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof" 2 When they are substituents represented by the structural formula (B), their physicochemical properties are also the same.
[0051] <Other processes> The above other processes are not particularly limited and can be selected as appropriate according to the purpose, such as purification process.
[0052] -Purification process- The above-mentioned purification process is a process of purifying and isolating the compound obtained in the above-mentioned reaction process. There is no particular limitation on the method of purification and separation, and it can be selected according to the purpose, such as liquid separation operation, distillation, sublimation, precipitation, crystallization, silica gel column chromatography with positive or reverse phase silica gel as filler, column chromatography using ion exchange resin, column chromatography using cellulose, etc., preparative thin layer chromatography, high performance liquid chromatography, etc. One method can be used alone, or two or more methods can be used simultaneously. The compound obtained in the above production process can also be appropriately used in subsequent processes without separation and purification.
[0053] Whether the obtained compound has the structure shown in the above-mentioned general formula (3) can be confirmed by various analytical methods selected as appropriate. The above-mentioned analytical method is not particularly limited and can be selected as appropriate according to the purpose, such as mass spectrometry, ultraviolet spectroscopy, infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, carbon 13 nuclear magnetic resonance spectroscopy, elemental analysis and other analytical methods. The above-mentioned analytical method can be used alone or in combination. In addition, although the measured values obtained by the above-mentioned various analytical methods may have errors, it is easy for those skilled in the art to identify that the compound has the structure shown in the above-mentioned general formula (3).
[0054] (Composition containing compound) The compound-containing composition of the present invention contains at least the compound represented by the general formula (2) of the present invention, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and may contain other components as necessary. The compound represented by the above general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof may be used alone or in combination of two or more.
[0055] <Compound represented by general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof> The compound represented by the above general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof, is the compound represented by the general formula (2) of the present invention, or a pharmaceutically acceptable salt thereof, or a solvate thereof. In the above-mentioned compound-containing composition, the total content of the compound represented by the above-mentioned general formula (2), or its pharmaceutically acceptable salt, or its solvate is not particularly limited and can be selected as appropriate according to the purpose. The above-mentioned compound-containing composition may consist only of the compound represented by the above-mentioned general formula (2), or its pharmaceutically acceptable salt, or its solvate.
[0056] <Other ingredients> The above-mentioned other ingredients can be selected as appropriate according to the purpose, and there are no special restrictions as long as they do not destroy the effects of the present invention, such as the ingredients described in "-Other ingredients-" of each preparation described in the "(protective agent, surfactant composition, blood sugar control composition, autophagy inducer, acid-fast bacteria stain or protein extractant)" item described later.
[0057] The content of other components in the above compound-containing composition is not particularly limited and can be appropriately selected according to the purpose without impairing the effect of the compound represented by the above general formula (2) or its pharmaceutically acceptable salt or solvate.
[0058] -use- The above-mentioned compound-containing composition, including the compound represented by any one of the above-mentioned structural formulas (2)-(9), or a pharmaceutically acceptable salt thereof, or a solvate thereof, can be preferably used as an active ingredient, such as a surfactant composition, a protein extractant, etc., due to its excellent surface activity and excellent protein extraction effect. The above-mentioned compound-containing composition containing the compound represented by the above-mentioned structural formula (10) or (11), or a pharmaceutically acceptable salt thereof, or a solvate thereof can be preferably used as an active ingredient of, for example, an acid-fast bacilli staining agent because it has the function of conveniently and efficiently staining or marking acid-fast bacilli.
[0059] The above-mentioned composition containing the compound can be used alone or together with a drug having other components as active ingredients. In addition, the above-mentioned composition containing the compound can also be added to a composition having other components as active ingredients. The composition containing the above other ingredients as active ingredients is not particularly limited and can be appropriately selected according to the purpose, such as food and beverage, medicine, cosmetics, reagents, etc.
[0060] (Method for preparing 4-trehalosamine) The method for preparing 4-trehalosamine includes a culture process and may include other processes as required. The method for preparing 4-trehalosamine has the advantage that 4-trehalosamine can be produced simply and efficiently. The 4-trehalosamine is a compound represented by the following structural formula (1). [Chemical formula 27]
[0061] <Cultivation process> The cultivation process is Streptomyces Cultivation process of sp.MK 186-mF5 (trust number: NITE BP-03495).
[0062] In the above-mentioned culture process, Streptomyces sp.MK186-mF5 can also further improve the production capacity of 4-trehalosamine by providing ultraviolet rays, X-rays, radiation, drugs and other mutation treatments. In addition, the production capacity of 4-trehalosamine can also be improved through genetic engineering methods.
[0063] The method for analyzing the ability of the above-mentioned microorganism to produce 4-trehalosamine is, for example, to detect 4-trehalosamine from the culture of the microorganism, preferably the culture supernatant after liquid culture or the solid culture medium after solid culture, by various analytical methods.
[0064] <<Culture medium>> As a medium used in the above-mentioned culture process, as long as it can culture Streptomyces sp.MK186-mF5 is not particularly limited, and can be used to culture Streptomyces The culture medium with known culture medium components of the genus bacteria can be a liquid culture medium or a solid (agar) culture medium. There are no special restrictions on the nutrient sources added to the above-mentioned culture medium, and they can be selected according to the purpose, such as commercially available soybean flour, wheat germ, pressed wheat, pepsin, cottonseed meal, yeast extract (such as brewer's yeast extract, baker's yeast extract, etc.), meat extract, corn syrup, ammonium sulfate, sodium nitrate, urea and other nitrogen sources; soluble starch, tomato paste, glycerol, glucose, galactose, dextrin, benzylpenicillin and other carbohydrates, fat and other carbon sources, etc. In addition, inorganic salts such as table salt, calcium carbonate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, sodium chloride, etc. may be added to the culture medium for use. Other trace metal salts such as zinc chloride and magnesium sulfate may also be added to the culture medium for use as needed. These materials are Streptomyces sp.MK186-mF5 can be used, as long as it is helpful for the production of 4-trehalosamine, and any known culture material can be used.
[0065] The culture medium used in the above-mentioned culture process preferably contains carbon sources such as soluble starch and glucose; nitrogen sources such as brewer's yeast and baker's yeast; inorganic salts such as calcium carbonate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, sodium chloride; and metal salts such as zinc chloride and magnesium sulfate. From the perspective of high production of 4-trehalosamine, it is best to contain at least one of soluble starch, potassium chloride, sodium chloride, calcium carbonate and zinc chloride. Among them, it is particularly preferred to contain soluble starch, potassium chloride, sodium chloride and zinc chloride without magnesium sulfate.
[0066] The concentration of the soluble starch in the culture medium is not particularly limited and may be appropriately selected according to the purpose. From the perspective of high production of 4-trehalosamine, the concentration is preferably 1% to 10% by mass, more preferably 3% to 9% by mass, and particularly preferably 5% to 6% by mass.
[0067] The concentration of zinc chloride in the medium is not particularly limited and can be appropriately selected according to the purpose, but is preferably 10 mass % or less, more preferably 0.001 mass % to 0.02 mass %, and particularly preferably 0.001 mass % to 0.015 mass %.
[0068] The concentration of potassium chloride in the medium is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0.1 to 1% by mass, more preferably 0.1 to 0.8% by mass, and particularly preferably 0.4 to 0.7% by mass.
[0069] The concentration of brewer's yeast in the above-mentioned culture medium is not particularly limited and can be appropriately selected according to the purpose, but as its lower limit, it is preferably 2% by mass or higher, and more preferably 3% by mass or higher. The upper limit of the brewer's yeast concentration in the above-mentioned culture medium and the yield of 4-trehalosamine are not particularly limited and can be appropriately selected according to the purpose, but for cost considerations, it is preferably 4% by mass or lower. The lower limit and upper limit of the brewer's yeast concentration in the above-mentioned culture medium can be appropriately combined, preferably 2% by mass to 4% by mass, more preferably 2% by mass to 3% by mass, and particularly preferably 3% by mass.
[0070] There are no particular restrictions on the production of 4-trehalosamine pre-culture solution, and it can be selected according to the purpose. Streptomyces The growth materials of sp.MK186-mF5, such as liquid culture medium, flat culture medium, slant culture medium, half-slope culture medium, etc.
[0071] The above-mentioned culture method is not particularly limited and can be appropriately selected according to the purpose, for example, shaking culture, static culture, tank culture, etc. The above-mentioned culture temperature can be selected according to the purpose. StreptomycesThere are no particular restrictions as long as the growth of sp.MK186-mF5 is not substantially inhibited and 4-trehalosamine can be produced, but 25°C to 35°C is preferred. The pH value of the above culture can be selected according to the purpose. Streptomyces There are no particular limitations as long as the development of sp.MK186-mF5 is not substantially inhibited and 4-trehalosamine can be produced. The culture cycle is not particularly limited and can be selected according to the accumulation of 4-trehalosamine.
[0072] The method for carrying out the above-mentioned culture process is not particularly limited and can be appropriately selected according to the purpose. The culture may be carried out on a laboratory scale in a flask or the like, or may be carried out using a large-scale culture apparatus or the like. Examples of the above-mentioned large-scale culture apparatus include MPF-U3 (produced by Marubi Bio Co., Ltd.).
[0073] <Other processes> The above other processes are not particularly limited and can be selected according to the purpose, such as the collection process.
[0074] - Collection process - The above-mentioned collecting process is a process of collecting 4-trehalosamine from the culture containing 4-trehalosamine obtained in the above-mentioned culturing process. 4-Trehalosamine has the above-mentioned physicochemical properties, and thus can be purified and separated from the culture according to its properties.
[0075] The above-mentioned culture is not particularly limited if it is obtained in the above-mentioned culture process and contains 4-trehalosamine, and can be selected as appropriate according to the purpose, including bacterial cells, culture supernatant after liquid culture, solid culture medium after solid culture, and mixtures thereof. Furthermore, when bacterial cells are used as the above-mentioned culture medium, 4-trehalosamine can be extracted from the bacterial cells by an extraction method using an appropriate organic solvent or a method of eluting by disrupting the bacterial cells, and can be used for separation and / or purification.
[0076] There is no particular limitation on the above-mentioned collection method, and a method for collecting metabolites produced by microorganisms can be selected as appropriate. For example, solvent extraction, methods utilizing differences in adsorption affinity to various adsorbents, chromatography, etc. These methods can be used alone or in appropriate combination, and in some cases repeatedly, to collect separated and / or purified 4-trehalosamine.
[0077] The solvent used in the above-mentioned solvent extraction method is not particularly limited and can be appropriately selected according to the purpose, such as ethanol, methanol, acetone, butanol, acetonitrile, etc.
[0078] The adsorbent is not particularly limited and may be appropriately selected from known adsorbents according to the purpose, for example, polystyrene adsorption resin.
[0079] The above-mentioned chromatography method is not particularly limited and can be appropriately selected according to the purpose, for example, thin layer chromatography (TLC) method, high performance liquid chromatography (HPLC for separation) method using a normal phase or reverse phase column for separation, etc. The carrier used for the above chromatography is not particularly limited and may be appropriately selected according to the purpose, for example, ion exchange resin, gel filtration, silica gel, alumina, activated carbon, etc. Specific examples of commercially available products of the carrier used in the above chromatography method include Amberlite (registered trademark) CG50 (manufactured by Sigma-Aldrich Co., Ltd.), DOWEX50W×4 column 50-100 (manufactured by Muromachi Chemical Co., Ltd.), Amberlite FPC3500 (manufactured by Organo Co., Ltd.), DIAION TM WA30 (manufactured by Mitsubishi Chemical Corporation), Sephadex (registered trademark) LH-20 (manufactured by GE Healthcare Japan Co., Ltd.), activated carbon (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), Hydrosphere C18 (manufactured by YMC Corporation), Hydrophic Interaction Chromatography column (manufactured by Waters), YMC-GELODS-A 6nm S-150μm (manufactured by YMC Corporation), YMC-Pack Polyamine II (manufactured by YMC Corporation), ACQUITY UPLC Ethylene Bridged Hybrid (BEH) Amide 1.7μm, 2.1×100mm (manufactured by Waters), etc.
[0080] The adsorbent and the method for eluting 4-trehalosamine from the carrier in the above-mentioned chromatography are not particularly limited and can be appropriately selected according to the type and properties of the adsorbent and the carrier. For example, in the case of a polystyrene adsorption resin, a method of eluting using aqueous ethanol, aqueous acetone, etc. as an elution solvent can be used.
[0081] 4-Trehalosamine can be produced according to the above method.
[0082] 4-trehalosamine does not constitute a carbon source or a nutrient source for microorganisms, and does not cause microorganisms to proliferate. Therefore, 4-trehalosamine has the advantage of not causing corruption. The microorganisms are not particularly limited and can be appropriately selected according to the purpose, for example Escherichia Microorganisms of the genus (e.g. Escherichia coli wait), SerratiaMicroorganisms of the genus (e.g. Serratia marcescens wait), Enterococcus Microorganisms of the genus (e.g. Enterococcus faecalis wait), Aspergillus Microorganisms of the genus (e.g. Aspergillus niger wait), Salmonella Microorganisms of the genus (e.g. Salmonella enteritidis wait), Mycobacterium Microorganisms of the genus (e.g. Mycobacterium smegmatis wait), Bacillus Microorganisms of the genus (e.g. Bacillus subtilis wait), Pseudomonas Microorganisms of the genus (e.g. Pseudomonas aeruginosa wait), Micrococci Microorganisms of the genus (e.g. Micrococcus luteus wait), Bacteroides Microorganisms of the genus (e.g. Bacteroides fragilis wait), Saccharomyces Microorganisms of the genus (e.g. Saccharomyces cerevisiae wait), White Microorganisms of the genus (e.g. Candida albicans etc.
[0083] The above-mentioned microorganisms may be commercially available products, microorganisms owned by the applicant, or newly isolated strains of the above-mentioned genus and species of microorganisms. For example, Escherichia coli include Escherichia coli K-12 (held by the Microbial Chemistry Research Society), Escherichia coli K-12 (National Biological Resources Program (NBPR)), etc. For example, Serratia marcescens include Serratia marcescens B-0524 (held by the Microbial Chemistry Research Association), Serratia marcescens JCM 1239T (RIKEN BRC), etc. For example, Enterococcus faecalis include Enterococcus faecalis JCM5803 (RIKENBRC), etc. For example, Aspergillus niger Including A black spergillus F16 (held by the Microbial Chemistry Research Institute), Aspergillus niger NBRC 13245T (NITEN BRC), etc. For example, Salmonella enteritidis include Salmonella enteritidis 1891 (held by the Microbial Chemistry Research Society), Salmonella enteritis JCM 1652 (RIKEN BRC), etc. For example, Mycobacterium smegmatis include Mycobacterium smegmatis ATCC-607 (ATCC) etc. For example, Bacillus subtle include Bacillus subtle 168, etc. For example, Pseudomonas aeruginosa include Pseudomonas aeruginosa A3 (held by the Microbial Chemistry Research Institute), Pseudomonas aeruginosa JCM 5962 T (RIKEN BRC), etc. For example, Micrococci yellow include Micrococci yellow IFO3333 (Institute of Fermentation Research (IFO)), etc. For example, Bacteroides fragile include Bacteroides fragile JCM11019 (RIKEN BRC), etc. For example, Saccharomyces yeast include Saccharomyces yeast F-7 (held by the Microbial Chemistry Research Association), Saccharomyces yeast JCM 7255 T (RIKEN BRC), etc. For example, White albicans include White albicans 3147(IFO), etc.
[0084] (Protective agent, surfactant composition, blood sugar control composition, autophagy inducer, acid-fast bacteria staining agent or protein extracting agent) The protective agent, surfactant composition, blood sugar control composition, autophagy inducer, acid-fast bacteria stain or protein extractant of the present invention contains a compound represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and may also contain other ingredients as required. [Chemical formula 28] However, in the above general formula (1), R 1 is -NH2, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14; [Chemical formula 29] [Chemical formula 30] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
[0085] <Protective agent> The present inventors have made a concentrated study and newly discovered that the compound represented by the general formula (1) has an excellent protective effect on starch, protein, microorganisms, etc. through a moisturizing effect and a pH buffering effect near neutrality, and can be used as a protective agent for them. Specifically, the protective agent has various excellent effects such as the effect of inhibiting starch aging, the effect of preventing or inhibiting the activity reduction of proteins when stored in a frozen or freeze-dried state, the effect of preventing or inhibiting the damage or killing of microorganisms when stored in a frozen or freeze-dried state, etc., based on the moisturizing effect and the pH buffering effect near neutrality of the compound represented by the general formula (1), and can be used as a starch aging inhibitor, a protein protective agent, a microorganism protective agent, a pH buffer, etc.
[0086] <<Starch Retrogradation Inhibitors>> The elastic modulus of starch in starch-containing foods varies over time during their manufacturing process, and stabilization requires time, so there is a problem that starch-containing foods are uneven and difficult to fix in quality. In addition, due to the aging of starch, the deterioration of food texture (losing of softness, moistness, etc.) has become a problem. In order to solve the above problems, a method has been proposed to use at least one of glucose, mannose and galactose as a natural polysaccharide or its decomposition product as a sugar to inhibit starch swelling, prevent gelatinization and the resulting food adhesion and taste deterioration (see Japanese Patent Publication No. 5-276882). However, the anti-aging effect of this method is not satisfactory. In view of this, the present inventors have conducted intensive research and newly discovered that the compound represented by the above general formula (1) has an excellent starch retrogradation inhibitory effect.
[0087] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the starch retrogradation inhibitor is R 1 A compound wherein -NH2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
[0088] In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0089] The total content of the compound (4-trehalosamine) represented by the general formula (1) in the above-mentioned starch retrogradation inhibitor, or a pharmaceutically acceptable salt thereof, or a solvate thereof is not particularly limited and can be selected as appropriate according to the purpose. The above-mentioned starch retrogradation inhibitor can be the compound represented by the general formula (1) itself.
[0090] - Other ingredients - Other ingredients in the above-mentioned starch retrogradation inhibitor can be selected as appropriate according to the purpose, and there is no particular limitation as long as they do not destroy the effect of the present invention, such as amino acids such as sodium L-aspartate; nucleic acids such as disodium 5'-inosinate; condiments represented by organic acids such as monopotassium citrate and inorganic salts such as potassium chloride; mustard extract, mustard extract, kojic acid and other day-lasting enhancers; preservatives such as glycoprotein extract, polyricin, sorbic acid; enzymes such as α, β-amylase, α, β-glucosidase, dog protease; pH adjusters such as citric acid, fumaric acid, succinic acid; sucrose fatty acid esters, glycerol fatty acid esters, organic acid monoglycerides. Emulsifiers such as esters and lecithin; flavors, pigments, water-soluble soybean polysaccharides, carrageenan, xanthan gum, hot gum, native selan gum, sodium alginate, agar, konjac, pectin, codfish gum, karaya gum, tragacanth gum, gati gum, lanzan gum, welan gum, karan, zhulan, salim seed gum and other thickening polysaccharides; bulking agents; proteins such as whey protein and soy protein; sugars such as sucrose, fructose, reduced starch saccharide, erythritol, xylitol; sweeteners such as sucralose, thaumatin, acesulfame potassium, aspartame; vitamins such as vitamin A, vitamin C, vitamin E, vitamin K; minerals such as iron and calcium, etc. In addition, there are additives described in "-Preparation form-" of "<Blood sugar control composition>" described later. One type can be used alone, or two or more types can be used simultaneously.
[0091] The content of other components in the starch retrogradation inhibitor can be appropriately selected according to the purpose and is not particularly limited as long as the effects of the present invention are not impaired.
[0092] -use- The starch retrogradation inhibitor contains the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and therefore can be added to starch-containing foods to play an excellent starch retrogradation inhibitory effect, and can be preferably used as a quality improver for starch contained in starch-containing foods. Therefore, the present invention also relates to a starch quality improver characterized by containing the starch retrogradation inhibitor, a preparation method thereof, and food and beverages and a preparation method thereof.
[0093] The above-mentioned foods containing starch are not particularly limited as long as they are foods containing starch, for example, breads such as white bread and sweet bread; noodles such as soba, udon noodles, vermicelli, dumpling wrappers, siomai wrappers, Chinese noodles, instant noodles, etc.; seasoning sauces such as white sauce and milk sauce; cakes such as sponge cake, butter cake, and fruit cake; donuts; wrappers for dumplings, siomai, spring rolls, wontons, etc.; steamed dim sum, Chinese steamed buns, steamed buns, etc.; croquettes, okonomiyaki, takoyaki, taiyaki, Imagawayaki, daifuku, dango, rice flour cake, vermicelli, Mitarashi dango sauce, egg custard, batter, and a variety of other foods, etc.
[0094] <<Protein Protectant>> Proteins such as enzymes and antibodies are useful as medicines, diagnostic drugs, and various reagents, but they have the property of losing their activity due to physical and chemical denaturation, and special care is required for their long-term storage. Generally, aqueous solutions of enzymes and antibodies are frozen and stored at low temperatures, or freeze-dried and stored in a dry state (solid). However, some enzymes and antibodies lose their activity when frozen or freeze-dried. Therefore, in order to prevent the activity from decreasing during storage, (1) Erwinia Belong to or Xanthomonas Cryoprotectants such as cryoprotectants produced by microorganisms (see Japanese Patent Publication No. 2001-139599), silkworm-derived sericin (see Japanese Patent Publication No. 2002-101869), (3) plant-derived protein dehydrogenase protein and its partial peptides (see Protein Science, 2011, January; 20(1): 42-50), (4) Poaceae-derived antifreeze proteins Wcs19 and Wcor410 (see U.S. Patent No. 5,731,419), (5) bovine serum albumin (BSA), and (6) human serum albumin (HSA) have been developed and utilized.
[0095] When using enzymes and antibody proteins as biopharmaceuticals, it is necessary to consider the risk of cryoprotectants causing immune responses in the human body, causing side effects such as inflammation and allergic reactions. There is a problem with the above (1) to (5), that is, they are proteins from non-human organisms and are not suitable as additives for human medicines. HSA in the above (6) already has medicinal effects as a blood preparation, so its use as a pharmaceutical additive is limited. In addition, plasma preparations of HSA have the risk of medical accidents such as mixing with viruses. In addition, recombinant HSA has the disadvantage of high cost. Therefore, people are looking forward to providing protein protectants that are highly versatile and suitable for human medicine. In view of this, the present inventors have devoted themselves to research and have newly discovered that the compound represented by the above general formula (1) has high safety and good protein protection activity.
[0096] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the above protein protecting agent is R 1 A compound wherein -NH2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
[0097] In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0098] The total content of the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned protein protecting agent is not particularly limited and can be appropriately selected according to the purpose. The above-mentioned protein protecting agent can be the compound represented by the general formula (1) itself.
[0099] The above protein protective agent can prevent or inhibit the decrease of protein activity (including loss of activity) as the protein is frozen or lyophilized. Therefore, the application of the above protein protective agent in the freezing or lyophilization process of the protein reduces the impact of freezing or lyophilization, thereby making the activity of the protein after being stored in a frozen or lyophilized state higher than that without the application of the above protein protective agent.
[0100] As long as the effect of the present invention is not impaired, the conditions for the freezing are not particularly limited. The protein to which the protein protective agent is applied (protection target) can be mixed with the protein protective agent and then frozen as usual. The freezing can be performed at -20°C to -160°C (using liquid nitrogen, etc.), at a room temperature of 35°C or below, 1.0×10 -1 Freeze-drying was performed under a vacuum of about torr.
[0101] - Other ingredients - Other components in the above-mentioned protein protective agent can be appropriately selected according to the purpose, and there are no particular restrictions as long as they do not destroy the effects of the present invention, such as the additives described in "-Preparation form-" of "<Blood sugar controlling composition>" described later.
[0102] The content of other components in the above-mentioned protein protecting agent is not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose.
[0103] -use- The amount of the protein protecting agent added to the protein is not particularly limited unless the effects of the present invention are impaired, and can be appropriately selected according to the purpose.
[0104] Since the above protein protective agent contains the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and is frozen or freeze-dried together with various proteins, the above proteins can be conveniently protected (preventing or inhibiting the reduction of protein activity (including loss of activity)), and is also suitable for reagents for protecting proteins in clinical or research sites, as well as methods for protecting and preserving proteins. Therefore, the present invention also relates to a protein protection method, a protein preservation method, and a protein-containing composition characterized by containing the above protein protective agent.
[0105] The proteins to which the above-mentioned protein protective agent is applicable (protected object) are not particularly limited and can be selected as appropriate according to the purpose, for example, enzymes such as digestive enzymes (such as amylase, lipase, cellulase, etc.), proteases (such as pepsin, trypsin, chymotrypsin, papaine, bromelain, coagulation factor Xa, etc.), glycolytic enzymes (such as galactosidase, lactase, saccharifying enzyme (ADH), etc.), dephosphorylating enzymes (such as alkaline phosphatase (CIP)), nucleases (such as DNaseI, RNaseH, etc.), restriction enzymes (EcoRI, NotI, etc.); antibodies such as polyclonal antibodies and monoclonal antibodies or their fragments.
[0106] The above-mentioned protein protective agent is not only applicable to single proteins, but also to the protection of various structures with proteins as components (complex proteins such as glycoproteins, lipoproteins, nucleoproteins, phosphoproteins, cells, tissues, etc.) during freezing or freeze-drying.
[0107] <<Microbial protection agent>> Microorganisms used in research and added to diets, etc., have the property of being damaged or dead due to physical and chemical denaturation, and their long-term storage requires special care. As in the case of the above-mentioned protein, the culture solution containing the microorganism is generally frozen and stored at low temperature, or freeze-dried and stored in a dry state (solid). However, some microorganisms are damaged or killed when frozen or freeze-dried. Therefore, in order to prevent the activity from decreasing during storage, protective agents such as skim milk, sodium glutamate, gelatin and sucrose (see, for example, JP-B 53-8792), phenylalanine, histidine, citric acid, succinic acid, tartaric acid and carbonate (see, for example, JP-A 61-265085), lactose, trehalose, skim milk powder, sorbitol, sodium ascorbate (such as Ana S. Carvalho et al. Relevant factors for the preparation of freeze-dried lactic acid bacteria. International Dairy Journa 1.14(10):835-847, 2004) have been developed and used.
[0108] However, even with these protective agents, the damage or killing of microorganisms during the freezing and freeze-drying process cannot be effectively suppressed, and it is also very difficult to prepare high-concentration and stable frozen or freeze-dried microorganisms. Especially when the microbial dispersion and the protective substances assimilated by the microorganisms are mixed during microbial preparation, if the freezing operation is not carried out quickly at the lowest possible temperature, the acid produced by the active metabolism of the microorganisms will cause the pH value of the bacterial dispersion that should be frozen to decrease, and the survival rate will be significantly reduced. In addition, the pH value of the microbial dispersion during freezing has a significant impact on the damage or killing of microorganisms during thawing or freeze-drying. Therefore, it is necessary to pay full attention to the pH value of the microbial dispersion before freezing, and neutralize it with alkali or the like according to the specific situation. Therefore, people have always hoped to provide a microbial protective agent that is highly versatile and can prevent the damage or killing of microorganisms when the microorganisms are frozen or freeze-dried. In this regard, the present inventors have devoted themselves to research and have newly discovered that the compound represented by the above general formula (1) has good microbial protection activity, is highly versatile, and will not be assimilated by microorganisms.
[0109] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the above-mentioned microorganism protection agent is R 1 A compound wherein -NH2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
[0110] In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0111] The total content of the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned microorganism protection agent is not particularly limited and can be appropriately selected according to the purpose. The above-mentioned microorganism protection agent can be the compound represented by the general formula (1) itself.
[0112] The above-mentioned microbial protective agent can prevent or inhibit the microorganisms from being damaged or killed during freezing or freeze-drying. Therefore, if the above-mentioned microbial protective agent is applied to the freezing or freeze-drying process of microorganisms, the impact of freezing or freeze-drying can be reduced, so that the survival rate of microorganisms after being stored in a frozen or freeze-dried state is higher than that without the application of the microbial protective agent. In addition, regarding the freezing conditions, freezing can be performed under the same conditions as those described in the above-mentioned item “<<Protein Protectant>>” except that “protein” is changed to “microorganism”.
[0113] - Other ingredients - The other components in the above-mentioned microorganism protection agent are not particularly limited as long as they do not impair the effects of the present invention, and can be appropriately selected according to the purpose, such as the additives described in "-Preparation Form-" of "<Blood Glucose Control Composition>" described later. One type can be used alone, or two or more types can be used simultaneously.
[0114] The content of other components in the microorganism protecting agent is not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose.
[0115] -use- Since the above-mentioned microorganism protective agent contains the compound (4-trehalosamine) represented by the above-mentioned general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and is frozen or freeze-dried together with various microorganisms, the microorganisms can be conveniently protected (preventing or inhibiting microorganism damage or killing), and is also suitable for agents for protecting microorganisms in clinical or research sites, as well as methods for protecting and preserving microorganisms. Therefore, the present invention also relates to: a method for protecting microorganisms, a method for preserving microorganisms, and a composition containing microorganisms characterized by containing the above-mentioned microorganism protective agent.
[0116] There are no particular restrictions on the microorganisms to which the microorganism protective agent can be applied (protected objects), and they can be appropriately selected according to the purpose. For example, Escherichia Microorganisms of the genus (e.g. Escherichia coli wait), Saccharomyces Microorganisms of the genus (e.g. Saccharomyces cerevisiae wait), Propionibacterium Microorganisms of the genus (e.g. Propionibacterium freudenreichii wait), Bacillus Microorganisms of the genus (e.g. Bacillus subtilis wait), Penicillium Microorganisms of the genus (e.g. Penicillium roquefortii wait), idobacterium Microorganisms of the genus (e.g. Bifidobacterium bifidum、Bifidobacterium breve、 Bifidobacterium longum subsp. Infantis, Bifidobacterium longum, Bifidobacterium of a young man wait), Lactobacillus Microorganisms of the genus (e.g. Lactobacillus casei wait), Streptomyces Microorganisms of the genus (e.g. Streptomyces griseus、Streptomyces kanamyceticus wait), Mycobacterium Microorganisms of the genus (e.g. Mycobacterium smegmatis etc.
[0117] The microorganisms to which the above-mentioned microorganism protective agent is applicable (the object of protection) may be commercially available products, microorganisms possessed by the applicant, or newly isolated strains of the above-mentioned genus and species of microorganisms. For example, Saccharomyces yeast include Saccharomyces yeastF-7 (held by the Microbial Chemistry Research Association), Saccharomyces yeast JCM 7255 T et al. For example, Escherichia coli include Escherichia coli K-12 (held by the Microbial Chemistry Research Society), Escherichia coli K-12 (National Biological Resources Program (NBPR)), etc.
[0118] <<pH Buffer>> The present inventors have made intensive studies and have newly discovered that the compound represented by the general formula (1) has an excellent pH buffering effect.
[0119] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the pH buffer is R 1 A compound wherein -NH2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
[0120] In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0121] The total content of the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the pH buffer is not particularly limited and can be appropriately selected according to the purpose. The pH buffer may be the compound represented by the general formula (1) itself.
[0122] - Other ingredients - Other components in the above-mentioned pH buffer can be appropriately selected according to the purpose, and are not particularly limited as long as they do not impair the effects of the present invention, such as the additives described in "-Preparation form-" of "<Blood sugar controlling composition>" described later.
[0123] The content of other components in the pH buffer can be appropriately selected according to the purpose, and is not particularly limited unless the effects of the present invention are impaired.
[0124] -use- The pH buffer contains the compound represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and has an excellent pH buffering effect. Therefore, the pH buffer can be used as a pH buffer in various fields such as household, medical, industrial, and agricultural use. Specific examples thereof include cleaning agents, emulsifiers, dispersants, penetrants, waste paper regeneration deinking agents, agricultural spreading agents, cosmetics, cell culture, microbial culture, plant cultivation, and acidosis therapeutic drugs. In addition, the pH buffer can also be used as a research reagent. Since the pH buffer can conveniently and efficiently inhibit pH changes, the present invention also relates to a pH adjuster characterized by containing the pH buffer, and a pH buffering method characterized by using the pH buffer.
[0125] <Surfactant composition and protein extractant> The present inventors have made intensive studies and have newly discovered that a novel compound, namely a compound represented by the general formula (1), has excellent surface activity and excellent protein extraction effect.
[0126] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the above surfactant composition and protein extractant is R 1 -NH(CH2) m CH3 and m is an integer from 7 to 14 (IMCTA-Cn), or a pharmaceutically acceptable salt thereof, or a solvate thereof. One species may be used alone, or two or more species may be used simultaneously. In the above general formula (1), R 1 -N(CH2) m The compound wherein CH3 and m is an integer between 7 and 14 is a compound (IMCTA-Cn) represented by any one of the above structural formulas (2) to (9). In the above general formula (2), R 2 -NH(CH2) m CH3 is a compound (IMCTA-Cn) represented by any one of the above structural formulas (2) to (9), and its physicochemical properties are also as described in the above item "(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)".
[0127] The total content of the compound (IMCTA-Cn) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned surfactant composition and protein extractant is not particularly limited and can be appropriately selected according to the purpose. The above-mentioned surfactant composition and protein extractant may be the compound represented by the general formula (1) itself.
[0128] - Other ingredients - Other ingredients in the above-mentioned surfactant composition and protein extractant can be selected as appropriate according to the purpose, as long as they do not destroy the effect of the present invention, they are particularly limited. Such as known surfactants such as anionic surfactants, cationic surfactants, amphoteric surfactants, oily components, polymer compounds, ultraviolet absorbers, bactericides, excipients, reinforcing agents, binders, wetting agents, disintegrators, lubricants, dispersants, buffers, preservatives, dissolution aids, flavoring deodorants, painless agents, stabilizers, hydrotropes, emulsifiers, thickeners, zeolites, phosphates, sulfates, sulfites, silicones, enzymes, re-pollution agents, bleaching agents, fluorescent agents, spices including various additives, such as materials, pigments, solvents, etc. One can be used alone, or two or more can be used simultaneously.
[0129] The anionic surfactant is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include carboxylic acid-based surfactants, sulfate-based surfactants, sulfonic acid-based surfactants, and phosphate-based surfactants.
[0130] The above cationic surfactants are not particularly limited and can be selected according to the purpose, such as higher amine salts, higher alkyl (or alkenyl) quaternary ammonium salts, higher alkyl (or alkenyl) pyridinium quaternary ammonium salts, etc.
[0131] The above-mentioned amphoteric surfactants are not particularly limited and can be selected according to the purpose, such as alkyl betaine type surfactants, alkyl amide betaine type surfactants, imidazoline type surfactants, alkyl aminosulfonic acid type surfactants, alkyl aminocarboxylic acid type surfactants, alkyl amide carboxylate type surfactants, amide amino acid type surfactants, phosphoric acid type surfactants, etc.
[0132] The content of other components in the surfactant composition can be appropriately selected according to the purpose and is not particularly limited as long as the effects of the present invention are not impaired.
[0133] -use- The surfactant composition contains the compound represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, and has excellent surface activity. Therefore, it can be used as various surfactants in the fields of household, industry, and agriculture, and specific examples thereof include: detergents, emulsifiers, dispersants, oil phase component regulators, penetrants, waste paper regeneration deinking agents, agricultural spreading agents, cosmetics, etc. In addition, the surfactant composition can also be used as a research reagent.
[0134] <Blood sugar control composition> Trehalose is used as a food additive such as a sweetener. However, since it is rapidly decomposed into glucose by trehalase in the body, there is a problem of causing blood sugar to rise. Therefore, people hope to provide a blood sugar control composition that is not decomposed in the body and does not raise blood sugar, and can also be used as a sweetener. In this regard, we have conducted intensive research and have newly discovered that the compound represented by the above general formula (1) is highly safe, does not degrade in the body, and has a good blood sugar control effect. In this detailed statement, "blood sugar control" means inhibiting the increase of individual blood sugar, maintaining normal blood sugar before blood sugar increases, etc.
[0135] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the above-mentioned blood sugar control composition is R 1 A compound wherein -NH2, or a pharmaceutically acceptable salt thereof, or a solvate thereof. In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0136] The total content of the compound (4-trehalosamine) represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned blood sugar control composition is not particularly limited and can be appropriately selected according to the purpose. The above-mentioned blood sugar control composition can be the compound represented by the general formula (1) itself.
[0137] - Other ingredients - Other components in the above-mentioned blood sugar controlling composition can be appropriately selected according to the purpose, and there are no particular restrictions as long as they do not impair the effects of the present invention, such as the additives described in "-Preparation form-" of "<Blood sugar controlling composition>" described later.
[0138] The content of other components in the above-mentioned blood sugar-controlling composition can be appropriately selected according to the purpose, and is not particularly limited as long as the effects of the present invention are not impaired.
[0139] -use- Since the blood sugar control composition contains the compound represented by the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, it will not increase blood sugar when administered to an individual, and can also be used to prevent or treat diseases caused by increased blood sugar (such as diabetes, myocardial infarction, liver cirrhosis, arteriosclerosis, etc.). Therefore, the present invention also relates to a method for preventing or treating a disease caused by increased blood sugar, a pharmaceutical composition characterized by containing the blood sugar control composition, and a method for preventing or treating a disease caused by increased blood sugar characterized by administering the blood sugar control composition to an individual.
[0140] -Preparation form- There is no particular restriction on the preparation form of the above-mentioned blood sugar control composition, which can be selected according to the purpose, such as injections mainly used for intravenous injection, intramuscular injection, etc.; oral preparations such as capsules, tablets, granules, powders, pills, fine granules, syrups, lozenges, etc.; ointments, eye drops, ear drops, nasal drops, eye ointments, skin and mucosal absorption agents, external medications, inhalants, suppositories, etc. non-oral external medications; other dry powders; nebulized aerosol formulations, etc.
[0141] The above-mentioned preparations can be produced by common methods using additives such as excipients, enhancers, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, dissolution aids, preservatives, flavoring agents, soothing agents, stabilizers, and the like. Specific examples of the above-mentioned additives include, for example, solubilizers or dissolution aids (distilled water for injection, physiological saline, ethanol, glycerol, propylene glycol, corn oil, sesame oil, etc.), pH adjusters (inorganic acid added salts, such as trisodium orthophosphate, sodium bicarbonate, etc.; organic acid salts such as sodium citrate; organic alkaline salts such as L-lysine, L-arginine, etc.), isotonic agents (sodium chloride, glucose, glycerol, etc.), buffers (sodium chloride, benzalkonium chloride, sodium citrate, etc.), surfactants (sorbitan monooleate, polysorbate 80, etc.), dispersants (D-mannitol, etc.), stabilizers (antioxidants such as ascorbic acid, sodium sulfite, sodium metabisulfite; chelating agents such as citric acid, tartaric acid, etc.), etc., which can constitute aqueous or time-soluble dosage forms in injections, eye drops, ear drops and nasal drops. For example, in eye ointments, skin mucosal absorption agents and external preparations, as appropriate formulation ingredients for ointments, creams and transdermal patches (white vaseline, macrogol, glycerin, liquid paraffin, cotton cloth, etc.), etc. For example, liquid inhalants include pH adjusters (sodium citrate, sodium hydroxide, etc.), isotonic agents (sodium chloride, benzalkonium chloride, sodium citrate, etc.), buffers (sodium chloride, benzalkonium chloride, sodium citrate, etc.), and the like. For example, powder inhalation includes lactose or the like as a carrier. For example, oral preparations and suppositories include excipients (lactose, D-mannitol, corn starch, crystalline cellulose, etc.), disintegrants (carboxymethyl cellulose, carboxymethyl cellulose calcium, etc.), binders (hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, etc.), lubricants (magnesium stearate, talc, etc.), coating agents (shellac, hydroxypropyl methyl cellulose, white sugar, titanium oxide, etc.), plasticizers (glycerol, polyethylene glycol, etc.), bases (cocoa butter, polyethylene glycol, hard fat, etc.), etc.
[0142] - Medication - There are no particular restrictions on the administration route, dosage, administration time and administration object of the above-mentioned blood sugar control composition, and they can be selected as appropriate according to the purpose. The above-mentioned administration route is not particularly limited, and can be administered orally or parenterally, depending on the pathogenic bacteria, the type of disease, the nature of the subject being administered, etc. The above-mentioned parenterally administered route includes, for example, intravenous injection, intramuscular injection, subcutaneous administration, rectal administration, transdermal administration, topical administration to the eye, and transpulmonary administration. There is no particular limitation on the above dosage, and it can be selected based on a variety of factors, such as usage, type of pathogens, age, sex, weight, constitution, severity of disease, whether drugs or pharmaceuticals with other ingredients as active ingredients are used, etc. When administered orally to humans, for example, an adult can be administered within the range of 100 mg / kg to 2,000 mg / kg per day, and when administered intravenously, it can also be administered within the range of 100 mg / kg to 2,000 mg / kg. The above administration time is not particularly limited and can be appropriately selected according to the purpose. The animal species of the above-mentioned administration subjects are not particularly limited and can be appropriately selected according to the purpose, for example, humans, monkeys, pigs, cattle, sheep, goats, dogs, cats, mice, rats, chickens, etc., among which humans can also be preferably used.
[0143] <Autophagy Inducers> Autophagy refers to a series of processes in which the isolation membrane produced at the contact site of the endoplasmic reticulum / mitochondria in the cell encapsulates the substrate to form a double-membrane structure called an autophagosome, which fuses with the lysosome (which contains hydrolases inside) to form a single-membrane autophagosome, and the internal substrate is decomposed. It has been found that autophagy plays a fundamental role in various physiological and even pathological functions of cells. During its research, many diseases are believed to be caused by abnormal autophagy. Known substrates of autophagy include α-synuclein (Syn) that causes neurodegeneration such as Parkinson's disease and huntingtin (Htt) that causes Huntington's disease. Trehalose is known to have autophagy inducing activity. However, as mentioned above, since it is rapidly decomposed into glucose by trehalase in the body, the amount added as a pharmaceutical is limited, and there is a problem that it is difficult to fully exert the autophagy inducing activity. Therefore, it is desired to provide an autophagy inducer that does not decompose in the body and has excellent autophagy inducing activity. In this regard, we have conducted intensive research and have newly discovered that the compound represented by the above general formula (1) is highly safe, is not degraded in the body, and has good autophagy inducing activity.
[0144] The induction of autophagy can be confirmed by conventional methods, for example, methods using known autophagy markers to confirm by Western blotting, immunostaining, PCR, etc.
[0145] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the above-mentioned autophagy inducer is R 1 -NH2 or -NH(CH2) m A compound wherein CH3, m is an integer between 7 and 14, or a pharmaceutically acceptable salt thereof, or a solvate thereof. One species may be used alone, or two or more species may be used simultaneously.
[0146] In the above general formula (1), R 1 The compound which is -NH2 is the compound represented by the structural formula (1) in the above-mentioned "(Method for preparing 4-trehalosamine)", and its physicochemical properties are also as described in the above-mentioned "(Method for preparing 4-trehalosamine)".
[0147] In the above general formula (1), R 1 -N(CH2) m CH3 and m is an integer between 7 and 14, which is the compound of the general formula (2) in the above-mentioned "(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)" 2 -NH(CH2) m The compound (IMCTA-Cn) represented by any one of the structural formulas (2) to (9) of CH3 has the same physicochemical properties as described in the above-mentioned "(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)".
[0148] The total content of the compound represented by the general formula (1) (4-trehalosamine or IMCTA-Cn), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned autophagy inducer is not particularly limited and can be selected as appropriate according to the purpose. The above-mentioned autophagy inducer can be the compound represented by the general formula (1) itself.
[0149] - Other ingredients - Other components in the above-mentioned autophagy inducer can be appropriately selected according to the purpose, and there are no particular restrictions as long as they do not destroy the effects of the present invention, such as the additives described in "-Preparation form-" of the above-mentioned "<Blood sugar control composition>".
[0150] The content of other components in the above-mentioned autophagy inducer can be appropriately selected according to the purpose, and is not particularly limited as long as the effects of the present invention are not impaired.
[0151] -use- Since the above-mentioned autophagy inducer contains the compound (4-trehalose amine or IMCTA-Cn) shown in the general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof, it is highly safe and will not degrade in vivo, so it is convenient to administer the drug over a long period of time. Therefore, the above-mentioned autophagy inducer can effectively prevent or treat various diseases or symptoms caused by abnormal autophagy, such as neurodegenerative diseases (Alzheimer's disease, Huntington's disease, Parkinson's disease, etc.), lung disease, amyotrophy, muscle disease, cardiomyopathy, brain swelling, fatigue, lack of sleep or fear of cold and other diseases or symptoms. Therefore, the present invention also relates to a composition for preventing or treating diseases caused by abnormal autophagy characterized by containing the above-mentioned autophagy inducer, and a method for preventing or treating diseases caused by abnormal autophagy characterized by using the above-mentioned autophagy inducer.
[0152] <Acid-fast bacteria stain> Acid-fast bacteria are a type of Gram-positive rods that are acid-resistant. Because they are pathogenic bacteria and can cause serious lesions, their examination is of vital importance in clinical practice. The above-mentioned acid-fast bacteria stain can dye acid-fast bacteria. The above-mentioned acid-fast bacteria have a rice cholic acid layer containing trehalose monocholic acid (TMM) and a rice cholic acid layer containing trehalose dicholic acid (TDM) as a cell wall component. The above-mentioned acid-fast bacteria protect themselves outside the arabinogalactose outside the cell wall (peptidoglycan), that is, at the outermost periphery. The above-mentioned rice cholic acid layer is combined with the internal arabinogalactose, and rice cholic acid is combined with trehalose. The above-mentioned acid-fast bacteria stain can appropriately dye acid-fast bacteria by replacing trehalose in the rice cholic acid layer of acid-fast bacteria. In addition, in this specification, "staining" means visualizing acid-fast bacteria by some method, which is also equivalent to "marking". Therefore, the above-mentioned acid-fast bacteria staining agent is also an acid-fast bacteria marking agent.
[0153] The acid-fast bacteria to be stained by the acid-fast bacteria staining agent are not particularly limited and can be appropriately selected according to the purpose, including: Mycobacterium smegma , Mycobacterium of birds , Mycobacterium intracellular , Mycobacterium Kansas , Mycobacterium xenopus , Mycobacterium scrofulous , Mycobacterium gordonii , Mycobacterium szulgai , Mycobacterium chance , Mycobacterium turtles , Mycobacterium hemophiliac , Mycobacterium marine , Mycobacterium shinjukuense , Mycobacterium tuberculosis , Mycobacterium leprosy , Mycobacterium abscess wait.
[0154] - Compound represented by general formula (1) - The compound represented by the general formula (1) contained in the acid-fast bacteria stain is R 1 A compound having a substituent represented by the structural formula (A) or a substituent represented by the structural formula (B), or a pharmaceutically acceptable salt thereof, or a solvate thereof. One type may be used alone, or two or more types may be used simultaneously.
[0155] The compound in which R1 in the compound represented by the above general formula (1) is a substituent represented by the structural formula (A) is the compound (IMCTA-fluorescein) represented by the structural formula (10) in the above-mentioned “(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)” item, and the structural formula (10) is the general formula (2) in which R2 is a substituent represented by the structural formula (A), and its physicochemical properties are also as described in the above-mentioned “(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)” item.
[0156] In the compound represented by the above general formula (1), R 1 The compound having a substituent represented by the structural formula (B) is the compound (IMCTA-biotin) represented by the structural formula (11) in the above-mentioned item "(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)", and the structural formula (11) is R in the general formula (2) 2 It is a substituent represented by structural formula (B), and its physicochemical properties are also as described in the above-mentioned item "(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)".
[0157] The total content of the compound represented by the general formula (1) (IMCTA-fluorescein or IMCTA-biotin), or a pharmaceutically acceptable salt thereof, or a solvate thereof in the above-mentioned acid-fast bacteria stain is not particularly limited and can be appropriately selected according to the purpose. The above-mentioned acid-fast bacteria stain can be the compound represented by the general formula (1) itself.
[0158] - Other ingredients - Other components in the above-mentioned acid-fast bacteria stain can be appropriately selected according to the purpose, and there are no particular restrictions as long as they do not destroy the effects of the present invention, such as the additives described in "-Preparation form-" of the above-mentioned "<Blood sugar control composition>". In addition, in the above-mentioned item “(new compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof)”, R in the above-mentioned general formula (3) 3The compound represented by the structural formula (12) which is -N3 (IMCTA-azide) can also stain acid-fast bacteria, and therefore can be contained as another component of the acid-fast bacteria staining agent.
[0159] The content of other components in the acid-fast bacteria stain can be appropriately selected according to the purpose, and is not particularly limited unless the effects of the present invention are impaired.
[0160] -use- The above-mentioned acid-fast bacteria stain contains the compound (IMCTA-fluorescein or IMCTA-biotin) shown in general formula (1), or its pharmaceutically acceptable salt, or its solvate, so that it can be easily and efficiently stained with acid-fast bacteria by culturing with acid-fast bacteria. Therefore, it is also suitable for reagents and detection methods for clinical and research on-site acid-fast bacteria detection. Therefore, the present invention also relates to an acid-fast bacteria detection reagent characterized by containing the above-mentioned acid-fast bacteria stain, and an acid-fast bacteria detection method characterized by the term above-mentioned acid-fast bacteria stain.
[0161] (microorganism) The microorganism of the present invention is Streptomyces sp.MK 186-mF5 (trust number: NITE BP-03495), has the ability to produce 4-trehalosamine. Above Streptomyces sp.MK186-mF5 (MK186-mF5) was isolated from soil in Japan by the Microbial Chemistry Research Institute of the Public Interest Foundation Streptomyces strains of the genus.
[0162] The partial base sequence (1,446 bp) of the 16S rRNA gene of the MK186-mF5 strain was determined and compared with the data of known strains registered in the DNA database. The results showed that the base sequence of the MK186-mF5 strain was the base sequence shown in sequence number: 1, which is similar to Streptomyces cirratus The 16S rRNA gene of Streptomyces cirratus NRRL B-3250 (Accession No. AY999794) had an identity of 99.72% (1,439 / 1,443).
[0163] Based on the above results, it can be considered that MK186-mF5 is Streptomyces Therefore, it is named Streptomyce sp.MK186-mF5. In addition, an application for international deposit of the MK186-mF5 strain was made to the Patent Microorganism Collection Center of the Institute of Technology for Product Evaluation (Room 122, 2-5-8 Kazusa Kamata, Kisarazu-shi, Chiba Prefecture), and it was deposited as MK186-mF5 on July 9, 2021.
[0164] In addition, it can also be found in other strains that the properties of the MK186-mF5 strain are easily changed, but mutant strains derived from the MK186-mF5 strain (such as artificial mutant strains that can be obtained through mutation treatments such as ultraviolet rays, X-rays, radiation, drugs, etc.), trait zygotes, genetically modified organisms, etc., that have the ability to produce 4-trehalosamine are all included in the microorganisms of the present invention. Example
[0165] The present invention is specifically described by the following manufacturing examples, synthesis examples and examples of the present invention, but is not limited to these manufacturing examples, synthesis examples and test examples. In addition, unless otherwise stated, the "%" in the following manufacturing examples, synthesis examples and test examples means "mass %".
[0166] (Production Example 1: Production of 4-trehalosamine 1) <Preparation of Ko medium> The following components were added to sterile water to give the following final concentrations (%) to prepare a "Ko medium" having a pH of 7.2. [composition]
[0167] <Cultivation process> 30 mL of the prepared Ko medium was placed in a flask (capacity 100 mL), and Streptomyces p. MK186-mF5 (trust number: NITE BP-03495) was planted in the medium, and cultured with shaking at 27° C. and 220 rpm for 12 days.
[0168] (Production Example 2: Production of 4-trehalosamine 2) <Preparation of Modified KO Medium 1> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 1" with a pH of 7.2. "Modified Ko Medium 1" is a composition in which the soluble starch concentration of the "Ko Medium" in Production Example 1 was doubled. [composition]
[0169] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 1".
[0170] (Production Example 3: Production of 4-trehalosamine 3) <Preparation of Modified KO Medium 2> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 2" at pH 7.2. "Modified Ko Medium 2" is a composition in which the soluble starch in the "Ko Medium" in Production Example 1 was changed to glucose. [composition]
[0171] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to the "Modified Ko medium 2".
[0172] (Production Example 4: Production of 4-trehalosamine 4) <Preparation of Modified KO Medium 3> The following components were added to sterilized water to give the following final concentrations (%) to prepare "Modified Ko Medium 3" at pH 7.2. "Modified Ko Medium 3" was a composition obtained by replacing EBIOS (beer yeast) of the "Ko Medium" in Production Example 1 with baker's yeast. [composition]
[0173] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 3".
[0174] (Production Example 5: Production of 4-trehalosamine 5) <Preparation of Modified KO Medium 4> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 4" with a pH of 7.2. "Modified Ko Medium 4" was a composition obtained by further adding zinc chloride to the "Ko Medium" in Preparation Example 1. [composition]
[0175] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 4".
[0176] (Production Example 6: Production of 4-trehalosamine 6) <Preparation of Modified KO Medium 5> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 5" having a pH of 7.2. "Modified Ko Medium 5" is a composition obtained by removing magnesium sulfate heptahydrate from the "Ko Medium" in Production Example 1. [composition]
[0177] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 5".
[0178] (Production Example 7: Production of 4-trehalosamine 7) <Preparation of Modified KO Medium 6> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 6" with a pH of 7.2. "Modified Ko Medium 6" is a composition in which the calcium carbonate concentration of the "Ko Medium" in Preparation Example 1 was changed to 1 / 10. [composition]
[0179] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 6".
[0180] (Production Example 8: Production of 4-trehalosamine 8) <Preparation of Modified KO Medium 7> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 7" with a pH of 7.2. "Ko Medium 7" is a composition in which the dipotassium hydrogen phosphate and potassium dihydrogen phosphate of the "Ko Medium" in Production Example 1 were replaced with potassium chloride. [composition]
[0181] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 7".
[0182] (Production Example 9: Production of 4-trehalosamine 9) <Preparation of Modified Ko Medium 8> The following components were added to sterilized water to give the following final concentrations (%) to prepare "Modified Ko Medium 8" having a pH of 7.2. [composition]
[0183] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to "Modified Ko medium 8".
[0184] -Purification process- pass Streptomyce Most of the 4-trehalosamine obtained by the cultivation of sp.MK 186-mF5 is released into the culture solution after the cultivation. Therefore, 8 L of the culture solution obtained in the above <Cultivation Process> was filtered with filter paper to remove the bacterial cells and recover the filtrate. The obtained filtrate was adjusted from pH 8.2 to 2.0 using a 1M hydrochloric acid aqueous solution, and then supplied to a 200 mL carbon column (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) to recover the passing fraction. The carbon column was washed once with 1L of water, and the washed fraction was also recovered. The above-mentioned passing fraction and the washed fraction were mixed and supplied to a 250 mL column (DOWEXTM50W×4, 50-100 mesh, strongly acidic cation exchange resin, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.). The column was washed once with 1.25L of water, and 4-trehalosamine was eluted with 0.1M ammonium hydroxide (NH4OH). The eluate was concentrated by an evaporator and supplied to a 1 L column (weakly acidic cation exchange resin FPC3500, manufactured by Organo Co., Ltd.). The column was washed once with 5 L of water and eluted with 0.1 M ammonium hydroxide (NH4OH). The eluate was concentrated by an evaporator and centrifuged, and the supernatant was vacuum filtered and freeze-dried to obtain a purified 4-trehalosamine.
[0185] (Production Example 10: Production of 4-trehalosamine 10) <Preparation of modified Ko medium 9> The following components were added to sterile water to give the following final concentrations (%) to prepare "Modified Ko Medium 9" having a pH of 7.2. [composition]
[0186] <Cultivation process> In the <Cultivation process> of Production Example 1, the culture was carried out in the same manner as in Production Example 1 except that the "Ko medium" was changed to the "Modified Ko medium 9".
[0187] (Production Example 11: Production of 4-trehalosamine 11) <Cultivation process> In a large-scale culture apparatus (MPF-U3 type 200L, produced by Maruhishi Bio Co., Ltd.), 130L of the culture medium to which a defoaming agent (0.05% KS-496A, produced by Shin-Etsu Chemical Co., Ltd.) was added, and the "modified Ko medium 8" prepared in Preparation Example 9 was placed. Streptomyce sp.MK186-mF5 was inoculated into a culture medium, and cultured at 27°C with an air supply of 100 NL / min and stirring at 370 rpm for 10 days to obtain a culture (first culture). Next, 140 L of the culture medium to which a defoaming agent (0.05% KS-496A, manufactured by Shin-Etsu Chemical Co., Ltd.) was added was placed in the "Modified Ko Medium 8" prepared in Preparation Example 9 in the large culture apparatus. Streptomyces sp.MK186-mF5 was inoculated in a culture medium and cultured at 27°C with an air supply of 100 NL / min and stirring at 370 rpm for 10 days (first culture).
[0188] -Purification process- By the same method as described in the purification process of Production Example 9, more than 520 g of purified 4-trehalosamine was obtained from the culture broth obtained from the first culture and the second culture.
[0189] -Physicochemical properties of the compound represented by structural formula (1) (4-trehalosamine)- The physicochemical properties of 4-trehalosamine obtained in Preparation Example 9 are as follows. Streptomyce The compound obtained by culturing sp.MK186-mF5 is 4-trehalosamine represented by the following structural formula (1). The compounds obtained in Production Examples 1-8, 10 and 11 also have the same physicochemical properties. (1) Appearance: White powder (2) Molecular formula: C 12 H 24 NO 10 In addition, it is a monohydrate in the normal state, which is expressed as C in elemental analysis. 12 H 24 NO 10 ·H2O. (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 342.1397 (M+H) + Calculated value: m / z 342.1400 (as C 12 H 24 NO 10 ) (4) Elemental analysis: Experimental values: C40.27±0.06%, H6.91±0.02%, N3.81±0.01% (n=3, mean±SD) Calculated value (C 12 H 24 NO 10 ·H2O): C40.11%H7.01%N3.90% (5) Specific rotation: [α] D 25 = +147.5° (c = 1.065, methanol) (6) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Figure 1A and as shown below. ν max (KBr)cm -1 : 3,403, 2,929, 1,607, 1,455, 1,347, 1,149, 1,040, 987, 803, 607 (7) Proton NMR spectroscopy: The results of the measurement in 600MHz heavy water at 25℃ are as follows Figure 1B and as shown below. 1 H NMR (600MHz, D2O): 5.21 (d, J=3.7Hz, 1H, H-1), 5.18 (d, J=3.7Hz, 1H, H-1'), 3.84 (t, J=9.8Hz, 1H, H-3'), 3.84 (dd, J=12.0, 2.1Hz, 1H, H-6), 3.84 (m, 1H, H-6'), 3.82 (m, 1H, H-5'), 3.78 (m, 1H, H-5), 3.75 (dd, J=12 .0, 5.2Hz, 1H, H-6'), 3.74 (dd, J=12.0, 5.0Hz, 1H, H-6), 3.72 (t, J=9.8Hz, 1H, H-3), 3.643 (dd, J=9.8, 3, 7 Hz, 1H, H-2), 3.636 (dd, J=9.8, 3, 7Hz, 1H, H-2'), 3.44 (t, J=9.8Hz, 1H, H-4'), 2.73 (t, J=9.8Hz, 1H, H-4). (8) Carbon 13 NMR spectrum: The results of the measurement at 150MHz heavy water and 25°C are as follows Figure 1C and as shown below. 13C NMR (150MHz, D2O): 96.2 (C-1), 96.0 (C-1'), 75.6 (C-5), 75.3 (C-3'), 75.2 (C-3), 74. 9(C-5'),74.1(C-2),73.8(C-2'),72.5(C-4'),63.6(C-6),63.3(C-6'),55.3(C-4).
[0190] [Chemical formula 31]
[0191] -4-Purity determination of trehalose amine- About 4 to 5 mg of 4-trehalosamine obtained in the <Purification Process> of Production Example 9 or 4-trehalosamine obtained in the <Purification Process> of Production Example 11 and about 1 mg of DSS-d6 (internal standard), a certified standard substance for quantitative NMR, were accurately weighed and dissolved in about 0.75 mL of heavy water as a test solution. The test solution was measured under the following conditions. 1 H(n=3). [NMR quantitative analysis conditions] · Apparatus: Varian NMR System 500 [Varian, Inc.] (hydrogen nucleus 500 MHz-NMR) Observation center and observation width: δ2ppm±20ppm Receiving time: 4.0 seconds Pulse angle: 90° Waiting time: 60 seconds Cumulative time: 16 times ·Measurement temperature: 50℃ Virtual scan: 2 times Rotation: Off · 13 C decoupling: open
[0192] The quantitative value of 4-trehalosamine was calculated according to the following formula. [Mathematical formula 1] Sample quantitative value (%) = (In the above calculation formula, "specimen" refers to 4-trehalosamine, "area intensity ratio (specimen)" refers to the area intensity ratio of each signal derived from the specimen, "area intensity ratio (internal standard)" refers to the area intensity ratio of each signal derived from the internal standard substance, "number of protons (internal standard)" is 9, "number of protons (specimen)" is 1, the molecular weight (specimen) is 341.311, the molecular weight (internal standard) is 224.360, the collected amount represents the value of the order of 0.1 μg weighed with an ultra-microbalance (MSE2.7 s-000-DM, manufactured by Sartoriu) (n = 3), and the purity (internal standard) is 92.4% compared with the certified value.)
[0193] As a result of the purity determination by the above NMR quantification, the purity of 4-trehalosamine in Production Example 9 was 92.7 ± 0.3%. Considering that the whole molecule is a monohydrate, the purity of 4-trehalosamine monohydrate was estimated to be about 97.6%. In addition, the same result was obtained for the purity of 4-trehalosamine in Production Example 11.
[0194] (Synthesis Example 1: Synthesis of IMCTA-C8) <Preparation of 4-trehalosamine aqueous solution> Dissolve 400 mg of the purified 4-trehalosamine obtained in the <Purification process> of Production Example 10 in 2 mL of water to prepare a 4-trehalosamine aqueous solution (1.11 mmol).
[0195] <Preparation of octanal solution> Dissolve 200 mg of octanal in 4 mL of 1-propanol (1-PrOH) to prepare an octanal solution (1.56 mmol).
[0196] <Preparation of sodium cyanoborohydride aqueous solution> Dissolve 4 g of sodium cyanoborohydride in 40 mL of water to prepare a sodium cyanoborohydride aqueous solution (NaCNBH3, 63.7 mmol).
[0197] <Synthesis of IMCTA-C8> Add 2 mL of the 4-trehalosamine aqueous solution to 4 mL of the octanal solution, and let it stand at room temperature (15 ± 2 °C) for 2 hours. Then, add 40 mL of the above sodium cyanoborohydride aqueous solution, and add 4 mL of 1-propanol to defoam. React directly at room temperature for 12 hours to synthesize a trehalose analog. The synthesized trehalose analog is also called "IMCTA-C8". The synthesized solution containing IMCTA-C8 was dissolved in 100 mL of LODS column (YMCGELODS-A, pore size 6 nm, particle size 150 μm, produced by YMC Co., Ltd.), and after the column and IMCTA-C8 were combined, the column was washed 3 times with 100 mL of water to remove water-soluble impurities. Then, IMCTA-C8 was eluted with 300 mL of methanol. After the solvent was dried and removed, water-methanol was used as the solvent, and HPLC purification was performed multiple times with a gradient from 100% water to 100% methanol using a reverse phase column (Hydrosphere C18, 250 mm long, 20 mm in diameter, 5 μm in particle size, 12 nm in pore size, produced by YMC Co., Ltd.). Thus, IMCTA-C8 was obtained in 129.6 mg with a yield of 25.7%. [Chemical formula 32]
[0198] -Physicochemical properties of the compound represented by structural formula (2) (IMCTA-C8)- The physicochemical properties of the obtained IMCTA-C8 are shown below: Thus, it was confirmed that the compound obtained in Synthesis Example 1 was a compound (IMCTA-C8) having the structure represented by the above structural formula (2). (1) Appearance: White powder (2) Molecular formula: C 20 H 40 NO 10 (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 454.2651 (M+H) + Calculated value: m / z 454.2652 (as C 20 H 40 NO 10 ) (4) Specific rotation: [α] D 23 = +153.3° (c = 1.015, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Figure 2A and as shown below. ν max (KBr)cm -1 : 3,389, 2,925, 2,854, 1,632, 1,462, 1,369, 1,148, 1,044, 992, 803, 606 (6) Proton NMR spectroscopy: The results measured in deuterated methanol at 600 MHz and 25 °C are as Figure 2B shown below. 1 1H NMR (600 MHz, CD3OD): δ 5.11 (d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.8 Hz, 1H), 3.74 - 3.85 (m, 6H), 3.65 - 3.69 (m, 2H), 3.48 (dd, J = 9.4, 3.8 Hz, 1H), 3.46 (dd, J = 9.8, 3.7 Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J = 10.0 Hz, 1H), 1.47 (m, 2H), 1.25 - 1.38 (m, 10H), 0.90 (t, J = 6.9 Hz, 3H). (7) Carbon-13 nuclear magnetic resonance spectrum: The results measured in deuterated methanol at 150 MHz and 25 °C are as Figure 2C shown below. 13 13C NMR (150 MHz, CD3OD): δ 95.0 × 2, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0, 63.7, 62.6, 62.1, 49.4, 33.0, 31.5, 30.7, 30.4, 28.4, 23.7, 14.4.
[0199] (Synthesis Example 2: Synthesis of IMCTA-C9) In Synthesis Example 1, except that <Preparation of octanal solution> was changed to <Preparation of nonanal solution> below, and <Synthesis of IMCTA-C8> was changed to <Synthesis of IMCTA-C9> below, the trehalose analog was synthesized in the same manner as in Synthesis Example 1. The obtained trehalose analog was also called "IMCTA-C9".
[0200] <Preparation of nonanal solution> 200 mg of nonanal was dissolved in 4 mL of 1-propanol to prepare a nonanal solution (1.41 mmol).
[0201] <Synthesis of IMCTA-C9> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except that the octanal solution was changed to a nonanal solution, IMCTA-C9 (purified product) was obtained in the same manner as <Synthesis of IMCTA-C8> of Synthesis Example 1. 138 mg of IMCTA-C9 was obtained, and the yield was 26.6%. [Chemical formula 33]
[0202] -Physical and chemical properties of the compound represented by structural formula (3) (IMCTA-C9)- The physicochemical properties of the obtained IMCTA-C9 are shown below: Thus, it was confirmed that the compound obtained in Synthesis Example 2 was a compound (IMCTA-C9) having the structure represented by the above structural formula (3). (1) Appearance: White powder (2) Molecular formula: C 21 H 42 NO 10 (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 468.2803 (M+H) + Calculated value: m / z 468.2809 (as C 21 H 42 NO 10 ) (4) Specific rotation: [α] D 23 = +155.5° (c = 1.025, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Figure 3A and as shown below. ν max (KBr)cm -1 : 3,370, 2,925, 2,854, 1,643, 1,466, 1,371, 1,148, 1,077, 1,048, 992, 942, 802, 606 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Figure 3B and as shown below. 1 H NMR (600MHz, CD3OD): 5.11 (d, J=3.7Hz, 1H), 5.09 (d, J=3.7Hz, 1H), 3.74~3.85 (m, 6H), 3.64~3.69 (m, 2H), 3.48 (dd, J=9.5, 3.7Hz, 1H), 3.46 (dd, J=9.8, 3, 7Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J=10.0Hz, 1H), 1.47 (m, 2H), 1.24~1.38 (m, 12H), 0.90 (t, J=7.1Hz, 3H). (7) Carbon 13 NMR spectrum: The results measured in deuterated methanol at 150 MHz and 25 °C are as follows Figure 3C and are shown below. 13 C NMR (150 MHz, CD3OD): 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0, 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.7×2, 30.4, 28.4, 23.7, 14.4.
[0203] (Synthesis Example 3: Synthesis of IMCTA-C10) In Synthesis Example 1, except that <Preparation of octanal solution> was changed to <Preparation of decanal solution> below and <Synthesis of IMCTA-C8> was changed to <Synthesis of IMCTA-C10> below, a trehalose analog was synthesized in the same manner as in Synthesis Example 1. The obtained trehalose analog was also called "IMCTA-C10".
[0204] <Preparation of decanal solution> Dissolve 200 mg of decanal in 4 mL of 1-propanol to prepare a decanal solution (1.28 mmol).
[0205] <Synthesis of IMCTA-C10> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except that the octanal solution was changed to a decanal solution, IMCTA-C10 (purified product) was obtained in the same manner as <Synthesis of IMCTA-C8> of Synthesis Example 1. 172.4 mg of IMCTA-C10 was obtained, and the yield was 32.2%. [Chemical formula 34]
[0206] - Physicochemical properties of the compound (IMCTA-C10) shown in structural formula (4)- The physicochemical properties of the obtained IMCTA-C10 are as follows. Thus, it was confirmed that the compound obtained in Synthesis Example 3 is the compound (IMCTA-C10) having the structure shown in the above structural formula (4). (1) Appearance: white powder (2) Molecular formula: C 22 H 44 NO 10 (3) High-resolution mass spectrometry (HRMS: ESI positive ion mode): Experimental value: m / z 482.2962 (M+H) + Calculated value: m / z 482.2965 (as C 22 H 44 NO 10 ) (4) Specific rotation: [α] D 23 = +146.0° (c = 1.010, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Figure 4A and as shown below. ν max (KBr)cm -1 : 3,372, 2,925, 2,853, 1,645, 1,466, 1,370, 1,148, 1,077, 1,042, 994, 942, 802, 607 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Figure 4B and as shown below. 1 H NMR (600MHz, CD3OD): 5.11 (d, J=3.8Hz, 1H), 5.09 (d, J=3.8Hz, 1H), 3.74~3.85 (m, 6H), 3.64~3.69 (m, 2H), 3.48 (dd, J=9.7, 3.6Hz, 1H), 3.46 (dd, J=9.7, 3, 7Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J=10.0Hz, 1H), 1.47 (m, 2H), 1.24~1.38 (m, 14H), 0.90 (t, J=7.0Hz, 3H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Figure 4C and as shown below. 13 C NMR (150MHz, CD3OD): 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0 , 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.8, 30.7×2, 30.5, 28.4, 23.7, 14.4.
[0207] (Synthesis Example 4: Synthesis of IMCTA-C11) In Synthesis Example 1, a trehalose analogue was synthesized in the same manner as in Synthesis Example 1, except that <Preparation of Octanal Solution> was changed to the following <Preparation of Undecanal Solution>, and <Synthesis of IMCTA-C8> was changed to the following <Synthesis of IMCTA-C11>. The obtained trehalose analogue is also referred to as "IMCTA-C11".
[0208] <Preparation of Undecanal Solution> 200 mg of undecanal was dissolved in 4 mL of 1-propanol to prepare an undecanal solution (1.17 mmol).
[0209] <Synthesis of IMCTA-C11> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except that the octanal solution was changed to an undecanal solution, IMCTA-C11 (purified product) was obtained in the same manner as in <Synthesis of IMCTA-C8> of Synthesis Example 1. 144.0 mg of IMCTA-C11 was obtained, and the yield was 26.2%. [Chemical Formula 35]
[0210] -Physicochemical properties of the compound (IMCTA-C11) shown in Structural Formula (5)- The physicochemical properties of the obtained IMCTA-C11 are as follows. Thus, it was confirmed that the compound obtained in Synthesis Example 4 is the compound (IMCTA-C11) having the structure shown in the above Structural Formula (5). (1) Appearance: White powder (2) Molecular formula: C 23 H 46 NO 10 (3) High-resolution mass spectrometry (HRMS: ESI positive ion mode): Experimental value: m / z 496.3110 (M+H) + Calculated value: m / z 496.3122 (as C 23 H 46 NO 10 ) (4) Specific rotation: [α] D 23 = +141.3° (c = 1.085, methanol) (5) Infrared absorption spectrum: The measurement results using infrared spectroscopy are as Figure 5A shown below. ν max (KBr) cm -1: 3,369, 2,924, 2,853, 1,467, 1,370, 1,148, 1,078, 1,048, 993, 939, 840, 802, 607 (6) Proton nuclear magnetic resonance spectrum: The results measured in deuterated methanol at 600 MHz and 25 °C are as Figure 5B shown below. 1 H NMR (600 MHz, CD3OD): 5.11 (d, J = 3.7 Hz, 1H), 5.09 (d, J = 3.7 Hz, 1H), 3.74 - 3.85 (m, 6H), 3.64 - 3.69 (m, 2H), 3.48 (dd, J = 9.5, 3.7 Hz, 1H), 3.46 (dd, J = 9.7, 3.7 Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J = 10.0 Hz, 1H), 1.47 (m, 2H), 1.24 - 1.38 (m, 16H), 0.90 (t, J = 7.1 Hz, 3H). (7) Carbon-13 nuclear magnetic resonance spectrum: The results measured in deuterated methanol at 150 MHz and 25 °C are as Figure 5C shown below. 13 C NMR (150 MHz, CD3OD): 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0, 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.8×3, 30.7, 30.5, 28.4, 23.7, 14.4.
[0211] (Synthesis Example 5: Synthesis of IMCTA-C12) In Synthesis Example 1, except that <Preparation of octanal solution> was changed to the following <Preparation of dodecanal solution>, and <Synthesis of IMCTA-C8> was changed to the following <Synthesis of IMCTA-C12>, a trehalose analog was synthesized in the same manner as in Synthesis Example 1. The obtained trehalose analog was also called "IMCTA-C12".
[0212] <Preparation of dodecanal solution> Dissolve 200 mg of dodecanal in 4 mL of 1-propanol to prepare a dodecanal solution (1.09 mmol).
[0213] <Synthesis of IMCTA-C12> IMCTA-C12 (purified product) was obtained by the same method as in <Synthesis of IMCTA-C8> in Synthesis Example 1, except that the octanal solution was replaced with a dodecanal solution. 96.0 mg of IMCTA-C12 was obtained with a yield of 17.0%. [Chemical formula 36]
[0214] -Physical and chemical properties of the compound represented by structural formula (6) (IMCTA-C12)- The physicochemical properties of the obtained IMCTA-C12 are shown below: Thus, it was confirmed that the compound obtained in Synthesis Example 5 was a compound (IMCTA-C12) having the structure represented by the above structural formula (6). (1) Appearance: White powder (2) Molecular formula: C 24 H 48 NO 10 (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 510.3278 (M+H) + Calculated value: m / z 510.3278 (as C 24 H 48 NO 10 ) (4) Specific rotation: [α] D 24 = +139.7° (c = 1.015, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig. 6A and as shown below. ν max (KBr)cm -1 : 3,371, 2,924, 2,853, 1,467, 1,370, 1,149, 1,043, 994, 942, 803, 607 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Figure 6B and as shown below. 11H NMR (600 MHz, CD3OD): δ 5.11 (d, J = 3.7 Hz, 1H), 5.09 (d, J = 3.7 Hz, 1H), 3.74 - 3.85 (m, 6H), 3.64 - 3.69 (m, 2H), 3.49 (dd, J = 9.5, 3.7 Hz, 1H), 3.46 (dd, J = 9.8, 3.7 Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J = 10.0 Hz, 1H), 1.47 (m, 2H), 1.22 - 1.41 (m, 18H), 0.90 (t, J = 7.1 Hz, 3H). (7) Carbon-13 Nuclear Magnetic Resonance Spectrum: The results measured in deuterated methanol at 150 MHz and 25 °C are as Figure 6C shown below. 13 13C NMR (150 MHz, CD3OD): δ 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0, 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.8×4, 30.7, 30.5, 28.3, 23.7, 14.4.
[0215] (Synthesis Example 6: Synthesis of IMCTA-C13) In Synthesis Example 1, except for changing <Preparation of Octanal Solution> to the following <Preparation of Tridecanal Solution> and changing <Synthesis of IMCTA-C8> to the following <Synthesis of IMCTA-C13>, a trehalose analog was synthesized in the same manner as in Synthesis Example 1. The obtained trehalose analog is also referred to as "IMCTA-C13".
[0216] <Preparation of Tridecanal Solution> Dissolve 200 mg of tridecanal in 4 mL of 1-propanol to prepare a tridecanal solution (1.01 mmol).
[0217] <Synthesis of IMCTA-C13> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except for changing the octanal solution to the tridecanal solution, IMCTA-C13 (purified product) was obtained in the same manner as in <Synthesis of IMCTA-C8> of Synthesis Example 1. 43.6 mg of IMCTA-C13 was obtained with a yield of 7.5%. [Chemical Formula 37]
[0218] - Physicochemical Properties of the Compound Shown in Structural Formula (7) (IMCTA-C13)- The physicochemical properties of the obtained IMCTA-C13 are shown below: Thus, it was confirmed that the compound obtained in Synthesis Example 6 was a compound (IMCTA-C13) having the structure represented by the above structural formula (7). (1) Appearance: White powder (2) Molecular formula: C 25 H 50 NO 10 (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 524.3428 (M+H) + Calculated value: m / z 524.3435 (as C 25 H 50 NO 10 ) (4) Specific rotation: [α] D 24 = +134.6° (c = 1.000, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig. 7A and as shown below. ν max (KBr)cm -1 : 3,358, 2,924, 2,853, 1,675, 1,468, 1,204, 1,147, 1,080, 1,043, 994, 837, 801, 721, 605 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Figure 7B and as shown below. 1 H NMR (600MHz, CD3OD): 5.11 (d, J=3.7Hz, 1H), 5.09 (d, J=3.7Hz, 1H), 3.74~3.85 (m, 6H), 3.64~3.69 (m, 2H), 3.48 (dd, J=9.6, 3.7Hz, 1H), 3.46 (dd, J=9.8, 3, 7Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J=10.0Hz, 1H), 1.47 (m, 2H), 1.23~1.39 (m, 20H), 0.90 (t, J=7.1Hz, 3H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Figure 7C and as shown below. 13 13C NMR (150 MHz, CD3OD): 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0, 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.8×5, 30.7, 30.5, 28.3, 23.7, 14.4.
[0219] (Synthesis Example 7: Synthesis of IMCTA-C14) In Synthesis Example 1, except that <Preparation of octanal solution> was changed to the following <Preparation of tetradecanal solution> and <Synthesis of IMCTA-C8> was changed to the following <Synthesis of IMCTA-C14>, a trehalose analog was synthesized in the same manner as in Synthesis Example 1. The obtained trehalose analog was also referred to as "IMCTA-C14".
[0220] <Preparation of tetradecanal solution> 200 mg of tetradecanal was dissolved in 4 mL of 1-propanol to prepare a tetradecanal solution (942 μmol).
[0221] <Synthesis of IMCTA-C14> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except that the octanal solution was changed to the tetradecanal solution, IMCTA-C14 (purified product) was obtained in the same manner as in <Synthesis of IMCTA-C8> of Synthesis Example 1. 370 mg of IMCTA-C14 was obtained with a yield of 73%. [Chemical Formula 38]
[0222] - Physicochemical properties of the compound (IMCTA-C14) shown in Structural Formula (8)- The physicochemical properties of the obtained IMCTA-C14 are as follows. Thus, it was confirmed that the compound obtained in Synthesis Example 7 was the compound (IMCTA-C14) having the structure shown in the above Structural Formula (8). (1) Appearance: White powder (2) Molecular formula: C 26 H 52 NO 10 (3) High-resolution mass spectrometry (HRMS: ESI positive ion mode): Experimental value: m / z 538.3589 (M+H) + Calculated value: m / z 538.3591 (as C 26 H 52 NO10 ) (4) Specific rotation: [α] D 22 = +121.0° (c = 1.045, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig. 8A and as shown below. ν max (KBr)cm -1 : 3,372, 2,919, 2,850, 1,468, 1,149, 1,042, 992, 802, 719, 607 s(6) proton NMR spectrum: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Figure 8B and as shown below. 1 H NMR (600MHz, CD3OD): 5.11 (d, J=3.7Hz, 1H), 5.09 (d, J=3.7Hz, 1H), 3.74~3.85 (m, 6H), 3.64~3.69 (m, 2H), 3.48 (dd, J=9.5, 3.7Hz, 1H), 3.46 (dd, J=9.8, 3, 7Hz, 1H), 3.31 (m, 1H), 2.71 (m, 2H), 2.49 (t, J=10.0Hz, 1H), 1.47 (m, 2H), 1.23~1.39 (m, 22H), 0.90 (t, J=7.1Hz, 3H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Figure 8C and as shown below. 13 C NMR (150MHz, CD3OD): 95.0, 94.9, 74.6, 74.0, 73.8, 73.2, 72.8, 72.7, 72.0 , 63.7, 62.6, 62.1, 49.4, 33.1, 31.5, 30.8×6, 30.7, 30.5, 28.4, 23.7, 14.4.
[0223] (Synthesis Example 8: Synthesis of IMCTA-C15) In Synthesis Example 1, a trehalose analog was synthesized by the same method as Synthesis Example 1 except that <Preparation of octanal solution> was changed to the following <Preparation of pentadecanal solution>, and <Synthesis of IMCTA-C8> was changed to the following <Synthesis of IMCTA-C15>. The obtained trehalose analog is also referred to as "IMCTA-C15".
[0224] <Preparation of Pentadecanal Solution> Dissolve 200 mg of pentadecanal in 4 mL of 1-propanol to prepare a pentadecanal solution (883 μmol).
[0225] <Synthesis of IMCTA-C15> In <Synthesis of IMCTA-C8> of Synthesis Example 1, except that the octanal solution was changed to a pentadecanal solution, the same method as <Synthesis of IMCTA-C8> of Synthesis Example 1 was used to obtain IMCTA-C15 (purified product). 41.6 mg of IMCTA-C15 was obtained, and the yield was 6.8%. [Chemical Formula 39]
[0226] -Physicochemical Properties of the Compound (IMCTA-C15) Shown in Structural Formula (9)- The physicochemical properties of the obtained IMCTA-C15 are as follows. Thus, it was confirmed that the compound obtained in Synthesis Example 8 is the compound (IMCTA-C15) having the structure shown in the above structural formula (9). (1) Appearance: White powder (2) Molecular formula: C 27 H 54 NO 10 (3) High-resolution mass spectrometry (HRMS: ESI positive ion mode): Experimental value: m / z 552.3741 (M+H) + Calculated value: m / z 552.3748 (as C 27 H 54 NO 10 ) (4) Specific rotation: [α] D 24 = +124.7° (c = 1.025, methanol) (5) Infrared absorption spectrum: The measurement results using infrared spectroscopy are as Fig. 9A shown below. ν max (KBr) cm -1 : 3,342, 2,918, 2,849, 1,557, 1,469, 1,041, 992, 720 (6) Proton nuclear magnetic resonance spectrum: The measurement results at 600 MHz in deuterated dimethyl sulfoxide at 25 °C are as Fig. 9B shown below. 1 H NMR (600MHz, DMSO-d6): 4.86 (d, J=3.5Hz, 1H), 4.84 (d, J=3.5Hz, 1H), 4.74 (d, J=5.2Hz, 1H), 4.71 ( d, J=4.9Hz, 1H), 4.69 (d, J=5.2Hz, 1H), 4.58 (d, J=6.5Hz, 1H), 4.55 (d, J=6.1, 1H), 4.32 (t, J=5.9, 1 H), 3.57~3.65(m, 3H), 3.50~3.56(m, 3H), 3.43~3.49(m, 2H), 3.23(m, 2H), 3.12(ddd, 9.7, 8.8, 5.3H z, 1H), 2.62 (m, 1H), 2.53 (m, 1H), 2.25 (t, J=9.8Hz, 1H), 1.16~1.35 (m, 13H), 0.84 (t, J=7.0Hz, 3H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated dimethyl sulfoxide and 25°C are as follows Fig. 9C and as shown below. 13 C NMR (150MHz, CD3OD): 93.1, 92.9, 72.9, 72.4, 72.3, 71.6, 71.5, 71.0, 70.1, 62.1, 60.7×2, 47.5, 31.3, 30.5, 29.1, 29.0×7, 28.7, 26.8, 22.1, 13.9.
[0227] <Synthesis Example 9: Synthesis of IMCTA-fluorescein> <4- Preparation of Trehaloseamine Aqueous Solution > The purified 4-trehalose amine product 200 mg obtained in the <Purification Process> of Production Example 10 was dissolved in 1 mL of water to prepare a 4-trehalose amine aqueous solution (557 μmol).
[0228] <Preparation of 5-carboxyfluorescein N-succinimidyl ester solution> 20 mg of 5-carboxyfluorescein N-succinimidyl ester was dissolved in 200 μL of DMSO to prepare a 5-carboxyfluorescein N-succinimidyl ester solution (44.2 μmol).
[0229] <Synthesis of IMCTA-fluorescein> 1 mL of 4-trehalosamine aqueous solution (excess) was added to the above 200 μL of 5-carboxyfluorescein N-succinimidyl ester solution and allowed to stand at room temperature for 48 hours to synthesize trehalose analogs. The synthesized trehalose analogs are also called "IMCTA-fluorescein". Using a 0.05% trifluoroacetic acid aqueous solution-acetone as the solvent, a reverse phase chromatography column (Hydrosphere C18, length 250 mm, diameter 20 mm, particle size 5 μm, pore size 12 nm, manufactured by YMC Co., Ltd.) was used to perform HPLC purification twice with a gradient from 0.05% trifluoroacetic acid aqueous solution 100% to acetone 100%. Thus, 16.5 mg of IMCTA-fluorescein was obtained with a yield of 56%. [Chemical formula 40]
[0230] -Physicochemical properties of the compound represented by structural formula (10) (IMCTA-fluorescein)- The physicochemical properties of the obtained IMCTA-fluorescein are shown below: Thus, it was confirmed that the compound obtained in Synthesis Example 9 was a compound having the structure represented by the above structural formula (10) (IMCTA-fluorescein). (1) Appearance: Turmeric yellow powder (2) Molecular formula: C 33 H 33 NO 16 Na (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 722.1698 (M+H) + Calculated value: m / z 722.1697 (as C 33 H 33 NO 16 Na) (4) Specific rotation: [α] D 23 = +89.0° (c = 0.255, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig. 10A and as shown below. ν max (KBr)cm -1 : 3,361, 1,593, 1,459, 1,369, 1,308, 1,241, 1,210, 1,173, 1,119, 992, 875, 850, 761, 722, 671 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Fig. 10B and as shown below. 1 H NMR (600MHz, CD3OD): 8.50 (brs, 1H), 8.26 (dd, J=8.0, 1.5, 1H), 7.33 (d, J=8.0, 1H), 6.71 (d, J=1.5, 2H), 6.62 (d, J =8.0, 2H), 6.56 (dd, J=8.6, 1.6, 2H), 5.22 (d, J=3.5, 1H), 5.16 (d, J=3.7, 1H), 4.11 (t, J=9.6Hz, 1H), 4.04 (t, J=9. 6Hz, 1H), 3.99 (ddd, J=10.6, 5.3, 2.1, 1H), 3.87 (ddd, J=10.1, 5.3, 2.2, 1H), 3.83 (t, J=9.3Hz, 1H), 3.82 (dd, J=11 .8, 2.2, 1H), 3.70 (dd, J=11.8, 5.3, 1H), 3.60~3.67 (m, 3H), 3.55 (dd, J=9.7, 3.6, 1H), 3.35 (dd, J=9.8, 9.1Hz, 1H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Fig. 10C and as shown below. 13 C NMR (150MHz, CD3OD): 170.4, 168.8, 161.7×2, 154.3×2, 137.7, 135.7, 130.3×2, 128.8, 125.9, 125.0, 1 13.9×2, 111.0×2, 103.6×2, 95.0, 94.9, 74.6, 73.9, 73.7, 73.2×2, 72.7, 72.0, 71.9, 63.1, 62.6, 54.1.
[0231] <Synthesis Example 10: Synthesis of IMCTA-biotin> <4- Preparation of Trehaloseamine Aqueous Solution > The purified 4-trehalose amine product 200 mg obtained in the <Purification Process> of Production Example 10 was dissolved in 1 mL of water to prepare a 4-trehalose amine aqueous solution (557 μmol).
[0232] <Preparation of D-biotin N-hydroxysuccinimide ester solution> Dissolve 20 mg of D-biotin N-hydroxysuccinimide ester in 200 μL of DMSO to prepare a D-biotin N-hydroxysuccinimide ester solution (58.6 μmol).
[0233] <Synthesis of IMCTA-biotin> 1 mL (excess) of 4-trehalosamine aqueous solution was added to 200 μL of D-biotin N-hydroxysuccinimide ester solution and the solution was allowed to stand at room temperature for 48 hours to synthesize trehalose analogs. The synthesized trehalose analogs are also referred to as "IMCTA-biotin". Using water-methanol as solvent, a reverse phase chromatography column (Hydrosphere C18, length 250 mm, diameter 20 mm, particle size 5 μm, pore size 12 nm, produced by YMC Co., Ltd.) was used to perform HPLC purification twice with a gradient of 100% water or 100% methanol. Thus, 26 mg of IMCTA-biotin was obtained with a yield of 78%. [Chemical formula 41]
[0234] -Physicochemical properties of the compound represented by structural formula (11) (IMCTA-biotin) - The physicochemical properties of the obtained IMCTA-biotin are as follows: Thus, it was confirmed that the compound obtained in Synthesis Example 10 was a compound having the structure represented by the above structural formula (11) (IMCTA-biotin). (1) Appearance: White powder (2) Molecular formula: C 22 H 37 N3O 12 SNa (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Expected value: m / z 590.1997 (M+H) + Calculated value: m / z 590.1996 (as C 22 H 37 N3O 12 SNa) (4) Specific rotation: [α] D 23 = +143.5° (c = 1.06, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig.11A and as shown below. ν max (KBr)cm -1 : 3,388, 2,931, 2,348, 1,680, 1,550, 1,464, 1,044, 990, 574 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Fig. 11B and as shown below. 1 H NMR (600MHz, CD3OD): 5.16 (d, J=3.7Hz, 1H), 5.11 (d, J=3.7Hz, 1H), 4.49 (dd, J=7.9, 5.0, 1H), 4.31 (dd, J=7.8, 4.5, 1H), 3.88 (t, J=9.7Hz, 1H), 3.71~3.85 (m, 5H), 3.68 (dd, J=11.8 , 5.4Hz, 1H), 3.49~3.59 (m, 4H), 3.33 (dd, J=9.8, 8.8, 1H), 3.21 (m, 1H), 2.93 (dd, J=12.8 , 5.0, 1H), 2.71 (d, J=12.8Hz, 1H), 2.27 (t, J=7.3Hz, 2H), 1.57~1.78 (m, 4H), 1.47 (m, 2H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Fig. 11C and as shown below. 13 C NMR (150MHz, CD3OD): 176.9, 166.2, 95.0, 94.9, 74.5, 73.8×2, 73.1×2, 72. 0, 71.8, 63.3, 63.0, 62.6, 61.6, 56.9, 53.2, 41.0, 37.0, 29.8, 29.4, 26.7.
[0235] <Synthesis Example 11: Synthesis of IMCTA-azide> <4- Preparation of Trehaloseamine Aqueous Solution > 15 mg of the purified 4-trehalosamine obtained in the <Purification Process> of Production Example 10 was dissolved in 150 μL of water to prepare a 4-trehalosamine aqueous solution (41.2 μmol).
[0236] <Preparation of a solution of 2-azido-1,3-dimethylimidazolium hexafluorophosphate> 100 mg of 2-azido-1,3-dimethylimidazolium hexafluorophosphate was dissolved in 200 μL of DMSO to prepare a 2-azido-1,3-dimethylimidazolium hexafluorophosphate solution (351 μmol).
[0237] <Preparation of N,N-dimethyl-4-aminopyridine solution> 100 mg of N,N-dimethyl-4-aminopyridine (DMAP) was dissolved in 600 μL of 50 vol% DMSO aqueous solution to prepare N,N-dimethyl-4-aminopyridine solution (819 μmol).
[0238] <Synthesis of IMCTA-azide> 200 μL of 2-azido-1,3-dimethylimidazolium hexafluorophosphate solution and 600 μL of N,N-dimethyl-4-aminopyridine solution were added to 150 μL of the above 4-trehalosamine aqueous solution and mixed, and allowed to stand at room temperature for 24 hours to synthesize a trehalose analog. The synthesized trehalose analog is also called "IMCTA-azido". After adding 1.2 mL of 8% sodium bicarbonate (NaHCO3) aqueous solution to the synthesized solution containing IMCTA-azide, HPLC purification was repeatedly performed several times using a reverse phase chromatography column (Hydrosphere C18, length 250 mm, diameter 20 mm, particle size 5 μm, pore size 12 nm, produced by YMC Co., Ltd.) and a YMC-Pack PolyamineII chromatography column (particle size 5 μm, pore size 12 nm, produced by YMC Co., Ltd.) with water-methanol as the solvent. As a result, IMCTA-azide (4-azido-4-deoxy-trehalose) was obtained in 9.9 mg with a yield of 61%. [Chemical formula 42]
[0239] -Physical and chemical properties of the compound represented by structural formula (12) (IMCTA-azide)- The physicochemical properties of the obtained IMCTA-azide are shown below. Thus, it was confirmed that the compound obtained in Synthesis Example 11 was a compound (IMCTA-azide) having the structure represented by the above structural formula (12). (1) Appearance: White powder (2) Molecular formula: C 12 H 21 N3O 10 Na (3) High resolution mass spectrometry (HRMS: ESI positive ion mode): Exp. value: m / z 390.1117 (M+H) + Calculated value: m / z 390.1125 (as C 12 H 21 N3O 10 Na) (4) Specific rotation: [α] D 21 = +184.1° (c = 0.500, methanol) (5) Infrared absorption spectrum: The results of infrared spectroscopy are as follows Fig. 12A and as shown below. ν max (KBr)cm -1 : 3,374, 2,934, 2,115, 1,637, 1,264, 1,149, 1,078, 1,045, 992, 935, 842, 801, 567 (6) Proton NMR spectroscopy: The results of the measurement at 600 MHz in deuterated methanol at 25°C are as follows Fig. 12B and as shown below. 1 H NMR (600MHz, CD3OD): 5.14 (d, J=3.8Hz, 1H), 5.06 (d, J=3.8Hz, 1H), 3.92 (t, J=9.5Hz, 1H), 3.72~3.83 (m, 5H), 3.65~3 .70 (m, 2H), 3.53 (dd, J=9.7, 3, 8Hz, 1H), 3.46 (dd, J=9.8, 3.8Hz, 1H), 3.40 (t, J=10.0Hz, 1H), 3.33 (t, J=9.4Hz, 3H). (7) Carbon 13 NMR spectrum: The results of the measurement at 150 MHz deuterated methanol and 25°C are as follows Fig. 12C and as shown below. 13 C NMR (150MHz, CD3OD): 95.2×2, 74.5, 73.8, 73.6, 73.3, 73.1, 72.1, 71.9, 63.8, 62.6, 62.3.
[0240] (Test Example 1: Content of 4-trehalosamine in culture medium) The 4-trehalosamine content (production amount) in each culture solution after 12 days of cultivation obtained in the cultivation process of Production Example 1-10 was confirmed by both simple evaluation by thin layer chromatography (TLC) and precise evaluation by liquid chromatography-mass spectrometry (LC-MS).
[0241] <TLC analysis> Each culture solution obtained in the culture process of Production Examples 1 to 10 was diluted to 1 / 10 with methanol and centrifuged at 25,300×g for 5 minutes to obtain a supernatant. The obtained culture supernatant was placed on a 2 mm thick TLC plate (Silica gel 60F 254, Merck, Darmstadt, Germany) on 5 μL and dried. Then, the TLC plate was immersed in 60% by volume 1-propanol as a developing solvent, developed and dried. A phosphomolybdic acid solution [2.4% disodium molybdate (Na2MoO4), 1.28% phosphoric acid (H3PO4) and 5% sulfuric acid (H2SO4)] was sprayed onto a dry TLC thin layer chromatography plate, heated with a hot plate for color development, and 4-trehalosamine was detected. The results are shown in Figure A-13. Fig.13A The numbers 1 to 10 on the horizontal axis represent Production Examples 1 to 10.
[0242] <LC-MS analysis> Each culture solution obtained in the culture process of Production Examples 1 to 10 was diluted to 1 / 10 with methanol and centrifuged at 25,300×g for 5 minutes to obtain a supernatant. The obtained culture supernatant was further diluted to 1 / 10 with methanol as a test sample, and 4-trehalosamine in each culture solution was detected by LC-MS analysis under the following analysis conditions. In addition, a standard curve was drawn using purified 4-trehalosamine owned by the inventors under the following analytical conditions. Based on the standard curve, the concentration (mg / mL) of 4-trehalosamine in each culture solution obtained in the culture process of Production Examples 1 to 10 was calculated. In addition, LC-MS analysis was performed with n=3 (mean±SD). The results are shown in Fig. 13B shown. Fig. 13B The numbers 1 to 10 on the horizontal axis represent Production Examples 1 to 10. [LC-MS analysis conditions] Device: Q-Exactive (produced by Thermo Fisher Scientific) Column: Hydrophilic Interaction Chromatography column (ACQUITY UPLC, ethylene bridged hybrid (BEH) particles, particle size: 1.7 μm, diameter: 2.1 mm, length: 100 mm, manufactured by Waters, Milford, MA) Column temperature: 40℃ Eluent: Solution A: acetonitrile: 5 mM ammonium acetate aqueous solution (9:1, v / v) Solution B: 5mM ammonium acetate aqueous solution Elution conditions: 0 min (A:B = 90:10) → 5.25 min (A:B = 40:60) → 6.25 min (A:B = 40:60) gradient elution Flow rate: 0.4mL / min Retention time: Retention time of 4-trehalosamine (3.42±0.2 minutes) Ionization: ESI, positive ion mode Spray voltage: 4KV Capillary temperature: 350℃ Capillary voltage: 5V Probe heater temperature: 400°C ·Detection: Exp. value: m / z 342.1397 (M+H) + Calculated value: m / z 342.1400 (as C 12 H 24 NO 10 )
[0243] according to Fig.13A As can be seen from the results of Figure B, when "Modified Ko Medium 8" was used in Production Example 9 and "Modified Ko Medium 9" was used in Production Example 10, the production of 4-trehalosamine in the culture process increased by 10 times or more compared to when "Ko Medium" was used in Production Example 1. More specifically, the results of LC-MS analysis showed that 4.72 g of 4-trehalosamine was produced per 1 L of "Modified Ko Medium 8" (96.2 g of solid content) in Production Example 9. In addition, 5.48 g of 4-trehalosamine was produced per 1 L of "Modified Ko Medium 9" (99.1 g of solid content) in Production Example 10.
[0244] (Test Example 2: Sweetness Test) The sweetness test of 4-trehalosamine was conducted by the following method. A 50 mg / 100 μL aqueous solution of the purified 4-trehalosamine obtained in the <Purification Process> of Production Example 10, trehalose (produced by Hayashibara Co., Ltd., the same in the following test examples), and sucrose was prepared as test samples. 12 professional panelists licked 10 μL of each of the above test samples, and scored the sweetness of each test sample, setting the sweetness of only water to "0" and the sweetest to "10", and calculated the average score of each professional panel on each test sample. In addition, when licking each test sample, the data name was hidden and the test was conducted. The results are shown in Table 1 below.
[0245] [Table 1] water 4-trehalose amine Trehalose sucrose average 0 7.04 5.5 9.83 SD 0 1.36 2.43 0.57 In addition, 4-trehalosamine tastes only sweet, without any special flavor or odor.
[0246] (Test Example 3: Properties of IMCTA-C8 to IMCTA-C15) For the IMCTA-C8, IMCTA-C9, IMCTA-C10, IMCTA-C11, IMCTA-C12, IMCTA-C13, IMCTA-C14, and IMCTA-C15 (IMCTA-Cn) obtained in Synthesis Examples 1-8, and dodecyl-β-D-maltoside (DDM) as a control, the "critical micelle concentration (CMC)", "micelle size", and "hydrophilic-lipophilic balance (HLB) value" were determined or calculated using the following methods. The results are shown in Table 2 below.
[0247] <Determination of Critical Micelle Concentration (CMC)> The CMC was determined using a Detergent Critical Micelle Concentration (CMC) Assay Kit (CMC1000, produced by ProFoldin) according to the product protocol.
[0248] <Determination of Micelle Size> The micelle size was measured using a Zetasizer Nano S (produced by Malvern Panalytical) by dynamic light scattering.
[0249] <Determination of HLB Value> The HLB value was calculated using Marvin Sketch (produced by ChemAxon) by the Griffin method.
[0250] [Table 2]
[0251] From the results in Table 2, it can be seen that IMCTA-Cn has surface-active effects. In addition, compared with IMCTA-C12 and DDM having the same fatty acid chain, the CMC value of IMCTA-C12 is higher than that of DDM, and the micelle size is larger.
[0252] (Test Example 4: Protein Extraction Test of IMCTA-C8 to IMCTA-C15) The protein extraction ability of IMCTA-Cn obtained in Synthesis Examples 1-8 was evaluated using the following method.
[0253] <Preparation of Test Samples> IMCTA-Cn obtained in Synthesis Example 1-8, and trehalose-C8 (hereinafter also referred to as "T8") (produced by Dojindo Chemical Research Institute Co., Ltd.), trehalose-C12 (hereinafter also referred to as "T12") (produced by Dojindo Chemical Research Institute Co., Ltd.), n-octyl-β-D-pyranoglucopyranoside (hereinafter also referred to as "OG") (produced by Dojindo Chemical Research Institute Co., Ltd.), Triton X-100 (hereinafter also referred to as "TR") (produced by MP Biomedicals), Tween 20 (hereinafter referred to as "TW") (manufactured by Tokyo Chemical Industry Co., Ltd.), dodecyl-β-D-maltoside (DDM) (manufactured by Dojindo Chemical Research Institute Co., Ltd.), 3-[(3-columnpropyl)dimethylamine]-1-propanesulfonamide (CHAPS, hereinafter referred to as "CPS") (manufactured by Dojindo Chemical Research Institute Co., Ltd.), sodium deoxycholate (hereinafter referred to as "DC") (manufactured by Tokyo Chemical Industry Co., Ltd.), and sodium dodecyl sulfate (SDS) (manufactured by Sigma-Aldrich) were suspended in tris-buffered saline (TBS, manufactured by Takara Bio Co., Ltd.) to prepare various test samples with concentrations of 0%, 0.005%, 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5% and 1%.
[0254] <Evaluation of protein extraction efficiency> -Determination of protein concentration- After human ovarian cancer cells OVK18 (obtained from the Bioresource Research Center (BRC) of the RIKEN Institute of Physical and Chemical Research) were proliferated in a culture dish until they covered the adhesive surface of the culture dish, the culture medium was removed, the cells were washed once with phosphate buffered saline (PBS, produced by Takara Bio Co., Ltd.), and treated with 0.05% trypsin-EDTA (produced by Thermo Fisher Scientific) for 5 minutes. After the trypsin treatment, a DMEM culture medium (10% fetal bovine serum (FBS, produced by Sigma-Aldrich) and 1 / 100 amount of penicillin-streptomycin-L-glutamine solution (×100) (produced by Fujifilm Wako Pure Chemical Industries, Ltd.) and 0.12% sodium bicarbonate (produced by Fujifilm Wako Pure Chemical Industries, Ltd.) containing 0.05% trypsin-EDTA 3 times the amount (V / V) was added to stop the trypsin reaction. Next, the cells were peeled off from the culture dish and recovered by pipetting seven times. The recovered cells were centrifuged at 400×g for 3 minutes. After the cells were precipitated, they were washed once with tris-buffered saline (TBS). The cell pellet was weighed and suspended in TBS at 40 mg / mL. 100 μL was distributed separately, and the above-mentioned test samples of various concentrations were added, and rotated at 4°C and 40 rpm for 1 hour. The mixed solution was centrifuged at 700×g for 5 minutes, and the protein concentration of the supernatant was measured using a BCAprotein assay kit (produced by Thermo Fisher Scientific) to evaluate the protein extraction efficiency (mean±SD, n=3). The results are as follows: Fig.14A shown.
[0255] Polyacrylamide gel electrophoresis (SDS-PAGE)- Using the 0.05% or 0.5% test sample prepared in the above <Preparation of test samples>, the cell supernatant obtained in the above <Evaluation of protein extraction efficiency> was added with an equal amount of 2×SDS-PAGE sample buffer (125mM tris(hydroxymethyl)aminomethane), 4% SDS, 10% sucrose, 10% 2-mercaptoethanol (2-ME) and 0.004% bromophenol blue (BPB, pH 6.8) to the cell supernatant, and boiled for 5 minutes to prepare a test sample for SDS-PAGE. The SDS-PAGE test sample was separated using SDS-PAGE using 12.5% acrylamide gel (produced by Antegrad) and stained with Quick-CBB (produced by Fujifilm Wako Pure Chemical Industries, Ltd.). The results of the 0.05% test sample are as follows: Fig. 14B As shown, the test sample is 0.5% and the results are as follows Fig. 14C shown.
[0256] according to Fig.14A The results of IMCTA-Cn to IMCTA-C14 show that IMCTA-Cn has the ability to extract proteins from cells. In particular, IMCTA-C11 to IMCTA-C14 have extraction efficiencies comparable to those of excellent surfactants with high extraction efficiencies such as DDM and TritonX-100.
[0257] - Confirmation of membrane protein extraction efficiency - The gel subjected to SDS-PAGE using the above-mentioned - polyacrylamide gel electrophoresis (SDS-PAGE) - was transferred to an Immobilon-P PVDF membrane (manufactured by Merck) and subjected to protein blotting. The first antibody was used as a control soluble protein with β-tubulin (manufactured by Cell Signaling Technology), as a membrane protein with EGFR, and with antibodies to Na+ / K+-ATPase (both manufactured by Cell Signaling Technology) and TRPV6 (manufactured by Proteintech), and reacted at 1 / 1,000 at 6°C for 12 hours. The second antibody corresponded to the above-mentioned first antibody, and HRP-labeled goat anti-rabbit IgG or HRP-labeled goat anti-mouse IgG (both manufactured by Cell Signaling Technology) was used at 1 / 5,000, and the protein was detected by the FastGene Protein Blot ECL Kit (manufactured by Japan Genetics Co., Ltd.). The results are as follows. Fig.14D shown.
[0258] according to Fig.14D The results showed that the extraction efficiency of membrane proteins of each test sample was basically the same as the block extraction efficiency of CBB for total protein and soluble tubulin. In particular, higher membrane protein extraction efficiency was confirmed in IMCTA-C11, IMCTA-C12, IMCTA-C13 and IMCTA-C14.
[0259] - Confirmation of denaturation - 1 μg of protein extracted from the above test sample 1% human ovarian cancer cell OVK18 was mixed with 200 mM p-nitrophenol phosphate (pNPP) in TBS containing 20 mM magnesium chloride and 0.5 mM dithiothreitol (DTT) and reacted at 37°C for 1 hour. After the reaction, the absorbance at 420 nm was measured using a microplate reader (Cytation5, produced by Bio Tek Instruments), and the CIP activity was measured using the amount of p-nitrophenol, the product of the enzyme reaction (n=3, mean±SD). The results are shown in Table 1. Fig.14E shown.
[0260] according to Fig.14EAs a result, the activity of CIP in SDS, DC, or OG decreased, indicating that it has a protein denaturing effect, but other than that, the activity of CIP including IMCTA-Cn did not decrease, that is, it does not have a general protein denaturing effect. Therefore, IMCTA-Cn is a mild surfactant that does not denature proteins, and is suitable for use in extracting and retaining membrane protein functions.
[0261] (Test Example 5: Effect of 4-trehalose amine on inhibiting starch aging) Using the purified 4-trehalosamine obtained in the <Purification Process> of Production Example 10, the starch retrogradation inhibitory effect of 4-trehalosamine was confirmed by the following two methods: enzymatic measurement and dynamic viscoelasticity measurement.
[0262] <Enzyme assay 1> The degradation degree of each test sample was evaluated by mixing it in a corn starch gel and leaving it at low temperature for 96 hours through a decomposition experiment using β-amylase. The following method is an evaluation method using only β-amylase, which is a modification of the BAP method (K. Kainuma, et al, Journal of the Japanese Society of Starch Science 1981, 28, 235.).
[0263] - Preparation of samples for measurement - 4-Trehalosamine (4TA), trehalose (TRH), sucrose (SCR) and glycerol (hereinafter also referred to as "GOL") obtained in Preparation Example 10 were dissolved in water to prepare an aqueous solution so that the final concentration was 10% (w / w). Corn starch (produced by Fujifilm and Wako Pure Chemical Industries, Ltd.) was mixed and evenly suspended in an aqueous solution containing various sugars or in water as a control so that the final concentration was 15% (w / w), and 33.3 μL was taken from each tube. Thereafter, the whole tube was treated with a heating block at 100°C for 5 minutes to gel. After 0 o'clock, one of the above 4 tubes was used as a sample for the following "-Confirmation of the effect of starch aging printing-". The remaining 3 tubes were left to stand at 6°C for 24 hours, 48 hours, and 96 hours, respectively, as samples after 24 hours, 48 hours, and 96 hours.
[0264] - Preparation of active enzymes and inert enzymes - 33 μg / mL (1.37 U / mL) of β-amylase (derived from barley, produced by Sigma-Aldrich) was dissolved in 0.8 M acetic acid-sodium hydroxide (NaOH) buffer (pH 6.0) as an active enzyme. A portion of the active enzyme was separated and treated in a heating block at 100°C for 30 minutes to prepare an inert enzyme.
[0265] - Confirmation of the inhibitory effect of starch aging - After the sample gelled after 0 hours, 0.8 M acetic acid-sodium hydroxide (NaOH) buffer (pH 6.0) was immediately added to make 0.9 mL. The gel in the buffer was dispersed by pipetting, and after being suspended as evenly as possible, it was divided into two tubes, 0.4 mL in each tube. 100 μL of the above active enzyme was added to one tube, and 100 μL of the above inert enzyme was added to another tube, and the mixture was stirred well with a vortex mixer, and then reacted at 37°C for 30 minutes. After the reaction, the mixture was treated at 100°C for 5 minutes to inactivate the enzyme, and then stirred well, 10 μL was transferred to another tube, 40 μL of water and 50 μL of Somogyi solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) were added, and the mixture was treated at 100°C for 15 minutes. After cooling to room temperature, 80 μL was transferred to a 96-well plate, 40 μL of Nelson solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added, and after 5 minutes, the absorbance at 660 nm was measured using a plate reader Cytation5 (manufactured by Bio Tek Instruments), and the absorbance value of the sample with the inert enzyme added as the background was subtracted from the absorbance value of the sample with the active enzyme added.
[0266] In the above-mentioned enzyme reaction and quantification of sugars (absorbance measurement) of the sample after 0 hour, the enzyme reaction and quantification of sugars (absorbance measurement) of the sample after 24 hours, 48 hours, and 96 hours were carried out using the same method as the enzyme reaction and quantification of sugars (absorbance measurement) of the sample after 0 hour.
[0267] The decomposition efficiency was 100% after subtracting the absorbance value of the sample with active enzyme added after 0 hours from the absorbance value of the sample with inert enzyme added. The absorbance value of the sample with active enzyme added after 24 hours, 48 hours or 96 hours was subtracted from the absorbance value of the sample with inert enzyme added as background. The decomposition efficiency was calculated based on the values to evaluate the starch retrogradation degree (n=5, mean±SD). Fig.15A shown.
[0268] according to Fig.15A The results showed that compared with other gels, the corn starch gel containing 4-trehalosamine (4TA) had a significantly higher β-amylase decomposition rate after 24 hours, and compared with trehalose (TRH), sucrose (SCR), and glycerol (GCL), 4-trehalosamine (4TA) had a better aging inhibition effect.
[0269] <Enzyme assay 2> In the "- Preparation of Assay Samples -" of the above <Enzyme Assay 1>, the starch retrogradation inhibitory effect was confirmed by the same method as <Enzyme Assay 1> except that the final concentrations of the aqueous 4-trehalosamine (4TA) solution, the aqueous trehalose (TRH) solution, the aqueous sucrose (SCR) solution, and the aqueous glycerol (GOL) solution were changed from 10% (w / w) to 2% (w / w), 5% (w / w), or 15% (w / w). The results when the final concentration of the aqueous solution of each sugar was 2% (w / w) are as follows: Fig. 15B The results when the final concentration of each sugar aqueous solution was 5% (w / w) were as shown in Fig. 15C The results when the final concentration of each sugar aqueous solution was 15% (w / w) were as shown in Fig.15D shown.
[0270] Fig. 15B The results showed that compared with other gels, the corn starch gel with a final concentration of 5% to 15% of 4-trehalosamine aqueous solution had a significantly higher β-amylase decomposition rate after 96 hours and a stronger starch aging inhibition effect.
[0271] <Enzyme assay 3> In the above <Enzyme Assay 1>, the starch retrogradation inhibitory effect was confirmed by the same method as <Enzyme Assay 1> except that "- Preparation of Assay Sample" and "- Confirmation of Starch Retrogradation Inhibitory Effect" were changed to the following method.
[0272] - Preparation of samples for measurement - 4-Trehalosamine (4TA), trehalose (TRH), sucrose (SCR) and glycerol (GOL) obtained in Preparation Example 10 were dissolved in water at a final concentration of 10% (w / w) or 15% (w / w) to prepare aqueous solutions. Potato starch (potato starch, produced by Yoshida Pharmaceutical Co., Ltd.) was mixed and evenly suspended in aqueous solutions containing various sugars or in water as a control so that the final concentration was 15% (w / w), and 33.3 μL was taken from each tube. Thereafter, the whole tube was treated with a heating block at 100°C for 5 minutes to gel. After 0 o'clock, one of the above three tubes was used as a sample for the following "-Confirmation of the effect of starch aging printing-". The remaining two tubes were left to stand at 6°C for 48 hours and 96 hours, respectively, as samples after 48 hours and samples after 96 hours.
[0273] - Confirmation of the inhibitory effect of starch aging - The starch aging inhibitory effect was confirmed by the same method as in "-Confirmation of starch aging inhibitory effect" in <Enzyme assay 1>, except that the absorbance measurement at 660 nm was changed to the absorbance measurement at 620 nm, and the enzyme reaction and sugar quantification (absorbance measurement) were performed on the samples after 0 hours, 48 hours, and 96 hours. The results when the final concentration of each sugar aqueous solution was 10% (w / w) are as follows: Fig.15E The results when the final concentration of each sugar was 15% (w / w) are as shown in Fig.15F shown.
[0274] according to Fig.15E Compared with the results of F, the potato starch gel containing 4-trehalosamine (4TA) had a significantly higher degradation rate of β-amylase after 48 hours compared with other gels, and 4-trehalosamine (4TA) had a better aging inhibition effect than trehalose (TRH), sucrose (SCR), and glycerol (GCL).
[0275] <Enzyme assay 4> In the "- Preparation of Assay Samples -" of the above <Enzyme Assay 3>, the starch retrogradation inhibitory effect was confirmed by the same method as the above <Enzyme Assay 3> except that potato starch was replaced with rice flour (manufactured by Ohsawa Japan Co., Ltd.). The results when the final concentration of each sugar was 10% (w / w) are as follows: Figure 15G The results when the final concentration of each sugar was 15% (w / w) are as shown in Fig.15H shown.
[0276] according to Figure 15G Compared with the results of H, the rice flour gel containing 4-trehalosamine (4TA) had a significantly higher β-amylase degradation rate after 48 hours compared with other gels, and 4-trehalosamine (4TA) had a better aging inhibition effect than trehalose (TRH), sucrose (SCR), and glycerol (GCL).
[0277] <Enzyme assay 5> In the "- Preparation of Assay Samples -" of the above <Enzyme Assay 3>, the starch retrogradation inhibitory effect was confirmed by the same method as the above <Enzyme Assay 3> except that the potato starch was replaced with flour (organic flour, produced by Kanazawa Daichi Co., Ltd.). The results when the final concentration of each sugar was 10% (w / w) are as follows Fig.15I The results when the final concentration of each sugar was 15% (w / w) are as shown in Fig.15J shown.
[0278] according to Fig.15ICompared with the results of J, the flour gel containing 4-trehalosamine (4TA) had a significantly higher β-amylase decomposition rate after 48 hours compared with other gels, and 4-trehalosamine (4TA) had a better aging inhibition effect compared with trehalose (TRH), sucrose (SCR), and glycerol (GCL).
[0279] <Dynamic viscoelasticity measurement> In a 20 mL glass vial, corn starch (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was mixed with 10% 4-trehalose (4TA) aqueous solution, 10% trehalose (TRH) aqueous solution, 10% sucrose (SCR) aqueous solution, 10% glycerol (GOL) aqueous solution of the above test sample and water as a control, and uniformly suspended to a final concentration of 15% (w / w), and sterilized by autoclave at 121°C for 20 minutes to gel. Samples after 0 hours and samples after 96 hours were prepared. After cooling to room temperature, the sample was subjected to dynamic viscoelasticity measurement within 4 hours after 0 hours and to dynamic viscoelasticity measurement after 96 hours after the sample was allowed to stand at 4°C for 96 hours. Dynamic viscoelasticity was measured using an MCR300 rheometer (manufactured by Physica, Stuttgart, Germany) with a 25 mm parallel plate and a fixture gap of 1.0 mm. Storage modulus (G') and loss modulus (G") were measured at a fixed frequency of 1.0 Hz, a strain amplitude of 1%, and 25°C, and the loss factor (tan δ = G" / G') was calculated. The results are shown in Figure 15K In addition, Figure 15K The vertical axis shows the value of tan δ (n=5, mean±SD).
[0280] according to Figure 15K The results showed that the loss factor value of corn starch gel containing 4-trehalosamine (4TA) did not change much after 96 hours, or increased slightly. In contrast, in corn starch gel containing other sugars, the loss tangent value decreased as a result of increased elasticity. Therefore, 4-trehalosamine (4TA) has a better aging inhibition effect than trehalose (TRH), sucrose (SCR), and glycerol (GCL).
[0281] (Test Example 6-1: Protective Effect of 4-Trehalosamine on Protein (CIP)) Test samples 1-12 containing calf intestinal alkaline phosphatase (CIP) were prepared as follows to evaluate the protein protective activity of various added sugars under lyophilization.
[0282] <Preparation of test samples> Test sample 1 enzyme solution Calf intestinal alkaline phosphatase (10 U / μL, manufactured by New England Biolabs) was diluted to 1 / 40 with TBS (manufactured by Takara Bio Co., Ltd.), and then dialyzed at 4°C for 2 hours in 1,000-fold amount of TBS as the enzyme diluent to remove glycerol. 40 μL of the dialyzed enzyme solution was added with 40 μL of TBS, mixed, and allowed to stand at 4°C for 20 hours to prepare an enzyme solution.
[0283] Test sample 2. Enzyme freeze-thaw An enzyme solution was prepared in the same manner as in Test Sample 1, and after freezing at -80°C for 20 hours, a freeze-thaw product of the enzyme was prepared.
[0284] Test sample 3. Lyophilized enzyme The enzyme solution was prepared in the same manner as for Test Sample 1, frozen at -80°C for 10 minutes, and then freeze-dried for 20 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHILSatoVac INC.) to prepare a lyophilized enzyme.
[0285] Test sample 4. Lyophilized product with 1% TRH enzyme added Calf intestinal alkaline phosphatase (10U / μL, manufactured by New England Biolabs) was diluted to 1 / 40 with TBS (manufactured by Takara Bio Co., Ltd.), and then dialyzed at 4°C for 2 hours in 1,000 times the amount of TBS as the enzyme diluent to remove glycerol. 40μL of the dialyzed enzyme solution was added with 40μL of TBS containing 2% trehalose (TRH) and mixed, and after freezing at -80°C for 10 minutes, the solution was freeze-dried for 20 hours in a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHIL Sato Vac INC.), to prepare a freeze-dried product to which 1% TRH enzyme was added.
[0286] Test sample 5. Lyophilized product with 3% TRH enzyme added In the preparation method of Test Sample 4, a lyophilized product to which 3% TRH enzyme was added was prepared in the same manner as the preparation method of Test Sample 4 except that the final concentration of trehalose was changed to 3%.
[0287] Test sample 6. Lyophilized product with 1% 4TRH enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% 4-trehalosamine (4TA) was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4TA.
[0288] Test sample 7. Lyophilized product with 3% 4TRH enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme supplemented with 3% 4-trehalosamine (4TA) was prepared in the same manner as the preparation method of Test Sample 5, except that trehalose was replaced with 4TA.
[0289] Test sample 8. Lyophilized product with 1% MLT enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% MLT was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was changed to maltose (MLT).
[0290] Test sample 9. Lyophilized product with 3% MLT enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% MLT was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was changed to maltose (MLT).
[0291] Test sample 10. Lyophilized product with 1% SCR enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% SCR was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with sucrose (SCR).
[0292] Test sample 11. Lyophilized product with 3% SCR enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% SCR was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was changed to sucrose (SCR).
[0293] Test sample 12. Lyophilized product with 3% GOL enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% GOL was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was replaced with glycerol (GOL).
[0294] <Evaluation of CIP protective activity> 80 μL of water was added to each lyophilized product of test samples 3 to 12, and diluted to 1 / 100 with TBS. In addition, test samples 1 and 2 were diluted to 1 / 100 with TBS. 10 μL of diluted samples 1 to 12 and 20 μL of 0.1M p-nitrophenylphosphate (pNPP)-TBS solution were added to 70 μL TBS, and the enzymatic reaction was carried out at 37°C for 1 hour. After the reaction, the absorbance at 420 nm was measured using a microplate reader (Cytation5, produced by Bio Tek Instruments), and the CIP activity was measured using the amount of the enzyme reaction product p-nitrophenol (n=3, mean±SD). The results are shown in FIG. Fig.16A shown.
[0295] according to Fig.16A As a result, the enzyme activity in test sample 2 (enzyme freeze-thaw) and test sample 12 (enzyme freeze-dried with 3% GOL) was greatly reduced. In contrast, after freeze-drying with 3% 4-trehalosamine, trehalose, maltose or sucrose, the activity was maintained appropriately. Among them, the protective effect of 4-trehalosamine was higher than that of other sugars.
[0296] (Test Example 6-2: Protective effect of 4-trehalosamine on protein (ADH)) Test samples 1-12 containing yeast alcohol dehydrogenase (ADH) were prepared as follows to evaluate the protein protection activity of various added sugars under lyophilization.
[0297] <Preparation of test samples> Test sample 1 enzyme solution Yeast alcohol dehydrogenase (produced by Oriental Yeast Co., Ltd.) was dissolved in water at 1,000 U / mL and diluted to 6 U / mL with TBS (produced by Takara Bio Co., Ltd.). 50 μL of TBS was added to 50 μL of the enzyme solution, mixed, and allowed to stand at 4°C for 20 hours to prepare an enzyme solution.
[0298] Test sample 2. Enzyme freeze-thaw An enzyme solution was prepared in the same manner as in Test Sample 1, and after freezing at -80°C for 20 hours, a freeze-thaw product of the enzyme was prepared.
[0299] Test sample 3. Lyophilized enzyme The enzyme solution was prepared in the same manner as for Test Sample 1, frozen at -80°C for 10 minutes, and then freeze-dried for 20 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHILSatoVac INC.) to prepare a lyophilized enzyme.
[0300] Test sample 4. Lyophilized product with 1% TRH enzyme added Yeast alcohol dehydrogenase (produced by Oriental Yeast Industry Co., Ltd.) was dissolved in water at 1,000 U / mL and diluted to 6 U / mL with TBS (produced by Takara Bio Co., Ltd.). 50 μL of the enzyme solution was added with 50 μL of TBS containing 2% trehalose (TRH) and mixed, and after freezing at -80°C for 10 minutes, freeze-dried for 20 hours in a freeze dryer (FLEXI-DRY, produced by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, produced by PHIL Sato Vac INC.) to prepare a lyophilized product with 1% TRH enzyme added.
[0301] Test sample 5. Lyophilized product with 3% TRH enzyme added In the preparation method of Test Sample 4, a lyophilized product to which 3% TRH enzyme was added was prepared in the same manner as the preparation method of Test Sample 4 except that the final concentration of trehalose was changed to 3%.
[0302] Test sample 6. Lyophilized product with 1% 4TRH enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% 4-trehalosamine (4TA) was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4TA.
[0303] Test sample 7. Lyophilized product with 3% 4TRH enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme supplemented with 3% 4-trehalosamine (4TA) was prepared in the same manner as the preparation method of Test Sample 5, except that trehalose was replaced with 4TA.
[0304] Test sample 8. Lyophilized product with 1% MLT enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% MLT was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was changed to maltose (MLT).
[0305] Test sample 9. Lyophilized product with 3% MLT enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% MLT was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was changed to maltose (MLT).
[0306] Test sample 10. Lyophilized product with 1% SCR enzyme added In the preparation method of Test Sample 4, a lyophilized product of the enzyme to which 1% SCR was added was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with sucrose (SCR).
[0307] Test sample 11. Lyophilized product with 3% SCR enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% SCR was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was changed to sucrose (SCR).
[0308] Test sample 12. Lyophilized product with 3% GOL enzyme added In the preparation method of Test Sample 5, a lyophilized product of the enzyme to which 3% GOL was added was prepared in the same manner as the preparation method of Test Sample 5 except that trehalose was replaced with glycerol (GOL).
[0309] <Evaluation of ADH protective activity> The enzyme solution of test sample 1, the freeze-thawed enzyme of test sample 2, and the lyophilized products of test samples 3 to 12 were diluted with TBS to 0.012U / mL, and 0.5mM β-NAD+ (produced by Oriental Yeast Industry Co., Ltd.) and 0.62M ethanol were added to carry out enzyme reaction at room temperature for 1 hour. After the reaction, the absorbance at 340nm was measured using a microplate reader (Cytation5, produced by Bio Tek Instruments) (n=3, mean±SD). The absorbance value at 340nm was divided by the absorbance value at 340nm of the enzyme solution of test sample 1 (control) to calculate the ADH activity. The results are as follows: Fig. 16B shown.
[0310] according to Fig. 16B The results showed that the enzyme activity of test sample 2 (freeze-thawed enzyme) and test sample 12 (freeze-dried product with 3% GOL enzyme added) was greatly reduced, similar to test example 6-1. In contrast, samples freeze-dried with 1% or 3% 4-trehalosamine, trehalose, maltose or sucrose maintained appropriate activity. Among them, the protective effect of 4-trehalosamine was higher than that of other sugars.
[0311] (Test Example 7-1: Protective Effect of 4-Trehaloseamine on Microorganisms (Baker's Yeast)) The microbial protective activity of various sugars under freeze-drying was evaluated using test samples 1 to 8 containing baker's yeast prepared by the following method.
[0312] <Preparation of test samples> Test sample 1. Control (NF: Non-freezing) A frozen stock of baker's yeast (Saccharomyces cerevisiae F-7, owned by the Microbial Chemistry Research Institute) was inoculated in 10 mL of YPD culture medium (1% exosomes, 2% peptides, 2% glucose) at 220 rpm and 27°C for 2 days. After culturing, centrifuge at 1,000 × g for 5 minutes, wash once with 10 mL of water, and suspend it in 10 mL of water to prepare a yeast suspension. 50 μL of water was added to 50 μL of yeast suspension and mixed, and the mixture was left to stand at 4°C for 12 hours as a control (NF).
[0313] Test sample 2. Freeze-Thaw of yeast (FT) After preparing a yeast suspension in the same manner as in Sample 1, the suspension was frozen at -80°C for 12 hours to prepare a freeze-thaw (FT) of yeast.
[0314] Test sample 3. Freeze-Dry yeast (FD) A yeast suspension was prepared in the same manner as in Test Sample 1, frozen at -80°C for 1 hour, and lyophilized for 12 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHILSatoVac INC.) to prepare a lyophilized enzyme.
[0315] Test sample 4. Lyophilized product of yeast supplemented with TRH After preparing a yeast suspension in the same manner as in Test Sample 1, 50 μL of a 6% trehalose aqueous solution was added to 50 μL of the yeast suspension and mixed, and the mixture was frozen at -80°C for 1 hour, and freeze-dried for 12 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHIL Sato Vac INC.) to prepare a TRH-added yeast lyophilized product (TRH).
[0316] Test sample 5. Lyophilized yeast with 4TA added In the preparation method of Test Sample 4, a lyophilized product of yeast supplemented with 4TA (4TA) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4-trehalosamine (4TA).
[0317] Test sample 6. Lyophilized yeast with MLT added In the preparation method of Test Sample 4, a lyophilized product of yeast to which MLT was added (MLT) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with maltose (MLT).
[0318] Test sample 7. Lyophilized yeast with SCR added In the preparation method of Test Sample 4, a lyophilized product of yeast to which SCR was added (SCR) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with sucrose (SCR).
[0319] Test sample 8. Lyophilized yeast with GOL added In the preparation method of Test Sample 4, a lyophilized product of yeast to which GOL was added (GOL) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with glycerol (GOL).
[0320] <Evaluation of baker's yeast protective activity> Test samples 1 and 2 were diluted 1 / 10 with physiological saline to prepare a series of suspensions. 100 μL of water was added to each lyophilized product of test samples 3 to 8, and each was diluted 1 / 10 with physiological saline to prepare a series of suspensions. 60 μL of water was added to 30 μL of each dilution. 2% Agar-YPD was prepared at 3 mL / well in a 6-well microplate, and 90 μL of each dilution was inoculated on 2% Agar-YPD and cultured at 30°C for 2 days. Fig.17A shown. In addition, when a well in which the number of colonies can be measured was selected and the number of surviving cells in each well of test sample 3 (FD) was set to "1", the number of surviving cells in each well of test samples 1, 2 and 4 to 8 (relative number) was calculated taking into account the dilution concentration of each test sample, as shown in Table 3 below.
[0321] [Table 3]
[0322] according to Fig.17A and the results of Table 3, comparing test sample 1 (NF) with test sample 3 (FD), it was found that baker's yeast ( Saccharomyces cerevisiae ) due to freeze-drying, the survival rate was greatly reduced. In contrast, when 6% (final concentration 3%) of sugar other than glycerol was added, the survival rate increased by more than 10 times. In particular, when 4-trehalosamine was added, the protective effect on microorganisms was stronger than when maltose and sucrose were added.
[0323] (Test Example 7-2: Protective Effect of 4-Trehalosamine on Microorganisms (Escherichia coli)) Using test samples 1 to 8 containing Escherichia coli prepared by the following method, the microbial protective activity of various sugars under freeze-drying was evaluated.
[0324] <Preparation of test samples> Test sample 1. Control (NF: Non-freezing) Escherichia coli ( Escherichia coli K-12, held by the Microbial Chemistry Research Association, a public interest foundation, was inoculated into 10 mL of Luria-Bertani (LB) medium (manufactured by Difco) and cultured at 220 rpm and 37°C for 24 hours. After culture, centrifugation was performed at 3,000 × g for 5 minutes, and after washing once with 10 mL of water, it was suspended in 10 mL of water to prepare an E. coli suspension. 50 μL of water was added to 50 μL of the E. coli suspension and mixed, and the mixture was left to stand at 4°C for 12 hours as a control (NF).
[0325] Test sample 2. Freeze-thawed Escherichia coli (FT) After preparing an E. coli suspension in the same manner as in Sample 1, the suspension was frozen at -80°C for 12 hours to prepare a freeze-thaw (FT) of yeast.
[0326] Test sample 3. Lyophilized product of Escherichia coli (FD) After preparing an Escherichia coli suspension in the same manner as in Test Sample 1, the suspension was frozen at -80°C for 1 hour and freeze-dried for 12 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHILSatoVac INC.) to prepare a lyophilized product of Escherichia coli.
[0327] Test sample 4: Lyophilized product of Escherichia coli supplemented with TRH After preparing the Escherichia coli suspension in the same manner as in Test Sample 1, 50 μL of a 6% trehalose aqueous solution was added to 50 μL of the Escherichia coli suspension and mixed, the mixture was frozen at -80°C for 1 hour, and lyophilized for 12 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHIL SatoVac INC.) to prepare a TRH-added Escherichia coli lyophilized product (TRH).
[0328] Test sample 5. Lyophilized product of Escherichia coli supplemented with 4TA In the preparation method of Test Sample 4, a lyophilized product of Escherichia coli supplemented with 4TA (4TA) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4-trehalosamine (4TA).
[0329] Test sample 6. Lyophilized product of Escherichia coli supplemented with MLT In the preparation method of Test Sample 4, a lyophilized product of Escherichia coli (MLT) supplemented with MLT was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with maltose (MLT).
[0330] Test sample 7. Lyophilized product of Escherichia coli supplemented with SCR In the preparation method of Test Sample 4, a lyophilized product of Escherichia coli to which SCR was added (SCR) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with sucrose (SCR).
[0331] Test sample 8: Lyophilized product of Escherichia coli supplemented with GOL In the preparation method of Test Sample 4, a lyophilized product of Escherichia coli (GOL) supplemented with GOL was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with glycerol (GOL).
[0332] <Evaluation of Escherichia coli protective activity> Test samples 1 and 2 were diluted 1 / 10 with water to prepare a series of suspensions. 100 μL of water was added to each lyophilized product of test samples 3 to 8, and each was diluted 1 / 10 with water to prepare a series of suspensions. 80 μL of water was added to 10 μL of each dilution. Prepare 2% Agar-LB at 3 mL / well in a 6-well microplate, inoculate 90 μL of each dilution on 2% Agar-LB, and culture at 37°C for 24 hours. Fig. 17B shown. In addition, when a well in which the number of colonies can be measured was selected and the number of surviving cells in each well of test sample 3 (FD) was set to "1", the number of surviving cells in each well of test samples 1, 2 and 4 to 8 (relative number) was calculated taking into account the dilution concentration of each test sample, as shown in Table 4 below.
[0333] [Table 4]
[0334] according to Fig. 17B and the results of Table 4. By comparing test sample 1 (NF) with test sample 3 (FD), it was found that Escherichia coli ( Escherichia coli ) had a significantly reduced survival rate due to freeze-drying. In contrast, when 6% (final concentration 3%) of sugar other than glycerol was added, the survival rate increased by more than 10 times. In particular, the addition of 4-trehalosamine had a stronger protective effect on microorganisms than other sugars and increased the survival rate of bacteria to the same level as that of the non-freeze-dried test sample 1 (NF).
[0335] (Test Example 7-3: Protective Effect of 4-Trehalosamine on Microorganisms (Bacillus subtilis)) The microbial protective activity of test materials 1 to 5 containing Bacillus subtilis prepared by the following method was evaluated under freeze-dried conditions of trehalose or 4-trehalose amine.
[0336] <Preparation of test samples> Test sample 1. Control (NF: Non-freezing) Bacillus subtilis ( Bacillus subtilis 168 (obtained from ATCC)) was inoculated in 10 mL of Luria-Bertani (LB) medium (manufactured by Difco), shaken at 220 rpm, and cultured at 37°C for 24 hours. After culture, centrifugation was performed at 3,000 × g for 5 minutes, washed once with 10 mL of water, and then suspended in 10 mL of water to obtain a suspension of Bacillus subtilis. 50 μL of water was added to 50 μL of the suspension of Bacillus subtilis, mixed, and left to stand at 4°C for 20 hours to serve as a control (NF).
[0337] Test sample 2. Freeze-thawed Bacillus subtilis (FT) A suspension of Bacillus subtilis was prepared in the same manner as in Sample 1 and then frozen at -80°C for 20 hours to prepare freeze-thawed yeast (FT).
[0338] Test sample 3. Freeze-dried Bacillus subtilis (FD) After preparing a suspension of Bacillus subtilis in the same manner as in Test Sample 1, the suspension was frozen at -80°C for 10 minutes and freeze-dried for 20 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHILSatoVac INC.) to prepare a freeze-dried product of Bacillus subtilis.
[0339] Test sample 4. Lyophilized product of Bacillus subtilis supplemented with TRH After preparing a Bacillus subtilis suspension in the same manner as in Test Sample 1, 50 μL of a 6% aqueous trehalose solution was added to 50 μL of the Bacillus subtilis suspension and mixed, the mixture was frozen at -80°C for 10 minutes, and freeze-dried for 20 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHIL Sato Vac INC.) to prepare a Bacillus subtilis lyophilized product (TRH) added with TRH.
[0340] Test sample 5. Lyophilized product of Bacillus subtilis supplemented with 4TA In the preparation method of Test Sample 4, a lyophilized product of Bacillus subtilis supplemented with 4TA (4TA) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4-trehalosamine (4TA).
[0341] <Evaluation of the protective activity of Bacillus subtilis> Test samples 1 and 2 were diluted 1 / 10 with water to prepare a series of suspensions. 100 μL of water was added to each lyophilized product of test samples 3 to 5, and each was diluted 1 / 10 with water to prepare a series of suspensions. 80 μL of water was added to 10 μL of each dilution. Prepare 2% Agar-LB at 3 mL / well in a 6-well microplate, inoculate 90 μL of each dilution on 2% Agar-LB, and culture at 37°C for 24 hours. Fig. 17C shown. In addition, when a well in which the number of colonies can be measured was selected and the number of surviving cells in each well of test sample 3 (FD) was set to "1", the number of surviving cells in each well of test samples 1, 2 and 4 to 5 (relative number) was calculated taking into account the dilution concentration of each test sample, as shown in Table 5 below.
[0342] [Table 5]
[0343] according to Fig. 17C and the results of Table 5, comparing test sample 1 (NF) with test sample 3 (FD), it was found that Bacillus subtilis ( Bacillus subtilis ) due to freeze-drying, the survival rate was greatly reduced. In contrast, when trehalose or 4-trehalosamine 6% (final concentration 3%) was added, the survival rate increased by more than 10 times. In particular, when 4-trehalosamine was added, the protection effect on microorganisms was stronger than when trehalose was added.
[0344] (Test Example 7-4: Protective Effect of 4-Trehalosamine on Microorganisms (Acid-Fasting Bacteria)) Using the test materials 1 to 5 containing acid-fast bacteria prepared by the following method, the microbial protective activity of trehalose or 4-trehalosamine under freeze-drying was evaluated.
[0345] <Preparation of test samples> Test sample 1. Control (NF: Non-freezing) The acid-fast bacteria (Mycobacterium smegmatis mc 2 155 strains (American Type Culture Collection (ATCC) 700084)) of frozen stock were inoculated in 10 mL Middlebrook 7H9 medium (Becton, Dickinson and Company) and cultured at 220 rpm and 37°C for 72 hours. After culture, centrifugation was performed at 3,000 × g for 5 minutes, and after washing once with 10 mL of water, the suspension was suspended in 10 mL of water to prepare an acid-fast bacteria suspension. 50 μL of water was added to 50 μL of the acid-fast bacteria suspension and mixed, and the mixture was left to stand at 4°C for 20 hours to serve as a control (NF).
[0346] Test sample 2. Freeze-thawed samples of acid-fast bacteria (FT) After preparing the acid-fast bacteria suspension in the same manner as in Sample 1, the suspension was frozen at -80°C for 20 hours to prepare a freeze-thaw product (FT) of the acid-fast bacteria.
[0347] Test sample 3. Freeze-dried product of acid-fast bacteria (FD) After preparing the acid-fast bacteria suspension in the same manner as test sample 1, freeze it at -80°C for 10 minutes and freeze-dry it for 20 hours using a freeze dryer (FLEXI-DRY, produced by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, produced by PHILSatoVac INC.) to prepare a freeze-dried product of acid-fast bacteria.
[0348] Test sample 4. Lyophilized product of acid-fast bacteria supplemented with TRH After preparing the acid-fast bacteria suspension in the same manner as in test sample 1, 50 μL of a 6% trehalose aqueous solution was added to 50 μL of the acid-fast bacteria suspension and mixed, and the mixture was frozen at -80°C for 10 minutes and freeze-dried for 20 hours using a freeze dryer (FLEXI-DRY, manufactured by FTSsystems INC., Warminster) connected to a vacuum pump (P65D, manufactured by PHIL Sato Vac INC.) to prepare a freeze-dried product (TRH) of acid-fast bacteria with added TRH.
[0349] Test sample 5. Lyophilized product of acid-fast bacteria with 4TA added In the preparation method of Test Sample 4, a lyophilized substance of acid-fast bacteria to which 4TA was added (4TA) was prepared in the same manner as the preparation method of Test Sample 4 except that trehalose was replaced with 4-trehalosamine (4TA).
[0350] <Evaluation of anti-acid bacteria protection activity> Test samples 1 and 2 were diluted 1 / 10 with water to prepare a series of suspensions. 100 μL of water was added to each lyophilized product of test samples 3 to 5, and each was diluted 1 / 10 with water to prepare a series of suspensions. 80 μL of water was added to 10 μL of each dilution. 2% Agar-Middlebrook 7H9 medium was prepared at 3 mL / well in a 6-well microplate, and 90 μL of each dilution was inoculated on the 2% Agar-Middlebrook 7H9 medium and cultured at 37°C for 24 hours. Fig.17D shown. In addition, when a well in which the number of colonies can be measured was selected and the number of surviving cells in each well of test sample 3 (FD) was set to "1", the number of surviving cells in each well of test samples 1, 2 and 4 to 5 (relative number) was calculated taking into account the dilution concentration of each test sample, as shown in Table 6 below.
[0351] [Table 6]
[0352] according to Fig.17D and the results of Table 5, comparing test sample 1 (NF) with test sample 3 (FD), it was found that acid-fast bacteria ( Mycobacterium smegmatis ) due to freeze-drying, the survival rate was greatly reduced. In contrast, when trehalose or 4-trehalosamine 6% (final concentration 3%) was added, the survival rate increased by more than 10 times. In particular, when 4-trehalosamine was added, the protective effect on microorganisms was stronger than when trehalose was added.
[0353] (Test Example 8: pH buffering effect of 4-trehalose amine) Using the purified 4-trehalosamine prepared in the <Purification Process> of Production Example 10, the function of 4-trehalosamine as a buffering agent was confirmed by the following method.
[0354] The pH change was measured by using a pH meter (LAQUAF-51, manufactured by Horiba Ltd.) when 50 μL to 100 μL of 1M hydrochloric acid (HCl) or 1M sodium hydroxide (NaOH) was added to 50 mL of 10 mM 4-trehalosamine aqueous solution (Production Example 10), 50 mL of 10 mM trehalose aqueous solution, 50 mL of 10 mM trishydroxymethylaminomethane, 50 mL of 10 mM MES (2-(N-morpholino)ethanesulfonic acid) aqueous solution, or 50 mL of 10 mM HEPES (4-(2-hydroxyethyl)-1-piperidinylethanesulfonic acid) aqueous solution. The results are as follows. Fig.18 shown.
[0355] according to Fig.18 The results confirmed that 4-trehalosamine (4TA) has a strong pH buffering effect comparable to that of tris(hydroxymethyl)aminomethane. The pH range of strong buffering is around pH 5.5 to pH 8.0, which is about 1.0 lower than that of tris(hydroxymethyl)aminomethane, and the pKa is estimated to be 6.99.
[0356] (Test Example 9-1: Confirmation 1 of the decomposition of trehalosamine by 4-trehalose degrading enzyme) Trehalose (TRH) or 4-trehalosamine (4TA) obtained in the <Purification Process> of Production Example 10 was added to 135 mM sodium citrate buffer (pH 5.7) and mixed to give a final concentration of 0 mM, 0.01 mM, 0.1 mM, 1 mM or 10 mM, respectively. Porcine kidney-derived trehalase (0.24 units / mL, manufactured by Sigma-Aldrich) was added here and reacted at 37°C for 20 minutes. A 3-fold amount of Glucose assay reagent (manufactured by Sigma-Aldrich) was added to the solution after the reaction. After reacting at room temperature for 15 minutes, the absorbance at 340 nm was measured using the onboard reader Cytation5 (manufactured by Bio Tek Instruments) to estimate the amount of glucose released as a decomposition product. The results are as follows. Fig.19A and B. In addition, Fig.19B yes Fig.19A Magnified image of .
[0357] Fig.19A The results of A and B showed that in this reaction, trehalase was decomposed and glucose was released, but 4-trehalosamine was not released into glucose, confirming that porcine trehalose could not be decomposed.
[0358] (Test Example 9-2: Confirmation 2 of the decomposition of trehalose amine by 4-trehalose degrading enzyme) <Production of KP4-TREH10 strain> In order to conduct degradation experiments using human trehalase, a strain highly expressing the enzyme was constructed. First, cDNA was synthesized from human small intestine total RNA (manufactured by TAKARA Biotech Co., Ltd.) using PrimeScript II Reverse Transcriptase (manufactured by TAKARA Biotech Co., Ltd.). Based on the cDNA, PCR was performed using primer TREH1F (TTAGCGGCCGCCCCATGCCAGGGAGGAC) of sequence number 2 and primer TREH1R (GGGAATTCTCCACAGGGCAGGAGGCTGA) of sequence number 3 and KOD-Plus DNA polymerase (manufactured by Toyobo Co., Ltd.) to amplify DNA of human trehalase gene TREH. The amplified DNA was digested with restriction enzymes EcoRI and NotI, and ligated with pSF-CMV-FMDV-Neo / G418 (manufactured by Oxford Genetics) digested with the same enzymes using Quick Ligation Kit (manufactured by New England BioLabs), and introduced into Escherichia coli DH5α competent unit (manufactured by Biodynamics Research Institute, Ltd.). The Escherichia coli into which the plasmid was introduced was cultured in a 2% Agar-LB medium containing 100 μg / mL kanamycin, and Escherichia coli clones that retained the target plasmid were selected. For multiple (about 10) clones, they were cultured in LB medium containing 100 μg / mL kanamycin, and the plasmids were purified using Wizard plasmid purification system (produced by Promega). The TREH partial DNA sequence of each plasmid clone was confirmed by ABI Prism 3130 Genetic Analyzer (produced by ABI), and the plasmid clone pSF-TREH3-3 with the target sequence correctly inserted was obtained.
[0359] This plasmid was introduced into various human cultured cells using Viafect (produced by Promega), and the expression level of transient trehalase protein was analyzed by Western Blotting with a trehalase antibody (produced by Santa Cruz) diluted 1 / 2,000. In this analysis, human pancreatic cancer cell KP4, which was found to express high levels of trehalase in subsequent experiments, was used as an expression cell. As described above, human pancreatic cancer cell KP4 introduced with the pSF-TREH3-3 plasmid was diluted to less than 1 cell per well, spread into a 96-well microplate, and cultured in a DMEM medium containing 400μg / mL G418 (produced by ThermoFisherScientific), and clones that stably expressed trehalase were selected and allowed to proliferate. The KP4-TREH10 strain was selected as the clone with the highest expression of trehalase and used in subsequent experiments.
[0360] <Confirmation of Trehalase Expression in Cultured Cells> The trehalase expression region in human pancreatic cancer cell line KP4 (obtained from RIKEN BRC) and KP4-TREH10, a cell line that stably and highly expresses trehalase, was confirmed by immunoblotting. In the detection of trehalase (primary antibody), an anti-trehalase antibody (manufactured by SantaCruz) was used at a dilution of 1 / 2,000. In addition, an anti-tubulin antibody (manufactured by Cell Signaling Technology) was used as a control at a dilution of 1 / 5,000. The results are shown in FIG. Fig.19C shown. It is noteworthy that, compared with the protein content and unit number of porcine kidney-derived trehalase used in Test Case 9-1, the amount of trehalase in the total extracted protein of KP4-TREH10 strain was estimated to be 0.32 U / mg to 0.45 U / mg.
[0361] (Confirmation of decomposition by human trehalase) The degradation of 4-trehalosamine and trehalose by the extracts of human pancreatic carcinoma cell line KP4 and human trehalase-high-expressing cell line KP4-TREH10 was studied. Human pancreatic carcinoma cell lines KP4 and KP4-TREH10 were grown in a CO2 incubator at 37°C using DMEM medium until synthesis. After that, the medium was removed, washed three times with PBS (produced by Takara Bio Co., Ltd.), and then recovered in PBS with a cell scraper. The recovered cell suspension was centrifuged at 400×g for 3 minutes, and after removing the supernatant, 135mM citric acid buffer (pH5.7) containing 0.5% Trisaccharide (registered trademark) 15 times the amount of precipitated cells was added, homogenized, and centrifuged at 21,300×g for 10 minutes to recover each supernatant. To each supernatant, 4-trehalose aqueous solution or trehalose aqueous solution was added at 20μg / mL and allowed to stand at 37°C. After 0 hours, 2 hours, 8 hours, or 24 hours from the start of the reaction, the reaction solution was recovered, diluted to 1 / 10 with methanol, and centrifuged at 21,300×g for 10 minutes. Each supernatant was collected and subjected to LC-MS analysis under the same conditions as in Experimental Example 1 to confirm the residual rates of 4-trehalosamine and trehalose in the reaction solution of 4-trehalosamine and human pancreatic cancer cell KP4 cell extract (4TAC), the reaction solution of 4-trehalosamine and KP4-TREH10 cell extract (4TAT), the reaction solution of trehalose and human pancreatic cancer cell KP4 cell extract (TRHC), and the reaction solution of trehalose and KP4-TREH10 cell extract (TRHT). The results are as follows. Fig.19D shown.
[0362] Fig.19D The results showed that neither trehalose nor 4-trehalosamine was degraded by the cell extract of human pancreatic cancer cell KP4. At the same time, trehalose was degraded by the cell extract of KP4-TREH10 strain, which is a cell with high expression of human trehalase, and basically disappeared after 8 hours. In contrast, 4-trehalosamine was almost not degraded or reduced in the cell extract of KP4-TREH10 strain.
[0363] (Test Example 9-3: 4- Dynamic confirmation when trehaloseamine is orally administered to mice) ICR mice (9-10 weeks old, female, n=5) fasted overnight were orally administered 4-trehalosamine or trehalose dissolved in saline at a dose of 0.5 mg / 10 μL per gram of body weight. Five mice with the same treatment were placed in the same cage.
[0364] <Confirmation of the cumulative excretion of 4-trehalosamine in urine and feces> Urine and feces were collected regularly. The recovered feces were suspended in water at 200 mg / mL and centrifuged at 21,300×g for 5 minutes. The centrifuged supernatant of the fecal suspension and the recovered urine were diluted to 1 / 1,000 with methanol, respectively, and LC-MS analysis was performed under the same conditions as in Experimental Example 1 to calculate the cumulative excretion of 4-trehalosamine (4TA) or trehalose (TRH) over time. The results of urine are shown in Fig.19E The results of feces are shown in Fig.19F shown.
[0365] -Confirmation of the blood concentration of 4-trehalosamine- 10 μL to 20 μL of blood was collected from the tail vein at regular intervals, and 200 μL of methanol was added after measurement. After stirring with a glass slide, centrifugation was performed at 21,000 × g for 5 minutes. The supernatant was diluted to 1 / 5 with methanol and LC-MS analysis was performed under the same conditions as in Experiment 1. The results of 4-trehalosamine for each individual are shown in Figure 1. Figure 19G The results for trehalose are shown in Fig.19H As shown (n=5).
[0366] Figure 19G The results showed that part of the oral 4-trehalosamine was absorbed and circulated in the blood for a certain period of time. The study also found that most of the absorbed 4-trehalosamine was excreted through feces and urine without being broken down or modified.
[0367] <Confirmation of changes in blood sugar levels> The supernatant sample of the centrifugation of the blood methanol dilution prepared by <Confirmation of 4-trehalosamine blood drug concentration> (the same sample as used in LC-MS analysis) was placed in a 96-well plate at 5 μL / well, and after being sucked dry by a vacuum pump, it was dissolved in 25 μL of water, and 75 μL of Glucose assay reagent (manufactured by Sigma-Aldrich) was added. After standing at 37°C for 1 hour, the absorbance at 340 nm was measured using a plate reader Cytation5 (manufactured by Bio Tek Instruments) to estimate the amount of glucose. The results of 4-trehalosamine are shown in Figure 1. Fig.19I The results for trehalose are shown in Fig.19J As shown (n=5).
[0368] according to Fig.19J The results showed that the blood sugar level of the group taking trehalose orally increased 30 minutes to 1 hour after administration, while the blood sugar level of the group taking 4-trehalosamine did not increase.
[0369] (Test Example 10-1: Autophagy-inducing effect of 4-trehalosamine and trehalose analogs on cultured cells) Immunoblotting confirmed the expression and phosphorylation patterns of autophagy-related proteins in human ovarian cancer cells or human malignant melanoma cells treated with 4-trehalosamine and trehalose analogs for 24 h.
[0370] Human ovarian cancer cells OVK18 (obtained from RIKEN BRC) and human malignant melanoma cells Mewo (JCRB0066) were cultured at 8×10 4 Cells / mL / well were seeded on 12-well microplates and cultured in DMEM medium at 37°C for 72 hours before being treated with test samples.
[0371] The test samples used were 4-trehalosamine (4TA) and trehalose (TRH) obtained in the <Purification Process> of Production Example 10, IMCTA-Cn compounds obtained in Synthesis Examples 1 to 8, trehalose ester (TRH-Cn) (produced by Dojin Chemical Research Institute), dodecyl-β-D-maltoside (DDM), maltose (MLT), sucrose (SCR), and rapamycin (RM). In addition, untreated cells to which no compound was added were used as controls (Control). When treating with the above test samples, in order to avoid local high concentrations of compounds contacting cells, take half of the culture medium in the well, dissolve the required amount of test sample in it, put it back to the original well after it is fully dissolved, and treat at 37°C for 24 hours.
[0372] Then, the medium containing the test sample was removed, and the sample was washed once with PBS and dissolved in a 2×SDS sample buffer without 2-mercaptoethanol (2-ME) and bromophenol blue (BPB). The protein concentration in the dissolved sample was measured using a BCA protein assay kit (manufactured by Thermo Fisher Scientific), and then 2-ME and BPB were added and boiled for 5 minutes to prepare a sample for immunoblotting.
[0373] Regarding immunoblotting, in the method described in Experimental Example 4, except that anti-LC3 antibody, anti-p62, anti-cathepsin D antibody, anti-Phospho-Akt (Ser473) antibody, anti-Akt antibody, anti-Phospho-p70S6K (T389) antibody, or anti-p70S6K antibody (all produced by Cell Signaling Technology) as autophagy markers were used at a dilution of 1 / 2,000 as the primary antibody, the other methods were the same as those in Experimental Example 4. Human ovarian cancer cell OVK18 results Fig. 20A As shown in Figure 4, the results of human malignant melanoma cell Mewo are as follows Fig.20D In addition, Fig. 20AIn FIGS. , B, D and E, “PCD” means precursors of cathepsin D, and “CD-HC” means cathepsin D heavy chain.
[0374] according to Fig. 20A -F results showed that in cells treated with 4-trehalosamine and trehalose analogs, although the treatment concentrations were different, upregulation of the autophagy marker LC3-II was found. Particularly strong expression was found in IMCTA-C13, IMCTA-C14, and IMCTA-C15, and more than equal expression was found at concentrations of a few thousandths of trehalose. In trehalose esters (TRH-Cn), LC3-II expression was also increased at low concentrations, but the activity was not as strong as that of IMCTA-Cn. In addition, LC3-II expression was also found at high concentrations of sucrose (SCR). Unlike the treatment with trehalose, the treatments with IMCTA-C13, IMCTA-C14, and IMCTA-C15 showed no accumulation of PCD, but showed the same results as trehalose in terms of the tendency of p62 accumulation, the tendency of pAkt decrease, and the lack of dephosphorylation of p70S6K. Therefore, it is believed that the mechanism of action of autophagy induction by IMCTA-Cn is basically the same as that of trehalose.
[0375] (Test Example 10-2: 4-trehalosamine or trehalose analogs combined with autophagy inhibitors confirm the nature of upregulation of autophagy marker expression) In addition to the frequent occurrence of autophagy, the up-regulation of LC3-II expression also occurs when autophagy is inhibited midway, resulting in the accumulation of autophagosomes. In order to confirm whether the up-regulation of LC3-II expression caused by the treatment of 4-trehalosamine or trehalose analogs in Experimental Example 10-1 is due to autophagy induction or inhibition, we conducted a combined experiment of 4-trehalosamine or trehalose analogs with autophagy inhibitors bafilomycin (BM) or chloroquine (CQ). If the expression level of LC3-II increases in the presence of an inhibitor, 4-trehalosamine or trehalose analogs is determined to have an autophagy inducing effect; if the expression level of LC3-II remains unchanged, 4-trehalosamine or trehalose analogs is determined to have an autophagy inhibiting effect.
[0376] As in Experimental Example 10-1, human ovarian cancer cells OVK18 (from RIKEN BRC) and human malignant melanoma cells Mewo (JCRB0066) were cultured at 8×10 4Cells / mL / well were seeded on a 12-well microplate and cultured in DMEM medium at 37°C for 72 hours. Half of the culture medium in the well was taken to dissolve each compound to a final concentration of 50 mM 4-trehalose, 50 μM IMCTA-C14 or 100 mM trehalose. After sufficient dissolution, the compound was returned to the original well and treated at 37°C for 14 hours. Untreated cells without compound addition were used as controls (Control).
[0377] Then, various autophagy inhibitors were added to a final concentration of 200 nM bafilmycin (BM) or 100 μM chloroquine (CQ), and cultured at 37°C for 4 hours. In addition, the group without the addition of inhibitors was cultured in the same manner. After culture, the samples were used for immunoblotting in the same manner as in Test Example 10-1.
[0378] The immunoblotting method described in Experimental Example 4 was the same as that in Experimental Example 4 except that the anti-LC3 antibody (produced by Cell Signaling Technology) was diluted 1 / 2,000 and used as the first antibody. Fig.21A As shown, the results of human malignant melanoma cell Mewo are as follows Fig. 21B shown. In addition, the results of immunoblotting and the results of image analysis by ImageJ (manufactured by National Institutes of Health) are shown in Figure 2. Fig.21A As shown in A and B (n = 10, mean ± SD). The vertical axis of the graph represents the expression value (expression ratio) of LC3-II in each compound-added group when the expression level of LC3-II in the control (untreated cells) is 1. When the result of the Dunnett test is significantly different from the control (p < 0.05), the graph bar is represented by a dotted oblique line, when there is a significant difference compared with the case where no inhibitor is added (p < 0.05), the graph bar is represented by gray, and when there is a significant difference compared with the case where no compound is added (control) or no inhibitor is added (p < 0.05), the graph bar is represented by black.
[0379] Fig.21A The results in A and B showed that the combination of 4-trehalosamine, trehalose, and IMCTA-C14 with bafilomycin (BM) or chloroquine (CQ) increased the expression of LC3-II, thus exhibiting an autophagy-inducing effect on cultured cells.
[0380] (Test Example 10-3: Confirmation of the effect of 4-trehalosamine or trehalose analogs on eliminating intracellular aggregated proteins) The researchers confirmed the effects of 4-trehalosamine or trehalose analogs on the partial peptide Q74 of the Huntington's disease-causing protein Htt and the mutant α-synuclein SynA53T of the Parkinson's disease-causing protein (both are aggregation proteins) by the following method.
[0381] Neuroblastoma SH-SY5Y cells (obtained from European Collection of Authenticated Cell Cultures (ECACC)) and human neuroblastoma NH-12 cells (obtained from RIKEN BRC) were cultured at 14×10 4 cells / mL, seeded in DMEM medium, and cultured at 37°C for 48 hours.
[0382] After the above culture of SH-SY5Y cells and NH-12 cells, the expression vector pEGFP-Q74 vector or EGFP-alphasynuclein-A53T (obtained from addgene) for agglutinin was transfected using a transfection reagent (Viafect, manufactured by Promega). 24 hours after the transfection, 100 mM 4-trehalosamine, 70 μM MCT A-C14 or 100 mM trehalose was added and treated for another 14 hours. In addition, untreated cells without the addition of the compound were used as controls (Control). After the cells were rinsed three times with PBS, a hypotonic solution (a solution prepared by dissolving 1 tablet of cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail (CM, manufactured by Merck) in 50 mL of pure water) was added, and after shaking on ice for 10 minutes, the cells were centrifuged at 21,300 × g for 10 minutes to separate the soluble protein (Sol) and agglutinin (Agg) in the supernatant. Thereafter, the samples were prepared as immunoblot samples in the same manner as in Test Example 10-1.
[0383] The immunoblotting method described in Experimental Example 4 was the same as that in Experimental Example 4 except that the anti-GFP antibody (manufactured by Proteintech) was diluted to 1 / 5,000 and the anti-LC3 antibody (manufactured by Cell Signaling Technology) was diluted to 1 / 2,000 before use as the first antibody. The results of neuroblastoma cell SH-SY5Y are shown in Fig.22A and B, the results for human neuroblastoma cell NH-12 are shown in Fig. 22C and D as shown. In addition, the results of immunoblotting and the results of image analysis by ImageJ (manufactured by National Institutes of Health) are shown in Figure 2. Fig.22A~D (n = 5, mean ± SD). The vertical axis of the graph represents the expression value (expression ratio) of each protein in the group with each compound added when the expression level of each protein in the control (untreated cells) is 1. When the result of the t-test is significantly different from the control (p < 0.01), the bar of the graph is represented by "*".
[0384] Fig.22A The results from 4-trehalose to D showed that the aggregates of the partial peptide Q74 of the Huntington's disease pathogenic protein and the Parkinson's disease pathogenic protein SynA53T expressed in SH-SY5Y cells and NH-12 cells used as neural cell models were significantly reduced by 4-trehalosamine, IMCTA-C14, and trehalose. In particular, IMCTA-C14 showed activity equal to or higher than that of trehalose at a concentration of 1 / 1,000 or less of trehalose.
[0385] (Test Example 10-4: 4-trehaloseamine or trehalose analogs confirm upregulation of expression and nuclear migration of autophagy-related transcription factor TFEB) By immunoblotting and immunostaining, we confirmed the upregulation of expression and nuclear translocation of autophagy-related transcription factor EB (TFEB) in human ovarian cancer cells or human malignant melanoma cells treated with 4-trehalosamine or trehalose analogs. The fractionation of nuclei and cytoplasm was performed according to the report of Dignam et al. (JD Dignam et al., Nucleic Acids Res, 1983, 11(5), p. 1475-1489) by the following method using a buffer modified based on the buffer solution.
[0386] <Confirmation by Western blotting> Human ovarian cancer cells OVK18 (from RIKEN BRC) and human malignant melanoma cells Mewo (JCRB0066) were cultured at 2×10 5 Cells / 2mL / well were seeded on a 6-well plate and cultured in DMEM medium at 37°C for 48 hours. Half of the culture medium in the well was taken to dissolve each compound to a final concentration of 50mM 4-trehalose, 50μM IMCTA-C14, 100μM IMCTA-C14, or 100mM trehalose. After sufficient dissolution, the mixture was returned to the original well and treated at 37°C for 14 hours. Untreated cells without compound addition were used as controls (Control).
[0387] After washing the cells treated with each compound once with PBS, they were treated with a lysis buffer (10 mM HEPES (pH 7.9), 10 mM potassium chloride, 1.5 mM magnesium chloride, 0.4% Igepal CA-630 (manufactured by Sigma-Aldrich), 1 mM DTT, 1 tablet / 50 mL CM (manufactured by Merck)) on ice for 30 minutes. Next, the cells were scraped with a cell scraper, recovered, and gently shaken at 6°C for 10 minutes. After centrifugation at 21,300 × g for 5 minutes, the supernatant was recovered as a cytoplasmic fraction.
[0388] The precipitate was washed once with a lysis buffer and then dissolved with a nuclear buffer (20 mM HEPES (pH 7.9), 0.4 M sodium chloride, 1.5 mM magnesium chloride, 5% glycerol, 1 mM DTT, 1 tablet / 50 mL CM). After centrifugation at 21,300 × g for 5 minutes, the supernatant was recovered as a nuclear fraction.
[0389] The protein concentration of each component was measured using a protein quantification reagent (XL-Bradford, integral), and the expression level of TFEB in each component was investigated using immunoblotting. In the method described in Experimental Example 4, as the first antibody, the anti-TFEB antibody (produced by Cell Signaling Technology) was diluted 1 / 2,000 and used. In order to show the accuracy of cytoplasm (Cyt) fractionation and nuclear (Nuc) fractionation, the anti-GAPDH antibody (produced by Medical Biology Research Institute Co., Ltd.) was diluted 1 / 40,000 and used. The anti-PARP antibody (produced by Cell Signaling Technology) was diluted 1 / 10,000 and used. Other than that, the same method as Experimental Example 4 was used. The results of human ovarian cancer cell OVK18 are as follows. Fig.23A As shown, the results of human malignant melanoma cell Mewo are as follows Fig. 23B shown.
[0390] <Confirmation by immunostaining> Human ovarian cancer cells OVK18 and human malignant melanoma cells Mewo were cultured at 2.4×10 4 Cells / 0.6mL / well were seeded on a 48-well microplate and cultured in DMEM medium at 37°C for 48 hours. Half of the culture medium in the well was taken to dissolve each compound to a final concentration of 50mM 4-trehalosamine, 100μM IMCTA-C14 or 100mM trehalose. After sufficient dissolution, the mixture was returned to the original well and treated at 37°C for 14 hours. Untreated cells without compound addition were used as controls (Control).
[0391] All subsequent reactions were carried out at room temperature with slow shaking. The culture medium was removed from the treated cells, and 300 μL / well of 4% paraformaldehyde-PBS (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added for fixation for 15 minutes. After washing with PBS three times, 300 μL / well of 0.3% TritonX-100-PBS containing 5% BSA was added for blocking for 1 hour. After removing the blocking solution, 50 μL / well of anti-TFEB antibody (manufactured by Santa Cruz Biotechnology) diluted 1 / 33 with 0.3% TritonX-100-PBS containing 1% BSA was added and reacted for 4 hours. After washing with PBS three times, 50 μL / well of Alexa Fluor 488-conjugated anti-mouse IgG antibody (manufactured by Cell Signaling Technology) diluted to 1 / 500 with 0.3% Triton X-100-PBS containing 1% BSA was added and reacted for 2 hours. After removing the antibody solution, add 0.3% Triton X-100-PBS 1mL / well to the cells and rinse for 5 minutes three times, then add PBS 300μL / well for microscopic observation. AlexaFluor 488 is detected using filter B (excitation filter (Ex) 420nm~490nm, absorption (Em) 520nm). After taking phase difference and fluorescence images, add 50ng / mL DAPI (4', 6-diamidino-2-phenylindole)-PBS solution at 50μL / well to the cells, treat for 2 hours, and rinse three times with PBS. Observe the stained nuclei using a UV filter (Ex.330nm~350nm, Em.420nm). Human ovarian cancer cell OVK18 results Fig.23C As shown, the results of human malignant melanoma cell Mewo are as follows Fig.23D As shown. Fig.23C In and D, "PC" indicates a phase contrast observation image, and "DAPI" indicates a nuclear staining area.
[0392] Fig.23A The results from 4-trehalosamine and trehalose analogs showed that TFEB expression was upregulated and translocated to the nucleus when autophagy was induced. In particular, IMCTA-C14 showed activity equal to or higher than that of trehalose at a concentration of 1 / 1,000 of trehalose.
[0393] (Test Example 11-1: Staining of acid-fast bacteria using IMCTA-fluorescein, IMCTA-biotin or IMCTA-azide) The IMCTA-fluorescein obtained in Synthesis Example 9, the IMCTA-biotin obtained in Synthesis Example 10, and the IMCTA-azide obtained in Synthesis Example 11 were used to carry out the Mycobacterium smegmatis )Staining test.
[0394] Store Mycobacterium smegmatis mc at 4°C 2 155 strains (ATCC700084) were inoculated at 0.5 μL / mL in Middlebrook 7H9 medium (Becton, Dickinson and Company) supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% BD BBL Middlebrook OADC Enrichment (Becton, Dickinson and Company), and cultured at 37°C for 24 hours. The trehalose aqueous solution or sucrose aqueous solution used was added to the culture solution to a final concentration of 1% or 3%, and then the following substances were added to a final concentration of 0.1% DMSO, 10 μg / mL 5-carboxyfluorescein (5-FC), 10 μg / mL IMCTA-fluorescein (Synthesis Example 9), 30 μg / mL IMCTA-biotin (Synthesis Example 10) or 10 μg / mL IMCTA-azide (Synthesis Example 11). After culturing at 37°C for 8 hours, the culture solution was centrifuged at 21,300×g for 1 minute, and the precipitate was washed three times with 0.05% Tween 80-PBS. The bacterial cells were suspended in 0.05% Tween 80-PBS to obtain a bacterial suspension. In addition, the cells were cultured in the same manner without adding trehalose aqueous solution or sucrose aqueous solution as "No block".
[0395] The bacterial suspension obtained by IMCTA-fluorescein was used to observe the phase difference and fluorescence image using a fluorescence microscope (ECLIPSE-TE2000-U, manufactured by Nikon Corporation). A B filter (Ex. 420nm to 490nm, Em. 520nm) was used for fluorescence observation. The results are as follows Fig.24A shown. After taking phase difference and fluorescence images, the fluorescence intensity per bacterial cell was analyzed using Image J (manufactured by National Institutes of Health), and the fluorescence intensity per bacterial cell was quantified and graphed (n=3, mean±SD). Fig.25A shown.
[0396] 30 μg / mL DyLight 488 Streptavidin (Vector Laboratories) was added to the bacterial suspension obtained with IMCTA-biotin, and cultured at 37°C for 1 hour. After washing three times with 0.05% Tween 80-PBS, the suspension was observed under a fluorescence microscope and image analysis was performed in 0.05% Tween 80-PBS under the same conditions as the bacterial suspension obtained with IMCTA-fluorescein. The results of fluorescence microscopy observation are shown in Figure 2. Fig. 24B The results of image analysis are shown in Fig.25B shown.
[0397] 5-FAM-Alkyne (final concentration 10 μg / mL, manufactured by Jena Bioscience), CuSO4·5H2O (100 μg / mL), and ascorbic acid (100 μg / mL) pre-mixed with 0.05% Tween 80-PBS were added to the bacterial suspension obtained using IMCTA-azide, and the mixture was treated at 37°C for 1 hour. The bacterial cells were washed three times with a 2% SDS aqueous solution, and then suspended in a 2% SDS aqueous solution. Fluorescence microscopy observation and image analysis were performed under the same conditions as for the bacterial suspension obtained using IMCTA-fluorescein. The results of fluorescence microscopy observation are shown in Figure 2. Fig.24C The results of image analysis are shown in Fig.25C shown.
[0398] In the fluorescent material processing of raw materials, it is considered Mycobacterium smegmatis The bacteria do not emit fluorescence and are not ingested, but according to Fig.24A The results of ~C, IMCTA-fluorescein, IMCTA-biotin, and IMCTA-azide were Mycobacterium smegmatis The bacteria take it up and emit fluorescence. The uptake of IMCTA-fluorescein was not significantly inhibited in the presence of excess sucrose, but was inhibited in the presence of 1% trehalose, thus indicating competitive uptake with trehalose. However, there were slight differences in the IMCTA-fluorescein, IMCTA-biotin, and IMCTA-azide staining areas. When equal amounts of markers were used, the strongest fluorescence was observed by IMCTA-azide treatment. On the other hand, the reason was unclear, but not only trehalose but also sucrose inhibited the uptake. IMCTA-biotin confirmed patchy staining areas. Inhibition of uptake by sucrose was also observed in the case of IMCTA-biotin treatment.
[0399] (Test Example 11-2: TLC analysis of lipid components in IMCTA-fluorescein-stained cells) The samples stained with IMCTA-fluorescein in Test Example 11-1 were Mycobacterium smegmatis Bacterial suspension or DMSO-treated Mycobacterium smegmatis The lipid components of the bacterial cell suspension were analyzed by TLC. TLC analysis was performed based on the method of Kai et al. (M. Kai et al., FEBS Lett 2007, 581, p. 3345-3350).
[0400] The samples stained with IMCTA-fluorescein in Experimental Example 11-1 were centrifuged at 21,300 × g. Mycobacterium smegmatis Bacterial suspension or DMSO-treated MMycobacterium smegmatis After 1 minute of the bacterial suspension, add 20 times the amount of chloroform / methanol (2:1, v / v) to the precipitate and stir vigorously for 5 minutes using a tube mixer (TWIN3-28N, produced by AGC Technoglass Co., Ltd.). After centrifugation at 21,300×g for 1 minute, recover the supernatant. The precipitate is subjected to the same extraction treatment twice more, the supernatant is collected, dried with a Savant SpeedVac (produced by Thermo Fisher Scientific), and the solvent is removed. The dried body is suspended in chloroform / methanol, the chloroform / methanol content being 0.75% of the initial culture amount in Test Example 11-1, and after vigorous stirring for 5 minutes, centrifuged at 21,300×g for 1 minute, and the supernatant is used as a thin layer chromatography sample.
[0401] In TLC analysis, Silica gel 60 TLC plates (Merck) were used, and the solvent was developed with chloroform / methanol / acetone / acetonitrile (90:10:6:1, v / v). The entire lipid was detected with the same phosphomolybdic acid solution as in Test Example 1, and fluorescence was detected with a UV trans-illuminator (NTFM-20, Analytik Jena US LLC). Phosphomolybdic acid stained blocks of the entire component Fig.26A As shown, the fluorescence detection block is as follows Fig.26B As shown. Fig.26A In A and B, "1" is the result of DMSO-treated cells, "2" is the result of IMCTA-fluorescein-treated cells, and "3" is the result of focusing on 1.3 μg of IMCTA-fluorescein itself. Fig.26B In the figure, the arrow indicates the component of fluorescence that is visible only in the IMCTA-fluorescein-treated sample.
[0402] Fig.26AThe results of A and B showed that two fluorescent lipids were detected in the bacteria containing IMCTA-fluorescein, and IMCTA-fluorescein instead of trehalose was contained in the trehalose moiety of trehalose monocholic acid and trehalose dicholic acid.
[0403] (Test Example 12-1: Confirmation of microbial decomposition of 4-trehalose amine) The following 12 microorganisms were confirmed to be able to degrade 4-algamine.
[0404] <Microorganisms> 1.EC: Escherichia coli K-12 (held by the Microbial Chemistry Research Society) 2.SM: Serratia marcescens B-0524 (held by the Microbial Chemistry Research Association) 3.EF: Enterococcus faecalis JCM5803 (obtained from RIKENBRC) 4.AN: Aspergillus niger F16 (held by the Microbial Chemistry Research Association) 5.SE: Salmonella enteritidis 1891 (held by the Microbial Chemistry Research Society) 6.MS: Mycobacterium smegmatis ATCC-607 (obtained from ATCC) 7.BS: Bacillus subtilis 168 (obtained from ATCC) 8.PA: Pseudomonas aeruginosa A3 (held by the Microbial Chemistry Research Society) 9.ML: Micrococcus luteus IFO3333 (obtained from IFO) 10.BF: Bacteroides fragilis JCM11019 (obtained from RIKEN BRC) 11.SC: Saccharomyces cerevisiae F-7 (held by the Microbial Chemistry Research Association) 12.CA: Candida albicans 3147 (obtained from IFO)
[0405] - Training methods - EC, SM, PA, and ML were pre-cultured using Nutrient medium (1% polypeptide (manufactured by Nippon Pharmaceutical Co., Ltd.), 1% fish extract for bacteria (manufactured by Far East Pharmaceutical Co., Ltd.), and 0.2% sodium chloride). MS was pre-cultured in Nutrient medium supplemented with 2% glycerol. EF and SE were pre-cultured in heart infusion medium (HI, manufactured by Becton, Dickinson and Company (BD)). BF was pre-cultured using Gifu anaerobic medium (GAM medium, manufactured by Nissui Pharmaceutical Co., Ltd.). SC, CA, and AN were pre-cultured using RPMI-1640 medium (manufactured by Nissui Pharmaceutical Co., Ltd.). BS was pre-cultured in LB medium (manufactured by Difco).
[0406] In a 96-well plate, 196 μL of the culture medium for each of microorganisms 1 to 12 was placed, and then 2 μL of the previously cultured suspension of each microorganism was added, followed by 2 μL of a mixture of a 5 mg / L 4-trehalosamine aqueous solution and a 5 mg / L trehalose aqueous solution (final concentrations of 50 μg / mL, respectively), and cultured under humid conditions at 37°C for bacteria and 30°C for fungi for 5 days. In addition, the so-called humid condition refers to a state in which the 96-well plate is wrapped in a paper towel saturated with water, placed in a zipper bag, and the zipper is loosened to serve as a vent of about 2 cm to 3 cm. After the culture, the culture solution was diluted to 1 / 10 with methanol, stirred vigorously with a slide, and centrifuged at 21,300×g for 5 minutes. The obtained supernatant was analyzed by LC-MS under the same conditions as in Experimental Example 1, and the residual rate (%) of 4-trehalosamine or trehalose was calculated. The results are as follows: Fig.27A shown.
[0407] according to Fig.27A The results showed that 4-trehalosamine was basically undetectable in 8 of the 12 microorganisms.
[0408] (Test Example 12-2: Confirmation of microbial assimilation of 4-trehalose amine) The assimilation of 4-trehalosamine was confirmed by the 12 kinds of microorganisms described in Test Example 12-1.
[0409] The 12 kinds of microorganisms described in Test Example 12-1 were cultured to saturation in the culture medium used, and then a carbon source-deficient culture medium in an amount less than 1 / 100 was added to each of them. -Carbon source deficient culture medium- RPMI-1640 (without glucose) (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was used for EC, SM, AN, SE, ML, and BF. MS, BS, and CA used a modified 805 medium (0.1% Dong extract (manufactured by BD), 0.07% dipotassium hydrogen phosphate, 0.01% potassium dihydrogen phosphate, 0.1% magnesium sulfate heptahydrate), which is the basis of NBRC805-1 medium (Independent Administrative Institution Product Evaluation Technology Foundation). For PA, a modified 805-4 medium (0.025% trypsin peptone (manufactured by BD), 0.07% dipotassium hydrogen phosphate, 0.01% potassium dihydrogen phosphate, and 0.1% magnesium sulfate heptahydrate) was used. LB medium (1% tryptone (manufactured by BD), 0.05% sodium chloride) containing no yeast extract was used for EF and SC.
[0410] Then, 4-trehalosamine, trehalose or glucose was added to PA to a final concentration of 0.1%, and to microorganisms other than PA to a final concentration of 0.4%, and the bacteria were cultured at 37°C and the fungi at 30°C under humid conditions (the same conditions as in Test Example 12-1) for 5 days. The absorbance of the culture solution after 5 days was measured at 620 nm using a plate reader Cytation 5 (manufactured by Bio Tek Instruments) to confirm the growth of each microorganism. The results are as follows Fig.27B shown. Fig.27B In the figure, "1" indicates a control without addition of 4-trehalosamine, trehalose and glucose, "2" indicates a control with addition of glucose, "3" indicates a control with addition of trehalose, and "4" indicates a control with addition of 4-trehalosamine.
[0411] In Test Example 12-2, the experiment was conducted under the condition that the growth rate of each microorganism increased when glucose was added. Fig.27B The results showed that when trehalose was added, the growth of 6 bacteria was activated, which suggests that trehalose was decomposed and assimilated in these bacteria. However, when 4-trehalamine was added, the growth of any of the 12 microorganisms was not activated. Fig.27A and Fig.27B The results showed that 4-trehalosamine was not decomposed by various microorganisms in the form of released glucose, but was no longer detected as 4-trehalosamine because part of the structure was modified, which confirmed that 4-trehalosamine would not become a carbon source or nutrient source.
[0412] (Test Example 13: Binding model diagram of 4-trehalosamine and human trehalase) The homology model of human trehalase (O43280) was constructed according to Promod3 3.1.1 of SWISS-MODEL web server (A. Waterhouse et al., Nucleic Acids Res, 2018, 46, W296., N. Guex et al., Electrophoresis, 2009, 30 Suppl 1, S162., and S. Bienert et al., Nucleic Acids Res, 2017, 45, D313. reference). Among 148 templates, a template (PDB5z66) showing 39% sequence homology was selected (refer to A. Adhav et al., FEBSJ, 2019, 286, 1700.) and used as a basis. The quality of the model was evaluated by Qmean and QMEANDisCo scoring of QMEAN-Server (https: / / swissmodel.expasy.org / qmean) (G. Studer et al., Bioinformatics, 2020, 36, 1765., M. Bertoni et al., Sci Rep, 2017, 7, 10480., C. Camachoetal., BMC Bioinformatics, 2009, 10, 421., M. Steineger et al., BMC Bioinformatics, 2019, 20, 473., and M. Mirdita et al., Nucleic Acids Res, 2017, 45, D170.). The QMEAN score was -3.15, and the QMEANDisCo Global score was 0.70±0.05. Next, a binding model of trehalase and trehalose (ZINC4095531) was constructed using AutoDock Vina on Chimera (see O. Trottetal., J Comput Chem, 2010, 31, 455. and EF Pettersen et al., J Comput Chem, 2004, 25, 1605.). Charge assignment was performed using AMBER ff14SB for standard amino acid residues and Gasteiger for others. The docking posture of 4-trehalosamine was constructed in the same manner as above. PyMOL (The PyMOL Molecular Graphics System, Version 2.1, Schrodinger, LLC. 2010.) was used to create the model diagram.
[0413] Fig.28A The binding model of trehalose to human trehalase is shown. Fig.28B The binding model of 4-trehalose to human trehalase is shown. Fig.28A The binding model of trehalose and human trehalase is the optimal model with -9.4 kcal / mol shown by AutoDockscore. The catalytic site of trehalase is very small, and there is almost no extra space after trehalose binds. It can be considered that molecules larger than trehalose cannot enter and therefore cannot be decomposed. For 4-trehalosamine, which is almost the same size as trehalose, the researchers established several binding models, but in each model, there was a repulsive amino acid residue in the amino group of 4-trehalosamine, which may make it difficult for them to bind.
[0414] This international application claims priority based on Japanese Patent Application No. 2021-144962 filed on September 6, 2021, the entire contents of which are incorporated herein by reference. Trustee Number
[0415] NITE BP-03495.
Claims
1. A protective agent, a surfactant composition, a blood sugar control composition, an autophagy inducer, an acid-fast bacteria stain or a protein extractant, characterized in that: Contains a compound represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, or a solvate thereof: [Chemical formula 1] However, in the above general formula (1), R 1 is -NH2, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14; [Chemical formula 2] [Chemical formula 3] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
2. A compound characterized by the following general formula (2), or a pharmaceutically acceptable salt thereof, or a solvate thereof: [Chemical formula 4] However, in the above general formula (2), R 2 is a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), or -NH(CH2) m CH3, wherein m represents an integer between 7 and 14, [Chemical formula 5] [Chemical formula 6] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
3. A compound-containing composition, characterized in that: Containing the compound according to claim 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
4. A method for preparing 4-trehalosamine, characterized in that it contains culture Streptomyces Cultivation process of sp.MK 186-mF5 (trust number: NITE BP-03495).
5. The method for preparing 4-trehalosamine according to claim 4, characterized in that: In the culture process, the culture medium contains at least one of 3 to 9 mass % of soluble starch, 0.001 to 0.02 mass % of zinc chloride, and 0.1 to 1 mass % of potassium chloride.
6. A method for preparing a compound represented by the following general formula (3), characterized in that: The method comprises using 4-trehalosamine as a starting material, reacting the 4th amino group of 4-trehalosamine with CH3(CH2) p COH (wherein p represents an integer between 6 and 13), 2-azido-1,3-dimethylimidazolium hexafluorophosphate, 5-carboxyfluorescein N-succinimide ester or D-biotin N-hydroxysuccinimide ester: [Chemical formula 7] However, in the above general formula (3), R 3 Yes -N(CH2) m CH3, or -N3, or a substituent represented by the following structural formula (A), or a substituent represented by the following structural formula (B), wherein m represents an integer between 7 and 14, [Chemical formula 8] [Chemical formula 9] However, in the above structural formula (A) or the following structural formula (B), "*" represents an atomic bond.
7. A microorganism, Streptomyces sp.MK 186-mF5 (trusteeship number: NITE BP-03495), characterized in that It has the ability to produce 4-trehalosamine.
